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Thesis Abstract 
This work explores the role of gap junctional proteins (GJP) in wound healing in two clinical 
settings: venous disease and epidermal grafting.  
Chronic wounds and ulcers are common and a feared problem particularly in the elderly, 
causing pain and disability. Treatment costs are estimated at £2-3 billion to the NHS with a 
further loss of 2 million workdays per year. Varicose veins are the major contributor to the 
prevalence of ulcers affecting about 0.3-0.5% of the population at any point of time.   
The expression of GPJ; connexins 43, 30 and 26 were explored in a cross-sectional study of 
patients with varicose veins at different stages of venous disease (CEAP stage). A stepwise 
increase in GJPs overexpression was seen corresponding to the clinical CEAP stage of the 
disease, supporting their role in the disease mechanism and as a biomarker of wound healing. 
This is also the first-time varicose veins were shown to be associated with poor wound healing. 
Concurrently, with the introduction of a new wound healing system for epidermal grafting, a 
sequential program of research was developed.  Initially, a systematic review using Cochrane 
methodology on epidermal grafting for wound healing, and a pilot case series to evaluate the 
novel surgical technology. Following positive outcomes; a patient reported outcome measure 
and cost evaluation study was performed.  
Combining these data, a pilot randomised controlled trial was performed to compare efficacy 
of epidermal grafting to standard of care. Alongside, translational studies on GJP were 
undertaken to outline the cellular mechanism of action of epidermal grafts.  
These data led to the development of a wound healing group at UCL and subsequent 
engagement with the MRC UCL clinical trials team to design a novel platform trial to further 
assess epidermal grafting. This platform will investigate the molecular mechanism of action 
and explore the most appropriate use for this technology. A NIHR EME and a collaborative 
industry grant is in progress.   
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Thesis Statement 
 
This thesis is divided into three parts. The first part explored the expression of gap junctional 
proteins in venous disease. The work done in this part formed the groundwork aimed at 
learning steps involved to perform a robust translational trial which requires thorough clinical 
and laboratory methodology. Having learned from this, I then designed a series of studies to 
evaluate a novel surgical technology for wound healing which formed the second part of this 
thesis. The third part of this thesis contains the overall conclusion and elaborates the future 
direction for both part one and two. 
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1.0 Literature review on skin changes in chronic venous disease and the role 
of Connexin in venous ulcer 
 
1.1 Chapter summary 
Varicose veins are common, affects 1 in 3 adults, and a feared complication is venous leg 
ulcer (VLU), which affects about 0.3-0.5% of the population at any point of time. However, the 
precise mechanism leading to skin changes in venous disease and the subsequent ulceration 
remains unclear. This chapter explores the mechanism of skin changes and its link with a 
potential biomarker, the Connexin (Cx) family of gap junctional proteins (GJPs), a known 
contributor to poor healing of VLUs. The skin changes seen in venous disease progression is 
attributed to venous reflux and venous hypertension that leads to chronic inflammation and 
ischaemia-reperfusion cycles, the likely trigger to Cx upregulation in VLUs. We evaluate and 
explain how these factors lead to skin changes in venous disease and cause upregulation of 
Cx and its consequences, based on clinical and in vitro studies. There is substantial 
associative and mechanistic evidence to support the role of Cx in poor healing of VLU and its 
likely overexpression in the early stages of venous disease. Elucidating the pathogenesis of 
venous disease with the use of a biomarker can inform clinical practise for a more targeted 
therapeutic intervention as well as for disease prevention. 
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1.2 Introduction 
About 1 in 3 adults have varicose vein (VV) and over 35,000 VV operations are carried out in 
the NHS per year[1, 2]. Within patients with VV, 10% may go on to develop skin changes, 
such as pigmentation and eczema, while 2-6% have a lifetime risk to develop a venous leg 
ulcer (VLU) [1, 3, 4]. This is likely to increase, in part at least, because of the increasing ageing 
population and prevalence of obesity[3-5]. VVs are a major contributor to the prevalence of 
VLU which affects about 0.3-0.5% of the population at any point of time[5, 6]. VLU are the 
most common type of lower limb ulcer, comprising about 70-80% of the ulcers in the 
community, with treatment costs of about £2-3 billion and loss of 2 million workdays per year 
[7-9].   
Venous disease derives most commonly from valve incompetence, but can also occur due to 
an obstruction of outflow; or due to immobility or obesity causing impedance of the mechanical 
pump generated by the muscles of the lower limb; or the combination of these [4]. In the 
Caucasian population the pattern of venous disease most commonly occur in superficial veins 
(45%), solely in the deep veins of the leg (12%) or a combination thereof (43%) [10]. The 
venous hypertension and the pressure gradient between the deep and superficial venous 
system leads to the plethora of complications and sequelae observed. 
Stage of venous disease can be classified according to the clinical, etiologic, anatomic, and 
pathophysiologic (CEAP) classification according to the disease severity[11]: C0 = no visible 
venous disease, C1 = spider veins, C2 = VV, C3 = oedema, C4 = lipodermatosclerosis, C5 = 
healed VLU, and C6 = active VLU (Figure 1.1). Despite good understanding of the clinical 
signs and symptoms of each class, the mechanism that influences the progression of skin 
changes from CEAP class C2 to C6 remains unclear [1, 12, 13] and reliance on the known 
risk factors will not predict those patients at risk of developing VLUs. Hence, a measurable 
biological element, a biomarker, that reflects the pathogenesis of the disease and which 
26 
correlate to the disease severity and effectiveness of a treatment is needed to guide early 
intervention of venous disease.  
 
 
Figure 1.1 Clinical spectrum of venous disease 
Venous disease can be classified into seven classes per CEAP Classification, from C0 to C6, 
according to the disease severity. The CEAP classification along with corresponding clinical 
photographs are shown here. 
 
This review explores the mechanism underlying skin changes and its link with a potential 
biomarker for venous disease, the Connexin (Cx) family of gap junctional proteins (GJPs). We 
first highlight the current understanding on the pathophysiology of the skin changes with 
venous disease progression. We then explore the role of Cx in VLUs, linking their expression 
with the pathogenesis of venous disease. We end by proposing models to evaluate the role of 
GJPs as a biomarker of venous disease progression.  
 
1.3 Skin changes in chronic venous disease 
The mechanism leading to changes in skin quality such as reduced elasticity and 
hyperpigmentation as seen in lipodermatosclerosis remain debatable. Histologically, 
lipodermatosclerosis is characterised by fibrous scar tissue of the reticular dermis built up of 
27 
collagen bundles replacing cellular components, whereas venous ulceration is characterised 
by the total loss of epidermis and partial loss of the matrix structures in the upper dermis[14]. 
The chronic venous insufficiency (CVI) related hyperpigmentation, as seen in 
lipodermatosclerosis, was initially assumed to be due to haemosiderin and/or melanin 
deposition[15]. The abnormal presence of these pigments in the dermis was explained by 
extravasation and lysis of red blood cells, followed by decomposition of haemoglobin into 
haemosiderin, which stimulates melanogenesis[16]. However, in an observational study 
involving skin biopsies from patients with lipodermatosclerosis, haemosiderin deposition and 
melanin aggregates were seen in the dermis even despite the lack of evidence of erythrocyte 
extravasation in 50% of the patients [17]. In a follow-up study performed by the same group 
involving patients from CEAP class C2-C6, the authors reported that the haemosiderin 
deposition was obligatory for severe venous disease (C4 onwards) and was not present in the 
earlier stages [18]. Based on these observations, they hypothesised that the dysregulation of 
melanin metabolism in advanced venous disease was not a result of erythrocyte 
extravasation, and instead is likely to be due to chronic inflammation. Inflammatory cytokines 
and growth factors such as alpha-melanocyte stimulating hormone, endothelin-1, or stem cell 
factors have been considered as possible mediators[19-21]. This finding was echoed in a 
larger study that similarly observed extravasation of erythrocytes taking place only in 
concomitance of severe dermal inflammation [22]. 
Chronic inflammation, venous dilatation and extravasation have been attributed to venous 
reflux and venous hypertension, which are the basis of several hypotheses on the 
pathogenesis of skin changes seen in advanced venous disease (Figure 1.2) [23, 24]. Three 
main hypotheses were proposed: fibrin cuff deposition, microvascular leukocyte-trapping and 
leukocyte activation [4]. The initial proposition of fibrin cuff deposition around capillaries 
secondary to filtration of fibrinogen has been superseded by the theory of chronic inflammation 
related leukocyte-trapping and neutrophil activation [4, 12]. The presence of chronic 
inflammation in the walls of VV and the skin of C4-C6 have been well established [12, 25-27]. 
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While none of the histological studies observed the presence of inflammatory cells in the skin 
of C2, a recent study investigating skin changes in patients with CVI using ultrasound, 
however, pointed out that inflammation and dermal oedema were present in apparently normal 
skin of C2 legs[28]. Despite demonstrating the ability to use a non-invasive technique to 
identify early skin changes in C2, the ultrasonographic findings in this study were not 
correlated with histological evaluation.  
 
 
Figure 1.2 Summary of the pathogenesis underlying skin changes and ulcer 
formation in venous disease.  
Flowchart summarised the pathogenesis underlying venous disease and the progression 
leading to skin changes and ulcer formation.  
 
Venous reflux and hypertension
Leukocyte-trapping and neutrophil activation
Chronic inflammation
Dysregulation of melanin metabolism and increased
protease production
Breakdown of extracellular matrix
Ulceration
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Chronic inflammation remains the only consistent mechanistic feature between C4 and C6 
[29, 30]. The high number of activated neutrophils that exist in the microenvironment of the 
chronically inflamed ulcers secrete excessive amount of proteases that can cause tissue 
destruction and persistent inflammation that perturbs healing[12, 31]. The prolonged activity 
of activated neutrophil proteases, such as the Human Neutrophil Elastase (HNE) and matrix 
metalloproteinase (MMP), causes degradation of ECM, receptors and growth factors, resulting 
in ulceration and impedes healing by thwarting cellular migration and attachment [32]. A recent 
multicenter study comprising 541 patients with CVI of CEAP class C1-C6, have for the first 
time, showed that each class may be described by expression of specific MMPs[33]. They 
found that the serum elevation of MMP-2, ADAMTS-1 and ADAMTS-7 correlates with the initial 
stages of CVI (C1-C2), while the serum elevation of MMP-1, MMP-8, MMP-9, NGAL, ADAM-
10, ADAM-17 and ADAMTS-4 were particularly involved in the more advanced stages (C4-
C6) [34]. Although the trigger for inflammation and the link between venous hypertension and 
chronic inflammation remains unclear, this interesting finding suggests that there are indeed 
early changes despite noticeable histological alteration to the skin, indicating the need to 
investigate at the cellular and molecular level, hence the need for a biomarker.  
 
1.4 Phases of wound healing 
Normal wound healing can be divided into 3 phases: inflammatory, proliferative, and 
remodelling [35]. Each of these phases will be explored in this section. 
1.4.1 Haemostasis and inflammatory phase 
The haemostasis and inflammatory phase of wound healing begins immediately following 
tissue injury. Upon injury, components of the injured tissue, including fibrillar collagen and 
tissue factor, act to activate the clotting cascade and prevent ongoing haemorrhage. During 
this process, platelets degranulate to release growth factors such as platelet-derived growth 
factor (PDGF) and transforming growth factor β (TGF- β)[35]. The result of this process is the 
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conversion of fibrinogen to fibrin and subsequent polymerization into a provisional matrix 
which provides scaffolding for cell recruitment and attachment. At the same time, the activation 
of the clotting cascade also attracts and activates inflammatory cells to the site of injury. Within 
the first 48 hours, neutrophils infiltrates into the fibrin matrix within the wound cavity to remove 
dead tissue by phagocytosis and prevent infection besides releasing a variety of proteases to 
degrade ECM to prepare the wound for healing. However, the prolonged presence of 
neutrophils in the wound has been proposed to be a primary factor in the conversion of acute 
wounds to non-healing chronic wounds.  
Neutrophils are then replaced by macrophages, which appears 48 to 72 hours post-injury. 
They are recruited primarily by expression of monocyte chemoattractant protein 1. 
Macrophages phagocytose debris and bacteria, but are especially critical for the orchestrated 
production of growth factors necessary to produce ECM by fibroblasts and new blood vessels 
in the healing wound. Among the chemokines, cytokines, and growth factors present in the 
healing wound are as follows: vascular endothelial growth factor, fibroblast growth factor 2, 
platelet-derived growth factor, keratinocyte growth factor, epidermal growth factor, 
transformation growth factor beta, tumour necrosis factor alpha, granulocyte macrophage 
colony-stimulating factor, interferon alpha, interleukin 1, 4 and 8, and endothelial nitric oxide 
synthase [35].  
1.4.2 Proliferative phase 
Although the phases of wound healing are not exclusive and have features that overlap, it is 
generally accepted that the proliferative phase occurs from day 4 to 21 following injury. Certain 
facets of the proliferative phase such as re-epithelialisation could begin almost immediately 
following injury. Keratinocytes at the wound edge alter their phenotype in the hours following 
injury. Regression of the desmosomal connections between keratinocytes and the underlying 
basement membrane frees cells and allow them to migrate laterally. Keratinocytes then move 
via interactions with ECM proteins (such as fibronectin, vitronectin, and type 1 collagen) via 
specific integrin mediators as they proceed between the desiccated eschar and the provisional 
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fibrin matrix beneath [35]. The provisional fibrin matrix is then gradually replaced by a new 
platform for migration, the granulation tissue, which is composed of three cell types: 
fibroblasts, macrophages, and endothelial cells. Fibroblasts are the workhorses during the first 
few days of injury to produce the ECM that fills the healing scar and provides a scaffold for 
keratinocyte migration. Macrophages continue to produce growth factors such as PDGF and 
TFG-β1 that induce fibroblast to proliferate, migrate and deposit ECM, as well as produces 
proangiogenic factors which stimulates endothelial cells to form new vessels.  
1.4.3 Remodelling phase 
The remodelling phase is the longest component of wound healing which lasts from 21 days 
up to 1 year and is characterised by the processes of wound contraction and collagen 
remodelling. Contraction is produced by wound myofibroblasts, which are fibroblasts with 
intracellular actin microfilaments capable of force generation and matrix contraction. Collagen 
remodelling involves replacing type III collagen laid down by fibroblasts during proliferative 
phase to type I collagen [35]. This slow remodelling phase is largely mediated by matrix 
metalloproteinases (MMPs) that are secreted in large part by macrophages, fibroblasts and 
endothelial cells. The strength of the wound improves slowly, reflecting the turnover in collagen 
subtype and increased collagen cross-linking, gradually improving to about 80% of the 
breaking strength of unwounded skin at 1 year.  
 
1.5 Connexin in venous disease 
The regulation of inflammation and tissue repair requires precise local intercellular 
communication via cell adhesion molecules and cell-cell junctions. The Cx family of GJPs are 
highly specialised transmembrane channels, which play a pivotal role in the healing of VLUs 
[36-38]. Cxs are clusters of plasma membrane protein (Figure 1.3), spanning adjacent cell 
membranes, leaving a 2-4nm extracellular “gap”, hence their name, and are described in terms 
of molecular mass (Cx43 represents the Cx protein of 43 kDa) [39]. This section will explore 
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the physiological roles of Cx, their expression and implication in VLU and the association 
between Cx and pathogenesis of venous disease. 
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Figure 1.3 The structural organisation of gap junctional protein (Connexin) 
(A, B) Cxs are specialised clusters of plasma membrane channels which assist cell-cell 
communication and exchange of metabolites. (C, D) Each Cx is made of a paired hemi-
channel known as a Connexon, which consists of six Connexin protein subunits. (E) Each 
Connexin protein subunit has four alpha-helical transmembrane proteins, two extracellular 
loops, a cytoplasmic loop, and a N- and C-terminus located within the cytoplasm. The C-
terminus binds to cytoskeletal elements within the cells to regulate cellular migratory 
properties. 
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1.5.1 Physiologic roles of Connexin 
Cxs facilitate cell-to-cell communication and exchange of ions and metabolites of less than 
1kDa in size between adjacent cells [40]. Nine different Cxs are expressed at different levels 
in human skin (including Cx26, 30, 30.3, 31.1, 32, 37, 40, 43, and 45), with Cx43 being the 
most ubiquitous, and found in epidermal keratinocytes, dermal fibroblasts, blood vessels, and 
appendages such as sweat glands, sebaceous glands, hair follicles, mast cells, and activated 
leukocytes [39-42]. They are present in precise temporal and spatial context within the 
epidermis and dermis. Intercellular communication mediated by the GJP is important during 
cellular growth and development as well as in the maintenance of normal metabolism and 
tissue homeostasis [37, 40, 43]. Cxs also act as a nexus interacting with adhesion molecules 
(Cadherin, α- and β-catenin), tight junctions (Zonular Occludin-1 (ZO-1) and ZO-2) and 
cytoskeletal components via the long cytoplasmic C-terminal tail, either directly or via adaptors 
in a cycle phase-specific manner [34, 44-46]. These multiprotein interaction influences both 
cell adhesion and cytoskeletal dynamics, which may require to be broken down to facilitate 
efficient cellular movement in wound healing [34]. In addition to its role in the migratory 
property of keratinocytes and fibroblasts, Cx is also required in other physiological processes, 
which include cell differentiation, proliferation, electrical transmission and inflammation[45]. 
Cxs have a short half-life, and therefore gap junction remodelling constantly occurs with a high 
turnover rate. For example, the half-life of Cx43 is only 1–3 h, much shorter than the average 
turnover time for other integral membrane proteins [47]. The dynamic nature of this protein 
and the regulation of their assembly and turnover therefore are important in the healing of 
VLUs.  
 
1.5.2 Connexin expression in VLU 
In acute wounding, Cx43 starts to downregulate about 6 h after injury, which correlates with 
the keratinocyte adopting a migratory phenotype as they start to crawl across the wound bed 
to re-epithelialise the wound[40]. In chronic VLUs, multiple Cxs are abnormally upregulated at 
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the wound margins and have been implicated in impaired keratinocyte and fibroblast 
migration, hence poor wound healing [34, 36, 48]. Figure 1.4 (below) summarises the effect 
of Cx downregulation and upregulation in skin wound healing.  
 
 
Figure 1.4 The effect of Connexin downregulation and upregulation in skin wound 
healing 
 
 
A recent observational study involving wound edge biopsies from patients with VLUs revealed 
that the principal epidermal and dermal Cxs (Cx43, Cx30 and Cx26) were consistently 
overexpressed in each patient (Figure 1.5) [36]. The levels of Cx43 at the wound edge 
epidermis was reported to be on average 14-fold higher than the normal skin from the arm of 
the same patient (p<0.001). Cx30 and Cx26, conversely, had a striking 226-fold and 123-fold 
increase at the wound edge compared to the matched intact, control skin (p<0.001).  
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Figure 1.5 Connexin expression in venous leg ulcer 
Expression of Cx43, Cx30 and Cx26 in control (unwounded) skin and wound edge of venous 
leg ulcer. Increased expression of the Cx proteins (green pixels) were seen in the epidermis 
of venous leg ulcer. Green: Cx43, Cx26 and Cx30; Blue: nuclei. Scale bar = 100µm. 
Magnification 40x. Figure reproduced with permission from Sutcliffe et al., 2015. Copyright © 
2015 John Wiley & Sons, Inc.  
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The negative effect of Cx overexpression on cellular migration is mediated by both gap-
junctional intercellular communication and non-junctional mediated effects. An increase of 
Cx43 by one-fold reduces cellular migration rate by half [34]. On the other hand, 
downregulation of Cx by Cx43 antisense in murine and humans have been shown to 
significantly accelerate wound healing [34]. The attenuation of Cx43 expression leads to 
reduced cell adhesion via a reduction in adhesion molecule (N-cadherin) expression and 
activation of regulators of cytoskeletal dynamics (GTPases Rac1 and RhoA), resulting in 
significantly longer migratory lamellipodial extension, enabling increased cell motility of 
fibroblasts cultured in-vitro[34]. Besides increasing the migratory activity of fibroblast, 
promoting Cx43 downregulation at a wound site also promotes angiogenesis, keratinocyte 
proliferation and migration, and decreases the number of infiltrating neutrophils and 
macrophages [49]. 
The precise mechanism which triggers Cx upregulation in VLUs remain to be elucidated, 
however this is likely to be related to venous hypertension induced ischaemia-reperfusion 
cycle and chronic inflammation[50].  
Under hypoxic conditions, Cx hemichannel opens to allow the release of signalling molecules 
into extracellular space [51]. The oxidative stress induces opening of the hemichannels, a 
result of a large drop in extracellular Calcium (CaP2+ P) concentration and membrane 
depolarisation, allowing movement of molecules down their respective concentration gradient 
to establish electrochemical equilibrium [52-54]. Such molecular transport leads to a loss of 
ionic homeostasis and destabilization of the membrane potential, further influencing and 
increasing the hemichannel activity, likely resulting in the upregulation of Cx expression. The 
excessive hemichannel opening is not favourable for cell survival as it contributes to lesion 
spread, inflammation and direct loss of cells’ ability to osmoregulation, leading to cell death 
[40, 55-57]. This has been reaffirmed through a reduction in cell death, both in vitro and in 
vivo, with inhibition of hemichannel opening by Cx mimetic peptides [40, 50, 58, 59].  
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In inflammatory skin disease, dysregulation of Cx hemichannels was observed as evidenced 
by extracellular ATP leakage and excessive cytosolic influx of calcium[60]. The extravasation 
of inflammatory cells increases expression of Cxs, especially Cx43, as the channels are 
involved in the release of cytokines and immunoglobulins[61, 62]. In wounds, treated with 
Cx43 antisense or mimetic peptide, significant reduction of neutrophils, macrophages, 
chemokine Ccl2 and cytokine TNF-α were seen, confirming the role of Cx43 expression in 
neutrophil extravasation and release of inflammatory cytokines[49, 63, 64]. Venous dilatation 
secondary to venous hypertension could also directly result in the disruption of tight junctions 
in between endothelial cells along the vessel wall, interfering cellular adhesion and 
communication [58]. This endothelial disruption results in pathological hemichannel opening, 
further worsening vascular leakage and inflammatory response[65]. The role of Cxs in 
vascular leakage have been previously reviewed [66]. A recent study highlighted that Cx37, 
Cx43, and Cx47 were also involved in the development of vein valves and lymphatic function, 
emphasising the important role these GJPs play in the formation of VV[67]. While the 
expression pattern and the effect of Cx gene knockout on embryonic valve development is 
shown in mouse models, it remains unclear if patients with VV are subjected to congenital 
mutation of these proteins.  
 
1.5.3 Therapies targeting Connexin in VLU  
The ability of GJPs to regulate immune responses, cellular proliferation, migration and 
apoptosis make them an attractive therapeutic target to improve wound healing. Cx expression 
can be targeted and manipulated for therapeutic benefit in wound healing via three 
approaches[65, 68]: 1)targeting transcription/translation modulation (antisense approaches); 
2)peptidomimetic approaches (such as Gap26, Gap 27, Peptide5, Gap19 and ACT-1); and 
3)non-specific compounds or small molecule approaches (such as fatty acids, volatile 
anaesthetics, alcohols, steroids, or quinine and derivatives) (Figure 1.6).  
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Figure 1.6 Mechanism of action of therapies targeting Cx expression. 
(A) Antisense oligodeoxynucleotide binds to mRNA to block Cx protein translation, thus 
downregulating the protein expression. (B) Mimetic peptides can act either cytoplasmically or 
extracellularly, blocking the function of Cx hemichannel, hence preventing cell-to-cell 
communication and exchange of ions and metabolites. 
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Of these, the antisense is very specific to Cx targets, while peptidomimetics are Cx-specific 
though not always isoform-specific, and the non-specific compounds often affect multiple 
channel types[65]. The antisense oligodeoxynucleotide works by binding to the messenger 
RNA (mRNA) to block Cx protein translation, reducing turnover, thus downregulating the gap 
junction expression [69]. The peptidomimetics, on the other hand, can either act 
cytoplasmically (targeting the amino or carboxyl–terminal tails, or the intracellular loop such 
as Gap19 and ACT-1) or externally (targeting extracellular loops such as Gap26, Gap27 and 
Peptide5) [70, 71]. These peptides inhibit Cx hemichannel function and are independent of Cx 
expression, however they can cause a downregulation of Cx proteins in long term and some 
peptides have been shown to be not Cx specific as is often claimed[50, 70, 72]. Efforts to 
improve the ability to target the Cx proteins are currently being intensified, with biotech 
companies developing peptides with several libraries of gap junction modulation compounds. 
This includes a library of 200 Cx43 interacting compounds, a library related to danegaptide 
/rotigaptide that contains 500 compounds, including hexapeptides, cyclic peptides, modified 
dipeptides and small molecules, a library containing of 150 modified Gap-peptides, and many 
more[72].  
Both the peptides and antisense approaches have been investigated in several multi-centre 
randomised clinical trials for treating VLUs, by using topical application and gel delivery 
systems, with positive outcomes in accelerating wound healing [59, 65]. These treatments 
exert effect via four key aspect: 1)enhancing cell migration (epithelial proliferation and 
granulation tissue formation); 2)reducing oedema; 3)reducing inflammation via targeting the 
inflammasome pathway; and 4)reducing vascular haemorrhage[34, 49, 59, 65, 70]. Newer 
tissue engineering approaches, such as sustained release of Cx43 antisense from coated 
collagen scaffolds, are currently underway [73].  Of course, the downside of all these drugs is 
that they might not go through the skin barrier and only work on open wounds, unless the 
molecules are under 500KD that will penetrate the skin and knock down the Cx proteins. 
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1.6 Models to evaluate Connexin as a biomarker of venous disease  
Cx upregulation is likely to take place in the early stages of venous disease as both 
inflammation and hypoxia underlies the pathogenesis of venous disease. While no notable 
histological changes are seen prior to C4, the upregulation of the plasma membrane channels 
can only be confirmed using immunohistochemical staining or gene array study. This can be 
established by taking skin biopsies from patients across the CEAP class, from C0 to C6, ideally 
from the distal part of the lower limb and a control biopsy either from the proximal part of the 
lower limb or from the upper limb. Analysis should include the principal epidermal and dermal 
Cx, which are Cx43, Cx30 and Cx26. The increased expression of these Cxs in C2 and C4 
compared to C0 and control skin can confirm that the upregulation of Cxs take place prior to 
ulceration as Cxs are currently often only thought to be a feature of chronic wounds. Effort 
should be taken to standardise the duration of VV among patients within the same class 
especially in the asymptomatic group. A large population based cohort study should be 
considered, with age and gender matching to limit heterogeneity within group. Thereafter, if 
Cxs are overexpressed as early as C2, a longitudinal study should then be undertaken to 
evaluate if early intervention of VV could downregulate Cx expression, given the short half-life 
of Cxs. As well as providing insight into the pathogenesis of venous disease, this could also 
indicate that VV predisposes skin to future ulceration, hence a biomarker for early surgical 
intervention.  
Sequencing technology should also be harnessed to identify alteration at the mRNA level, 
which may translate into new therapeutic targets to regulate Cx protein expression, for disease 
prevention or treatment. This can identify at risk patients who would benefit from early 
treatment with molecular pharmaceutical agents to prevent disease progression, an aspiration 
towards personalised medical care. Gene analysis could also be performed using blood serum 
or punch biopsy of the skin and vein wall. This should be correlated with the genetic profile of 
patients with CVI to look for any association, which could be used to predict patients who are 
more likely to form future VLUs. Efforts are currently being undertaken to identify genes 
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involved in CVI, which includes analysis of heredity, differential gene expression and novel 
metabolic pathways involved in primary VV[74]. Current work on the differential gene 
expression in patients with VV identified that the up-regulation of extracellular matrix 
components and cytoskeletal proteins involved in CVI is a pathological response to injury and 
subsequent repair[74, 75]. However, further in-depth mechanistic study is necessary to further 
validate this in larger patient cohorts with high-throughput genotyping platforms[74].   
 
1.7 Conclusion 
In this chapter, I have highlighted the mechanism underlying skin changes in venous disease 
and the role of Cxs in VLU and its potential as a biomarker of venous disease. There is 
substantial evidence to support the role of Cx in poor wound healing of VLU as well as its likely 
overexpression in the early stages of venous disease. However, more work needs to be done 
to confirm the expression pattern of the principal Cxs in the pre-wounded skin. Cxs have a 
potential to provide deeper insight on the mechanism of skin changes in venous disease and 
assist in early identification of patients at risk of future ulceration. Elucidating the pathogenesis 
with the use of a biomarker can inform clinical practise for a more targeted therapeutic 
intervention as well as for disease prevention. 
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Chapter 2 
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2.0 Methods and Materials 
 
 
2.1 Study aim 
The aim of this study is to determine and compare the principal epidermal GJP levels in venous 
disease: Connexin 43, Connexin 30 and Connexin 26.  We hypothesise that venous disease 
affects skin and induces an up regulation of the GJPs from the early stages of the disease. 
This in turn predisposes skin to poor wound healing.  
 
2.2 Objectives of the study 
The primary objective is to determine and compare Connexin levels in human epidermis at 
different stages of venous disease.   
The secondary objectives are to determine if Connexin can be used as a biomarker to identify 
whether patients with venous disease are at risk of poor wound healing. If we could identify 
Cx as a biomarker for poor wound healing, this may help identifying patients at risk of venous 
ulceration. Thereby appropriate treatment could be initiated to treat the patients early and 
prevent venous ulceration. 
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2.3 Clinical study protocol 
 
2.3.1 Study Design 
We designed an observational study that involves taking skin biopsies from patients 
undergoing routine elective care. The biopsies were taken at the normal surgical incision site.  
There were no therapeutic interventions, changes to patient care, or patient treatment options.   
Brief description of the study design and research participant’s journey throughout the study 
is illustrated in Figure 2.1 (below). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Flow chart illustrating patient journey through study 
Patient identified from 
vascular outpatients or varicose vein waiting list 
Routine clinic notes suggest varicose veins or 
venous disease 
Patient approached for study 
 
Patient screening & patient information leaflet given 
 
Patient consents 
 
Patient undergoes 4-mm wound edge punch biopsies during elective surgery 
Sample undergoes laboratory analysis  
 
Routine follow up as part of normal clinical care and discharged 
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2.3.2 Patient selection  
Patients from four main stages of the CEAP classification, namely C0, C2, C4, and C6, were 
enrolled, with a total of 12 patients in each CEAP class. The total sample size was 48 patients. 
Patients were eligible for study inclusion if they were aged >18 years and fulfilled the CEAP 
classification criteria. The inclusion and exclusion criteria are listed in Table 2.1 below.   
 
Inclusion Criteria Exclusion Criteria 
1. Male or female 
2. Age 18-90 
3. Patients with a venous disease 
4. Patients undergoing planned 
surgery or leg ulcer care 
 
1. Ulcers not due to conditions specified in the 
inclusion criteria (such as neoplastic or 
rheumatoid) 
2. Presence of arterial disease, connective 
tissue disorders, systemic inflammatory 
disorder, diabetic mellitus, cancer and 
concurrent skin disease 
3. Patients known to have a bleeding disorder 
4. Previous history of excessive bleeding 
associated with surgical biopsies or trauma 
5. Allergies to local anaesthesia 
6. Any other relevant medical concerns causing 
concern 
 
Table 2.1 Inclusion and Exclusion Criteria for Study Participants 
 
2.3.3 Biopsy acquisition 
Paired 4mm punch biopsies of the skin were taken from each patient: one below the knee (15-
20cm above the ankle) as the pathological skin and one above the knee (5-10cm above the 
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knee) as the control skin. Biopsies from the C0 group were taken from patients undergoing 
total knee replacement surgery while biopsies for the C2 and C4 groups were taken at the 
endovenous catheter insertion sites during surgery for the treatment of VV. Punch biopsies for 
the C6 group were performed at the wound edge and 5-10 cm above the knee. The wound 
edge biopsy was taken at 1mm away from the wound margin to obtain the highest Cx 
expression, as per our previous protocol[36]. All patients in the C2, C4 and C6 group were 
scanned with duplex ultrasonography to confirm the presence of venous reflux and screened 
to exclude mixed arteriovenous disease. Patients from the C0 group were screened to ensure 
the absence of clinical signs of venous disease. 
 
2.3.4 Ethics 
All biopsies were taken after written informed consent was obtained from the patients. This 
study was executed in accordance with the principles of the Declaration of Helsinki and the 
recommendations of Good Clinical Practice. Ethical approval was obtained from the National 
Research Ethics Service Committee London - South East (project ID: 11/LO/1483) and 
Nanyang Technological University Institutional Review Board (project ID: IRB-2015-05-003) 
(See Appendix A1). All biopsies were obtained at the University College London Hospital, UK 
and the Royal Free Hospital London, UK. Preliminary laboratory analysis was performed at 
the Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, and 
the final analysis was performed at the University College London, UK under similar laboratory 
conditions. 
 
2.3.5 Participants Recruitment & Consent 
Participants were identified from the vascular outpatient clinic, waiting lists and medical 
records. Patients were offered participation in the research and given a written patient 
information sheet (see Appendix A2). This was followed by explanation on the aims, methods, 
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anticipated benefits and potential hazards of the study. Patients are given sufficient time 
(offered a minimum of 24 h) to consider whether they wish to participate before written 
informed consent was obtained (see Appendix A3). All patients were consented and enrolled 
by myself. A total of 18 months was taken to complete enrolment. 
 
2.3.6 Data collected 
Details on patient’s demographics, co-morbidities, CEAP classification, wound location, 
wound size and wound duration were recorded in the wound assessment form (see Appendix 
A4) prior to biopsy. This data was collected to correlate the clinical information with the 
histological analysis of the biopsy samples. Clinical photographs were often taken as part of 
routine care.   
 
2.3.7 Sample size calculation 
The sample size was determined through discussion with academic clinical (Professor Toby 
Richards, Professor Ash Mosahebi) and laboratory supervisors (Professor David Becker). 
Twelve patients per CEAP class for C0, C2, C4 and C6 were enrolled. The principle factors 
were pragmatic based on the number of patients that could be screened for inclusion. We 
considered technical difficulties of obtaining and using the biopsies (such as insufficient 
biopsies identified at time of microscopy). 
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2.4 Laboratory study protocol 
 
2.4.1 Biopsy preservation and cryosectioning 
All biopsies were fixed overnight in 4% paraformaldehyde, then transferred to 20% sucrose in 
phosphate buffered saline (PBS), and stored at 4PoPC until processing. Prior to cryosectioning, 
tissues were embedded in optimal cutting temperature (OCT) medium (BDH-Poole, UK) and 
stored at -20PoPC for 24 h. Frozen sections, 10 μm thick, were obtained using a Leica CM1900 
UV cryostat (Leica, Wetzlar, Germany).  
A pair of samples from C4, and another from C6, were damaged during the collection process 
and were not included in the final analysis. Samples included in the final analysis were as 
follows: C0 (n=12), C2 (n=12), C4 (n=11) and C6 (n=11).  
 
2.4.2 Haematoxylin and eosin (H&E) staining 
Cryosectioned slides were removed from -20PoPC freezer and placed in slide rack and left at 
room temperature (RT) for 1 min to allow the tissue to thaw and immediately immersed in 
Acetone for 10 min at -20P oPC to prevent drying. The slides were the placed in xylene for 1-2 
min and rehydrated by placing in 95% ethanol followed by 70% ethanol for 1 min each at RT 
and washed with purified water. Slides were then stained with Hematoxylin solution for 2 min 
and washed in purified water for 1 min. Slides were then washed with Scotts Tap Water for 1 
min and then washed with purified water for another minute. Slides were then dehydrated by 
placing in 70% and 90% ethanol for 1 min each before counter-staining with Eosin for 30 sec. 
Slides were then placed in 95% ethanol and 100% alcohol for 1 min and placed in xylene for 
5 min before left to air dry for 5 min in a hood. Mounting was then performed using DPX 
mounting medium and allowed to dry overnight in the hood before imaging.  
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2.4.3 Slide scanner 
Imaging for H&E was performed using a Zeiss AxioScan Z1 slide scanner at 20x magnification 
at the Division of Biosciences with the assistance of Mr Christopher Thrasivoulou. 
 
2.4.4 Histological analysis 
The average epidermal thickness was calculated by dividing the epidermal cross-sectional 
area by the average epidermal length. Measurements were performed using ImageJ 
(http://imagej.nih.gov/ij/). 
The number of epidermal rete ridges per millimetre were calculated using a selected section 
(1mm) of the epidermis that best represented the skin section. The average depth of the rete 
ridge was calculated by dividing the depth of each rete ridge along the selected area by the 
total number of rete ridges. The epidermal rete ridge depth was defined as the distance 
between the upper pole of stratum corneum and the rete ridge trough (Figure 2.2).  
 
Figure 2.2 H&E section of a skin illustrating rete ridge depth measurement 
 
2.4.5 Immunohistochemistry 
Tissue sections were thawed, immersed in PBS to dissolve excess OCT, permeabilized for 
15 min in 0.2% Triton X-100 and blocked using 0.1M lysine-PBS for 30 min to block non-
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specific binding. Primary antibodies were prepared in PBS: anti-Cx43 (1:4000; C6219, Sigma 
- Poole, UK), anti-Cx26 (1:200; 10202093, Fisher Scientific, UK), and anti-Cx30 (1:200; 
10795723, Fisher Scientific, UK). The tissues stained for Cx43 were incubated with the 
primary antibody for 1h at RT, while tissues stained for Cx30 and Cx26 were incubated with 
the primary antibody overnight at 4PoPC. For negative controls, the primary antibody was omitted 
from the preparation. The tissues were washed with PBS for 3 x 5 min and stained with 
secondary antibody (Alexa Fluor 488 goat anti-rabbit, 10729174, 1:400; Fisher Scientific, UK) 
at RT for 1h. Nuclei were stained using Hoechst (1:10000; 10150888, Fisher Scientific, UK) 
for 5 min followed by 3 x 5 min PBS washes. Coverslips were mounted using Citifluor 
(Glycerol/PBS solution, Citifluor Ltd, London, UK) and sealed with nail varnish.  
 
2.4.6 Confocal microscopy 
A Leica TCS SP8 confocal microscope (Leica, Mannheim, Germany) (Figure 2.3) was used 
to obtain 40x images of the epidermis. The 4mm biopsies were examined across their 
diameter at six locations: Hoescht was excited by a 405nm laser and Alexa Fluor 488 by a 
488nm laser. Six images per biopsy were taken to ensure that the staining pattern observed 
truly represented the distribution of the protein of interest (Figure 2.4). All parameters were 
kept constant between the patient’s control and pathological skin sections to allow direct 
comparison.  
 
Figure 2.3 Leica TCS SP8 Confocal Microscope used for imaging  
52 
 
Figure 2.4 Confocal image of the epidermis 
(A) Confocal image of an entire skin section. High magnification images were taken at six 
random locations (as represented by the white boxes) along the epidermis to quantify the 
absolute Cx expression.  Scale bar = 500µm. Magnification 10x. (B) High magnification images 
were used to quantify the Cx levels. Connexins were stained green (excited with 488nm laser) 
while the nuclei were stained blue (excited with 405nm laser). Scale = 25µm. Magnification 
40x. 
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2.4.7 Connexin quantification 
ImageJ was used for Cx quantification. Each image was converted to binary images (black 
and white) using an identical threshold. Epidermal threshold was kept constant between all 
images, being set at 80, with a recognised pixel threshold size of 2-infinity used for all 
images[36]. Regions of interest were manually marked to selectively include the epidermis 
only, excluding any areas of auto-fluorescence in the stratum corneum.  
The Cx levels from the six confocal images from each tissue section were used to quantify the 
mean Cx expression. This data was presented as ‘absolute connexin expression’, which was 
used for statistical analysis and presented in graphs. The corresponding fold-increase data, 
comparing the Cx expression in the pathological and control skin, was presented in a table as 
‘mean fold increase’. This was based on each individual’s fold difference between the 
pathological skin section to their matched control, following which the mean fold difference for 
each group was calculated. 
Mean Cx expression per cell was calculated by the ratio of the overall Cx expression to the 
corresponding number of nuclei present in each tissue section. The average Cx expression 
per cell was compared between groups. 
 
2.4.8 Statistical analysis 
All data were presented as mean ± standard deviation. Statistical differences were determined 
using paired t-test for paired group and independent t-test for two unpaired groups. For more 
than two groups, one-way analysis of variance (ANOVA) test, followed by post-hoc Bonferroni 
test for multiple comparisons, was applied. The relationship between the Cx protein 
expression in the pathological and control skin was tested by Pearson correlation. Significance 
was taken at values p<0.05. Normality testing was performed using Shapiro-Wilk test; the Cx 
expression was normally distributed in each class. All statistical analyses were performed 
using IBM SPSS Statistics 22 software.   
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3.0 An observational study of Connexin protein expression in patients with 
venous disease 
 
3.1 Chapter summary 
 
We investigated the expression pattern of GJP, Connexin (Cx), a known biomarker of poor 
wound healing, across stages of venous disease. Patients undergoing intervention for VV 
were assessed according to CEAP classification: C0(n=12), C2(n=12), C4(n=12), and 
C6(n=12). Paired 4mm punch biopsies were taken from above the ankle (pathological) and 
above the knee (control). Tissues were stained for H&E, Cx43, Cx30, and Cx26. The 
pathological skin revealed progressive epithelial hyper-thickening, increase in the number and 
depth of rete ridges, increased inflammation and loss of dermal architecture with disease 
progression from C4 onwards. The overall absolute Cx expression and mean Cx expression 
per cell in the pathological skin similarly increased across the CEAP from as early as C2. 
Increasing levels of Cx in the control skin was also seen, indicating the progression of the 
disease proximally. Elevated Cx43 expression had the strongest positive correlation between 
the pathological and control skin. Cxs were overexpressed as early as C2, suggesting that 
skin is preconditioned by VV for poor wound healing. The stepwise sequential increase in 
Cx43, prior to histological changes, suggest that it is a sensitive biomarker for poor wound 
healing and ulceration. Our finding suggests that VV predisposes skin to poor wound healing, 
indicating a need for early surgical intervention to prevent ulceration.   
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3.2 Aim 
 
This chapter aims to observe the expression pattern of the principal epidermal Cx proteins 
across the CEAP classification in patients with venous disease to better understand the early 
skin changes and the expression of these proteins in the pre-wounded skin.  
As described in chapter two, patients undergoing intervention for VV were assessed according 
to CEAP classification: C0(n=12), C2(n=12), C4(n=12), and C6(n=12). Paired 4mm punch 
biopsies were taken from above the ankle (pathological) and above the knee (control). Tissues 
were stained for H&E, Cx43, Cx30, and Cx26.   
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3.3 Results 
 
3.3.1 Patient demography 
A total of forty-eight patients were enrolled into this study. The average age was 59.2 ± 17.5 
years (range: 32-89 years). The demographic data is summarised in Table 3.1 below.  
 
 
Table 3.1 Patient demography 
Table shows the overall mean age, the mean age for patients in each CEAP class, and the 
overall gender breakdown. Values represent mean ± standard deviation.  
  
Overall mean age (years) 66.1 ± 21.1 (range: 32-89 years) 
Mean age per class (years) 
CO 
C2 
C4 
C6 
 
63.6 ± 11.5 
44.4 ± 9.0 
57.1 ± 13.1 
77.3 ± 10.1 
Overall Gender 
Male 
Female 
 
22 (45.8%) 
26 (54.1%) 
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3.3.2 Histological features of skin with disease progression 
The histology of the pathological skin revealed distinct and consistent features within each 
CEAP class. A progressive change in structure is seen with disease severity: progressive 
epithelial hyper thickening, increase in the depth and number of epidermal rete ridges, 
increase in inflammatory cells, and loss of dermal architecture in the upper dermis (Figure 3.1, 
next page). The most prominent change observed was the increase of the epithelial thickness 
at C6. The number of rete ridges per millimetre of the epidermis was, however, significantly 
increased in the pathological skin as early as C2 and the depth was significantly increased 
from C4 onwards. This was accompanied by the loss of dermal architecture.  
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Figure 3.1 Epithelial thickness 
(A) Haematoxylin and eosin-stained section of the skin section for each CEAP class. The 
mean epithelial thickness of each CEAP class is indicated at the bottom of the image. Scale 
bar = 200µm. Magnification 20x. Bar charts show the (B) mean epithelial thickness, (C) 
number of epidermal rete ridges, and (D) depth of epidermal rete ridges in each CEAP class. 
Values represent mean ± standard deviation. *P<0.05 (paired t-test) 
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3.3.3 Epidermal Cx proteins overexpression 
The overall absolute Cx expression for Cx43, Cx30 and Cx26 in the pathological skin were 
similarly increased across the CEAP class (Figure 3.2, Figure 3.3, Figure 3.4). The 
overexpression of the Cxs in C6 has been previously described [36]. Interestingly, here we 
note that the principal epidermal Cxs were significantly overexpressed as early as C2 and C4. 
No significant overexpression was noted at C0. Cx43 had the highest expression in each 
class. Cx30 had lesser expression in C0, C2 and C4 but increased significantly in C6, as did 
Cx26.  
The mean Cx expression per cell in the epidermis corresponds to the trend of the absolute Cx 
expression across the CEAP class. A significant overexpression of the mean Cx per cell was 
observed as early as C2 for all three Cxs. No significant difference was noted in the Cx 
expression per cell between the control and pathological skin in C0. 
An increasing trend of Cx expression was also observed in the control skin across the CEAP 
class, suggesting the progression of the disease proximally. A significant increase of Cx43 
expression in the control skin was seen from C4 onwards: C4 vs C0 (p<0.001) and C6 vs C0 
(p<0.001). No significant difference was noted between C4 vs C6. For Cx30, significant 
difference was only observed between C4 vs C0 (p=0.003); while for Cx26, significant 
difference was only observed between C6 vs C0 (p<0.001). 
Compared to the control skin, Cx proteins were overexpressed multiple fold higher in the 
pathological skin (Table 3.2).  Cx 26 and Cx30 had a greater mean fold increase compared to 
Cx43 as they were expressed at relatively lower levels in the control skin at each CEAP class.  
There was a striking and significant 431-fold and 38-fold increase in Cx30 and Cx26 at C6. In 
contrast, Cx43 was elevated by an average of 6-fold at C6. 
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Figure 3.2 Connexin 43 expression across the CEAP classification 
(A) Confocal images of Cx43 expression in each group. Scale bar = 50µm. Magnification 40x. 
(B) Mean absolute Cx expression. (C) Mean Cx expression per cell for each CEAP class. 
Values expressed as mean ± standard deviation. *P<0.05 (paired t-test) 
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Figure 3.3 Connexin 30 expression across the CEAP classification 
(A) Confocal images of Cx30 expression in each group. Scale bar = 50µm. Magnification 40x. 
(B) Mean absolute Cx expression. (C) Mean Cx expression per cell for each CEAP class. 
Values expressed as mean ± standard deviation. *P<0.05 (paired t-test)  
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Figure 3.4 Connexin 26 expression across the CEAP classification 
(A) Confocal images of Cx26 expression in each group. Scale bar = 50µm. Magnification 40x. 
(B) Mean absolute Cx expression. (C) Mean Cx expression per cell for each CEAP class. 
Values expressed as mean ± standard deviation. *P<0.05 (paired t-test) 
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C0 C2 C4 C6 
Connexin 43 2.03 ± 2.04 2.06 ± 0.76 2.12 ± 0.72 6.52 ± 3.66 
Connexin 30 3.03 ± 1.50 3.50 ± 2.24 4.92 ± 4.72 431.80 ± 614.74 
Connexin 26 2.27 ± 1.94 2.04 ± 2.85 0.80 ± 3.39 38.14 ± 55.48 
 
Table 3.2 Mean fold increase of the Cx proteins in the pathological skin compared 
to control skin 
Table shows the mean fold increase of Cx43, Cx30 and Cx26 expression in the pathological 
skin compared to control skin in each CEAP class. Compared to the control skin, the Cx 
proteins were overexpressed multiple fold higher in the pathological skin. Cx 26 and Cx30 had 
a greater mean fold increase compared to Cx43 as they were expressed at relatively lower 
levels in the control skin at each CEAP class. Values represent mean ± standard deviation, 
corrected to second decimal place. 
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3.3.4 Distribution pattern of Cx proteins with disease progression 
Cx43 was generally expressed in all layers of the epidermis with the highest intensity in the 
stratum spinosum and lowest intensity in the stratum basale (Figure 3.2, above). The 
expression pattern changed with disease progression; in C2 and control, the highest 
expression was seen along the upper portion of the stratum spinosum, in C4, Cx43 was 
expressed further down the stratum spinosum, approaching the stratum basale, and in C6, 
Cx43 was expressed throughout the epidermis, producing a “fish scale” pattern. 
Similar to Cx43, Cx30 was expressed throughout the epidermis in C6 (Figure 3.3, above). The 
expression of Cx30 in C0, C2, C4, and control skin was, however, very weak and sporadic. 
Although expressed with low intensity, it was visible along stratum spinosum and granulosum. 
Despite no noticeable difference in the distribution pattern in the pre-wounded skin, the 
intensity was higher in C4. The temporal and spatial expression pattern of Cx26 was similar 
to Cx30 throughout the four classes (Figure 3.4, above).  
 
3.3.5 Correlation of the Cx protein expression between the pathological and control 
skin 
Compared to the expression pattern of all the Cx proteins, Cx43 had the strongest positive 
correlation between the expression in the pathological skin and control skin (r=0.63, p=0.001) 
(Figure 3.5). This suggests that Cx43 expression increases steadily with the disease 
progression.  
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Figure 3.5 Correlation of absolute Cx proteins expression  
Pearson’s correlation of the absolute Cx proteins expression in the pathological skin versus 
control skin. 
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3.4 Discussion 
Cx proteins were previously shown to be upregulated in diabetic ulcers, pressure ulcers and 
VLUs[36]. Here, we sought to understand the expression pattern of the principal epidermal Cx 
proteins across the stages of venous disease, especially in pre-wounded skin. We 
demonstrated that there is a stepwise sequential increased expression in the principal 
epidermal Cx proteins as early as C2. This finding likely suggests that VVs predispose skin to 
poor wound healing and increase the risk of future ulceration. This is the first time it has been 
shown that VVs, even as early as C2, are associated with poor wound healing. Additionally, 
our finding suggests that Cx43 is a sensitive biomarker of venous disease progression. These 
findings support a conclusion that treating VV early, to improve circulation, could help prevent 
future ulceration.  
Cx43 upregulation in VLUs has been implicated in impaired keratinocyte migration and poor 
wound healing[34]. The negative effect of the Cx protein overexpression on cellular migration 
is mediated by both gap-junctional intercellular communication and non-junctional mediated 
effects. Cx proteins act as nexus interacting with adhesion molecules, tight junctions and 
cytoskeletal components via the long cytoplasmic C-terminal tail, either directly or via 
adaptors[34, 44, 45]. An increase of Cx43 by one-fold was shown to halve cellular 
migration[34]. The striking multiple-fold increase that we observed in C6 could have a profound 
negative effect on healing. Despite increased absolute Cx levels at C2 and C4, the fold-
increases were comparable to that of C0. This is due to the increased Cx levels in the control 
skin at C2 and C4, signifying the clinical progression of the disease from the distal to proximal 
part of the lower limb. These skin changes, secondary to venous hypertension, were 
previously not known to extend proximally as the clinical signs are confined to the medial-
distal aspect of the lower limb. The Cx upregulation identified here suggests that skin is 
preconditioned to poor wound healing and this extend proximally with disease progression. 
This finding advances our understanding on the pattern of Cx overexpression, which, in the 
context of VLUs, was previously thought only to be a feature of wound chronicity.   
68 
Cx30 and Cx26 were previously only known to be overexpressed at the wound edge and 
hyperproliferative skin disease. The persistent Cx26 overexpression maintains a hyper-
proliferative state, slowing down healing, stalling the transition to the remodelling stage, and 
leads to immune cell infiltration[76]. We found that Cx30 and Cx26 in the pre-wounded skin 
were expressed in low levels, but were significantly overexpressed after wounding. The 
observed upregulation at C2 and C4, which were also related to epidermal hyper-thickening, 
suggests that the overexpression takes place prior to wounding, contributing to the chronicity 
of non-healing VLUs.  
We observed early histological changes at C2 and C4. The increase in the number and depth 
of the rete ridges indicates that perfusion of the epidermis is compromised secondary to the 
recurrent ischaemia-reperfusion cycle; a consequence of venous hypertension. The avascular 
epidermis is entirely dependent on the highly-vascularised dermis for perfusion. The 
hypoperfusion in the superficial vessels (nutritive vessels) which happens concurrently with 
hyperperfusion in the deeper vessels (shunt vessels) stimulates the epidermis to project 
further into the dermis for perfusion[77]. The increase in epidermal thickness and worsening 
hypoperfusion could ultimately result in skin breakdown at C6; a consequence of imbalance 
between supply and demand.  
The chronic inflammation seen in C4 has been previously reported by several studies, which 
documented the presence of inflammatory cells in the skin of patients with 
lipodermatosclerosis and venous ulcer [12]. The exact mechanism that triggers this chronic 
inflammation remains unclear, however, it had been hypothesised to occur due to leukocyte-
trapping and neutrophil activation secondary to ischaemia-reperfusion cycles, a consequence 
of venous hypertension [4, 12]. This also leads to leukocyte sequestration, and upon 
reperfusion as seen with leg elevation, the leukocytes are activated and release reactive 
species causing further oxidative damage to the ischemic tissue[78, 79]. This cycles could 
lead to hypoxia though it is not known if prolonged hypoxia is the trigger of this sterile 
inflammation.  
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This study has several limitations. Ultrasound duplex assessment was not performed for the 
patients in the C0 group although the prevalence of venous reflux in the general population is 
estimated to be about 20 percent[80]. Patients were, however, clinically assessed to ensure 
absence of signs of venous disease. In patients with leg ulceration (C6), some (segmental) 
deep venous reflux was seen in 4 of 12 patients. However, there was no difference in the 
distribution pattern or expression intensity of Cx observed within these patients.  Additionally, 
a formal sample calculation was not performed as the difference in Cx expression between 
the CEAP classes was previously not known, and this is the first time that it has been 
established that Cxs were overexpressed prior to wounding.  
 
3.5 Conclusion 
This is the first study to show that the presence of VV is associated with elevated Cx levels, 
likely suggesting that skin is preconditioned for poor wound healing prior to ulceration. The 
cellular and structural changes correlate with the clinical stage of the disease. Our data 
suggests that treating VVs early could prevent future ulceration. 
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Part 2  
 
  
71 
 
Summary of Part 2 
In this part, I have used GJP to explore the mechanism of healing of a novel technology in 
wound healing involving epidermal grafting. In order to do this, I have first conducted a 
systematic review using Cochrane methodology and a descriptive review on the mechanism 
of wound healing by epidermal graft. I then performed a pilot case series to evaluate the 
feasibility of using this technology in the outpatient setting, which was followed by a cost 
analysis study and patient reported outcome measure. Combining all these data, I then 
designed a randomised controlled trial (RCT) with a translational component to evaluate the 
efficacy and mechanism of healing of this technology against the current standard of care. 
Within this RCT, I have employed GJP to explore the mechanism of action of epidermal grafts. 
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4.0 Systematic review and mechanistic review of epidermal grafting for wound 
healing 
 
4.1 Systematic review of epidermal grafting for wound healing 
 
4.1.1 Chapter summary 
 
Epidermal grafting (EG) enables epidermal transfer to the wound with minimal donor site 
morbidity. However, data to date has been heterogeneous. This study aims to synthesise the 
current evidence on EG for wound healing to establish the efficacy of this surgical technique. 
A comprehensive search in the MEDLINE, EMBASE and CENTRAL database was conducted 
from 1946 until November 2015. The endpoints assessed were; proportion of wounds healed 
and mean wound healing time. This systematic review was conducted and reported according 
to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines. We 
identified 1088 articles, of which 6 articles were included in this review; a total of 126 wounds 
in 107 patients. The mean wound duration was 48.39 weeks (95 percent c.i. 3.35 to 69.88). 
Of these, 57.0 percent (95 percent c.i. 36.0 to 76.7) of the wounds achieved complete healing. 
Mean time for complete wound healing was 4.87 weeks (95 percent c.i. 2.57 to 9.27). The 
mean donor site healing time was 7.25 days (95 percent c.i. 4.9 to 12.54), with no reported 
donor site morbidity. The current data are small and lacks level 1 evidence.  
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4.1.2 Introduction 
Wound care presents a significant financial and resource burden to the healthcare system, 
reported to account for over 5 percent of National Health Service (NHS) expenditure. Between 
£2⋅3–£3⋅1 billion is spent in caring for patients with chronic wounds in the United Kingdom 
alone [9]. Chronic wounds account for a burdening problem with over 100,000 new ulcers 
anticipated every year, with an ageing population and rising prevalence of obesity and 
diabetes.  
In most cases management is conservative, by wound care and dressings. Intervention by 
autologous skin grafting is an important modality for wound coverage [35]. Skin grafting can 
be classified based on the thickness of the harvested skin (Figure 4.1), namely, full thickness 
skin graft (FTSG), split thickness skin graft (SSG) and epidermal graft (EG) [81, 82]. 
 
 
Figure 4.1 Illustration of the skin layers involved in autologous skin graft harvest. 
 
FTSG consists of the epidermis and the entire dermis of the skin. FTSG is normally reserved 
for smaller wounds as the donor site must be closed primarily. Thus, only selected areas with 
sufficient skin laxity is suitable for skin harvest, commonly the retroauricular area, 
cervicopectoral area, and groin [35]. Larger areas can be managed by SSG which involves 
shaving the epidermis and part of the dermis of the skin. This is best performed by an electric 
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air dermatome and the donor site regenerates by secondary intention from the residual 
reticular dermis [35]. SSG is the commonest form of autologous skin grafting performed and 
can be meshed to cover a wide surface area. A major consideration for SSG is that the donor 
site may itself develop as a second, often painful wound, which may take more time to heal 
than the graft site itself and holds the risk of infection and scarring [83]. Both the FTSG and 
SSG often require hospital admission, even as a day case, anaesthesia, and a period of 
immobility for some patients. 
EG, on the other hand, is an emerging and promising option. EG involves harvesting only the 
epidermal layer of the skin from the donor site by applying continuous negative pressure on 
the normal skin to raise blisters. The roof of the blister, which is the epidermis, is then excised 
and transferred onto the wound. As the dermis in the donor site remains untouched, the skin 
regenerates itself without scar. This procedure is also often painless as the pain fibres in the 
dermis are unstimulated, allowing autologous skin grafting in the outpatient setting without 
administration of anaesthesia and with minimal donor site morbidity [84]. 
The use of EG for wound healing has been on the rise of late, with several recent publications 
in the last couple of years. However, data to date has been heterogeneous on the outcome 
and on when and in which patient group this surgical technique should be employed. This 
systematic review synthesises the current evidence on EG for wound healing to establish the 
efficacy of this technique in the clinical setting, by measuring the proportion of wounds healed 
and the mean wound healing time. It is timely that the evidence is assessed to guide clinical 
decision making and to further facilitate future research. 
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4.1.3 Materials and methods 
 
The protocol for this systematic review was registered with the PROSPERO international 
prospective registration of systematic reviews (registration number: CRD42016033051) (see 
Appendix B1), and a detailed protocol was peer reviewed and published [85]. There was no 
deviation from the published protocol. This systematic review was conducted and reported 
according to the Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines 
[86].  
 
4.1.3.1 Search strategies  
We searched the MEDLINE (OvidSP), EMBASE (OvidSP), and Cochrane Central Register of 
Controlled Trials (CENTRAL) database from 1946 until November 2015 to identify studies of 
relevance to this review. The search strategy included a combination of text words and Medical 
Subject Headings (MeSH) terms relating to the use of EG for treating wounds. No language 
or publication restrictions were applied. The reference list of all articles included were cross-
checked for further articles of relevance. A sample search strategy for MEDLINE (OvidSP) is 
shown and similar strategy was adapted for other databases.  
1. [epidermal graft*] OR [blister graft*] OR [suction blister*] OR [suction graft*] 
2. Epidermis/su, tr [Surgery, Transplantation] 
3. [1] or [2]  
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4.1.3.2 Inclusion criteria 
The inclusion criteria used were: (i) studies involving adult patients above 18 years old; (ii) EG 
for wound healing; (iii) English language; (iv) available information containing at least the 
following: number of subjects, method of EG harvest, and healing time.  
 
4.1.3.3 Exclusion criteria 
The exclusion criteria were: case reports or case series of lesser than five patients; studies 
describing the use of EG in skin pigmentation disorder such as vitiligo; studies combining EG 
with other treatments such as stem cells or dermal substitutes; and studies describing only 
the harvest technique without treatment outcome. 
 
4.1.3.4 Outcome measures 
The primary efficacy outcome measures were the proportion of wounds healed and the mean 
wound healing time (time for complete healing). Secondary outcome measures were the mean 
donor site healing time, need for anaesthesia, economic evaluation based on the cost 
associated with resources used, health-related quality of life, and proportion of patients with 
adverse event. Subgroup analysis was performed for the proportion of wounds with complete 
healing based on the wound aetiology.  
 
4.1.3.5 Study selection 
The retrieved articles’ titles and abstracts were scanned for potential eligibility, using the 
predetermined selection criteria, after excluding duplicate records. Full-text review was 
undertaken for studies that met the inclusion criteria. Abstracts and conference proceeding 
without full text were not included because of the difficulty in evaluating incomplete 
information. Ongoing trials without complete data were not included. 
78 
4.1.3.6 Data extraction 
Data from all full-text articles accepted for final analysis were independently retrieved by two 
authors (Mr Oliver Smith and myself) using a standardised data extraction form. Discrepancies 
were resolved by discussion. The following data were extracted: study characteristics (first 
author, year of publication, country, study design), patient demography (number of studied 
subjects, sex, mean age, comorbidity, number of wounds treated), wound characteristics 
(wound aetiology, mean wound duration, mean wound size, pre-grafting wound quality), 
characteristics of EG harvest technique, use of anaesthesia, outcomes (wound healing time, 
number and type of wounds with 100 percent healing, number of wounds with 50-99 percent 
healing, number and type of wounds failed to heal, donor site healing time), and complications 
or adverse events. Data were extracted from the studies as presented or were calculated (e.g.: 
mean age and mean wound size).  
 
4.1.3.7 Assessment of risk of bias of included studies 
A formal risk of bias assessment was not performed as the included studies were mostly small 
case series.  
 
4.1.3.8 Data analysis and synthesis 
The main outcome measures of the included studies were the pooled estimate of the 
proportions of wounds healed, the mean wound healing time, and the mean donor site healing 
time with the corresponding 95 percent confidence intervals (c.i.). Meta-analysis of proportion 
was performed for the proportion of wounds healed. Meta-analysis of summary was performed 
for the mean wound and donor site healing time, mean wound size, mean wound duration and 
mean age of the patients. The clinical and methodological heterogeneity were assessed. 
Random effects model was used for the pooled estimates as the included studies 
demonstrated high clinical and statistical heterogeneity[87]. The outcomes were analysed 
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using StatsDirect Statistical software (StatsDirect statistical software, version 2.8.0; 
StatsDirect, Altrincham, UK).  
 
4.1.4 Results 
 
4.1.4.1 Literature search results 
We found 1088 articles in the MEDLINE database search, 946 articles in the EMBASE 
database search, and 271 articles in the CENTRAL database search. References from these 
three searches were combined and after removing the duplicates, 1541 articles were available 
for title and abstract reviewing. Of these, 1373 articles did not meet the inclusion criteria and 
were excluded. Following full text review of the remaining 168 articles, 162 articles were 
excluded as the inclusion criteria was not met. A total of 6 articles were included and formed 
the basis of this systematic review [88-93] (Figure 4.2). Cross-checking of the reference list 
revealed that no article was missed by the initial search. Details of the included studies are 
summarised in Table 4.1.  
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Figure 4.2 Flow diagram of literature search 
 
  
Records after duplicates removed  
(n = 1541) 
Records excluded  
(n = 1373) 
Full-text articles 
assessed for eligibility  
(n = 168) 
Full-text articles excluded, 
with reasons  
(n = 162) 
animal model = 1 
blister fluid analysis = 2 
case report <5 cases = 6 
chemical separation of 
epidermis/non-suction harvest = 1 
conference proceeding = 2 
donor site healing = 16 
histology = 3 
non-english = 4 
vitiligo = 98 
other skin diseases = 4 
technical description = 24 
tissue engineering = 1 
 Studies included in 
qualitative synthesis  
(n = 6) 
Records screened  
(n = 1541) 
Records identified through 
database searching  
(n = 2305) 
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Citation Hentzer B 
et al, 
1975[90] 
Costanzo 
U et al, 
2006[88] 
Hanafusa 
T et al, 
2008[89] 
Gabriel A 
et al, 
2014[91] 
Richmond 
NA et al, 
2014[92] 
Serena T et 
al, 2015[93] 
Year 1975 2006 2008 2014 2014 2015 
Country Denmark Switzerland Japan USA USA USA 
Study type Case series Case series Case series case series Case 
series 
Case series 
Number of 
patients 
12 18 61 4 5 7 
Male N/R 5 N/R    
Mean age (year) N/R 76.5 I/R 50.25 50 45.6 
Number of 
wounds 
12 29 69 4 5 7 
Mean wound     
  duration 
(week) 
N/R 21±178.7 I/R 106.5±178.
7 
65.6 ± 
72.38 
105.6 ± 
121.67 
Average wound 
size  
  (cm P2P) 
N/R 6.70 ± 5 27.80 ± 
7.10 
N/R 9.56 ± 
10.03 
30.29 ± 
16.07 
Epidermal graft        
  harvesting  
  technique 
          
Device Suction 
device 
Dermovac® 
Suction 
device 
Dermovac® 
Syringe  CelluTome CelluTome CelluTome 
Negative 
pressure 
(mmHg) 
250-300 
mmHg 
200-300 N/R 400-500 400-500 400-500 
Duration 1-2 h 2 to 3 h 16-128 min 35-45 min N/R 25-35 min 
Use of 
anaesthesia 
No No LA in 27 
patients 
No No No 
Donor site 
dressing 
N/R Antiseptic 
cream and 
gauze 
N/R N/R N/R N/R 
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Wound site 
dressing 
Gauze + 
wet 
dressing 
with 2% 
boric acid. 
Non-
adherent 
dressing 
(Sofra-
Tulle), 
gauze, 
compressio
n bandage 
N/R Gauze + 
occlusive 
dressing 
(n=3), 
foam + 
occlusive 
dressing 
(n=1) 
Absorbent 
foam 
dressing 
and 4-layer 
compressio
n bandages 
Adhesive 
dressing + 2 
layered 
compression 
bandage 
Wounds with  
  complete 
healing 
10 16 18 3 3 1 
Duration for  
  complete 
healing (week)  
2 ± 1.98 3.6 ± 1.98 8.3 ± 0.9 N/R 8 ± 2.94 4  
Wounds with 
50-   
  99% healing 
1 10 N/R 1 2 5 
Number of 
failure 
1 3 N/R 0 0 1 
Donor site 
healing 
10 days N/R N/R 1-2weeks 1 week 3-4days 
Legend:  N/R=Not reported I/R=Incomplete reporting LA=local anaesthesia 
Table 4.1 Overview of the included studies 
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4.1.4.2 Wound healing outcome 
A total of 126 wounds in 107 patients were treated with EG, with the average wound size of 
10.98 cmP2P (95 percent c.i. 2.58 to 46.73). The mean age of the patients was 67.53 years (95 
percent c.i. 29.75 to 153.31). The mean wound duration of the 45 reported wounds was 48.39 
weeks (95 percent c.i. 3.35 to 69.88). 
The number of wounds that achieved complete wound healing was reported in five studies 
involving 57 wounds. The proportion of wounds that achieved complete healing was 57.0 
percent (95 percent c.i. 36.0 to 76.7) (Figure 4.3), with the mean time for complete wound 
healing of 4.87 weeks (95 percent c.i. 2.57 to 9.27) (Figure 4.4).  
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Figure 4.3 Proportion of wounds with complete healing 
Meta-analysis of proportion of wounds with complete healing (random-effects plot). 
Proportions are shown with 95 per cent confidence intervals. 
  
Proportion meta-analysis plot [random effects]
0.0 0.2 0.4 0.6 0.8 1.0
combined 0.570 (0.360, 0.768)
Richmond NA et al, 2014 0.600 (0.147, 0.947)
Serena T et al, 2015 0.143 (0.004, 0.579)
Gabriel A et al, 2014 0.750 (0.194, 0.994)
Costanzo et al, 2006 0.552 (0.357, 0.736)
Hentzer B et al, 1975 0.833 (0.516, 0.979)
proportion (95% confidence interval)
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Figure 4.4 Time for complete healing 
Meta-analysis of summary of time for complete wound healing (random effect plot). Sumaries 
are shown with 95 per cent confidence intervals. 
 
  
Summary meta-analysis plot [random effects]
0.2 0.5 1 2 5 10 100 1000
combined 4.88 (2.57, 9.27)
Serena T et al, 4.00 (0.56, 28.40)
Richmond NA et 8.00 (0.29, 222.81)
Hanafusa T et al, 2008 8.30 (5.48, 12.58)
Costanzo et al, 2006 3.60 (1.36, 9.50)
Hentzer B et al, 1975 2.00 (0.59, 6.82)
odds ratio (95% confidence interval)
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EG was used to treat wounds of various aetiologies, duration and size. The following wide 
range of wounds were treated: venous ulcer (n=34), arterial ulcer (n=2), mixed arteriovenous 
ulcer (n=3), diabetic ulcer (n=7), vasculitis (n=9), trauma (n=2), burns (n=1), pyoderma 
granulosum (n=5), and lymphoedema (n=1) (Table 4.2). Most of the treated wounds were 
chronic wounds (more than or equal to three months in duration), except for 13 wounds that 
were acute wounds (less than three months in duration). All treated diabetic foot ulcer, arterial 
ulcer, trauma and burns wounds achieved complete healing. Wounds of other aetiologies 
demonstrated a lower success rate.  
 
Table 4.2 Healing by wound aetiology 
  
Wound aetiology 
Number 
treated 
Completely 
healed wounds 
Percentage healed (%) 
Diabetic foot ulcer 7 7 100.00% 
Burn 1 1 100.00% 
Arterial 2 2 100.00% 
Trauma 2 2 100.00% 
Venous 34 33 97.06% 
Mixed 3 2 66.67% 
Pyoderma granulosum 5 3 60.00% 
Vasculitis 9 5 55.56% 
Lymphatic 1 0 0.00% 
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Partial healing of between 50-99.9 percent healing was achieved by 34.8 percent (95 percent 
c.i. 17.6 to 54.4) of the wounds within the follow up duration while failure or no healing (0-49.9 
percent healing) was reported in 10.9 percent (95 percent c.i. 4.4 to 19.8) of the wounds. The 
failures were mainly attributed to wound infection. There was lack of reporting on the time for 
partial healing and there was no consistency in the follow up duration in the included studies.  
 
4.1.4.3 Donor site healing 
Three different EG harvesting systems were used: Dermovac (Oy Instrumentarium, Helsinki, 
Finland), syringe system, and CelluTome Epidermal Harvesting System (Acelity, San Antonio, 
Texas) (Figure 4.5).  
 
Figure 4.5 EG harvesting systems used. 
(A) Dermovac harvesting system. Figure reproduced from Kiistala U et al., 1967. (B) Syringe 
system. Figure reproduced from Yamaguchi Y et al., 2004 (C) CelluTome Epidermal 
Harvesting System. Figure reproduced from Hachach Haram N et al., 2016. 
 
Although these systems harvest different sizes of grafts, they share the similar harvest 
principle that applies continuous negative pressure on normal skin to raise blisters. The donor 
site healing time was reported in five studies involving 28 patients, whereby one study used 
the Dermovac system while two studies used the CelluTome Epidermal Harvesting System.  
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The pooled mean donor site healing time was 7.25 days (95 percent c.i. 4.9 to 12.54). The 
donor site healing time of the CelluTome Epidermal Harvesting System alone, which is the 
latest EG harvesting system, is 5.71 days (95 percent c.i. 2.76 to 11.77). The Dermovac 
system, which raises blisters measuring 5-15 mm, has a donor site healing time of 10 days 
[90].  
Hentzer et al. reported slight diffuse pigmentation at the donor site while Costanzo et al. 
reported occasional hypopigmentation by the Dermovac system, but all donor sites healed 
without scar [88, 90]. The donor site healing time and quality of the donor site healing by the 
syringe system was not reported by any of the included studies.  
 
4.1.4.4 Use of anaesthesia 
Only one study reported on the use of local anaesthesia during graft harvest which used the 
syringe system. In this retrospective study, Hanafusa et al. compared pain during harvest 
using syringes of different sizes (5ml, 10ml and 20ml) with and without the use of anaesthesia 
[89]. Pain at graft harvest was eliminated among patients that received local anaesthesia 
(n=27), while 50 percent of patients (n=34) without local anaesthesia felt pain. However, the 
pain severity at harvest was not reported using a validated pain measurement scale. By 
contrast, the CelluTome Epidermal Harvesting System and the Dermovac system, which 
harvests multiple small blisters, were reported to be painless even without the administration 
of local anaesthesia although this was also not reported using a pain measurement scale.  
 
4.1.4.5 Cost, quality of life and adverse events 
None of the included articles measured the health-related quality of life or patient satisfaction. 
The economic evaluation of the various harvesting systems was also not reported. No adverse 
events were reported in any study. 
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4.1.5 Discussion 
 
The aim of this systematic review was to evaluate the efficacy of epidermal grafting for wound 
healing. We found 6 articles, no RCTs exist now. The current evidence on the efficacy of 
epidermal grafting involves small case-series with huge heterogeneity in the study population.  
We found that complete healing was achieved by 57.0 percent (95 percent c.i. 36.0 to 76.7) 
of the wounds with the mean time for complete healing of 4.87 weeks (95 percent c.i. 2.57 to 
9.27). None of the studies compared the healing outcome with conservative management or 
SSG, which are the current standard of care.  The average time for complete donor site healing 
was 7.25 days (95 percent c.i. 4.9 to 12.54), with no reported donor site morbidity. EG was 
performed on wounds of various aetiologies, duration and size. The diabetic foot ulcer, arterial 
ulcer, trauma and burn wounds achieved complete healing while the other wounds had low 
success rate. Despite demonstrating the wide applicability of this technique, there was lack of 
consistency in between studies to make a strong recommendation on the type of wound that 
would best benefit from this treatment. The broad heterogeneity in between studies with large 
variation in the wound aetiology, patient demographic and harvest technique resulted in a 
huge difference in the wound healing outcome in between studies, leading to an overall 
success rate of just over 50 percent. 
Although the success rate of EG in direct comparison to SSG is yet to be known, the lack of 
donor site morbidity and the ability to perform this procedure in the outpatient setting without 
the use of local anaesthesia are major advantages this technique offers over conventional 
techniques. The mechanism of healing between EG and SSG is expected to be different, 
whereby EG is expected to behave more like a bioactive dressing which stimulates the wound 
bed to regenerate (reviewed in the next section of this chapter). The difference in the success 
rate between the various wound aetiologies suggest that the EG is sensitive to the 
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microenvironment of the wound. This also suggests that post grafting wound care should be 
specific to the wound aetiology.  
The various EG harvesting systems used in the included studies varied in the amount of 
negative pressure generated and the size of graft harvested despite relying on the similar 
principle. The EG harvesting system that was most widely used in the included studies was 
the CelluTome Epidermal Harvesting System, which was used in three studies, and is the 
latest technology for EG. This system has the shortest graft harvest time, fastest donor site 
healing, no reported donor site morbidity, and can be performed in outpatient setting without 
anaesthesia. Being an automated system, the procedure is easily reproducible with consistent 
graft quality. The short harvest time is contributed by the high negative pressure which is 
applied concurrently with mild thermal energy of 40 PoPC and its design which harvests an array 
of 128 micro-blisters, each measuring 2mm in diameter and spaced 2mm apart, within an area 
measuring 5cm x 5cm [91]. The earlier systems used to harvest EG, Dermovac and syringe 
system, faced several challenges which limits its clinical applicability. The Dermovac, which 
has an adapter plate that allows user to determine the number and size of blisters to be 
harvested, has a long harvest time and requires a large equipment [94]. The reliability of the 
syringe system, on the other hand, had been described to depend on numerous patient and 
environmental factors, requires skill, time consuming, causes pain and tedious to use with 
often inconsistent blister shape and size formation [91]. The evolution of the harvesting 
systems will be thoroughly reviewed in the next section of this chapter. 
The evidence in this study is limited by the lack of high-quality, level-1 evidence. The existing 
studies were mostly small, retrospective case-series that are often at risk of bias. There were 
no comparative data to evaluate that healing outcome of EG against the current standard of 
care such as advanced dressings or SSG. Formal bias assessment was not performed due to 
the study design of the included studies. In terms of the search strategy, as there is no Medical 
Subject Heading (MeSH) term available for EG, potentially valuable and informative studies 
published with other keywords may therefore been missed. The definition of wound healing 
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was also not clearly defined in the included papers although time for 100% wound closure was 
accepted to fit the definition for the purpose of this review. Further, several different harvesting 
systems were used in the included studies. Proportion of healing based on the size and depth 
of wound as well as device utilized were not performed due to incomplete reporting in most of 
the studies. Similarly, subgroup analysis for healing based on the wound aetiology was not 
performed due to the broad heterogeneity in the study population. The EG harvested by the 
different harvest systems were assumed to produce similar graft quality for the purpose of this 
review as the grafts were all harvested by blister formation. 
 
4.1.6 Conclusion 
 
In conclusion, EG offers a healing rate of over 50 percent and allows painless autologous skin 
grafting to be performed without donor site morbidity. The rapid donor site healing could have 
a major impact in the patient’s quality of life. Our conclusions are limited by the small size and 
heterogeneity of the studies and the different techniques of EG. Methodologically sound RCTs 
to compare EG against SSG or conservative treatment are therefore necessary.  
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4.2 Mechanistic review on the harvesting systems, the ultrastructure of the 
graft and mechanism of wound healing by epidermal graft 
 
4.2.1 Chapter summary 
 
The structural difference of epidermal graft in comparison to split thickness skin graft and full 
thickness skin graft contributes to the mechanism of effect. Whereas skin grafting is an 
epidermal transfer, little is known about the precise mechanism of wound healing by epidermal 
graft. This study explored the evolution of the epidermal graft harvesting system over the last 
five decades, the structural advantages of epidermal graft for wound healing and the current 
hypotheses on the mechanism of wound healing by epidermal graft. Three mechanisms were 
proposed: keratinocyte activation, growth factor secretion and re-epithelialisation from the 
wound edge. We evaluated and explained how these processes work and integrate to promote 
wound healing based on the current in vivo and in vitro evidence. We also review the ongoing 
clinical trials evaluating the efficacy of epidermal graft for wound healing. Epidermal graft is a 
promising alternative to the more invasive conventional surgical techniques as it is simple, 
less expensive, and reduces the surgical burden for patients in need of wound coverage. 
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4.2.2 Introduction 
 
The mechanism of wound healing by SSG is well understood, however very little is currently 
known on the precise mechanism of healing by EG. The EG has been reported to behave 
more like a tissue engineered skin graft or a cultured keratinocyte sheet [92, 93], which 
stimulates the wound to regenerate by itself rather than to provide instant wound coverage as 
seen with FTSG and SSG (see Figure 4.6 for images comparing wound healing by EG and 
SSG). Cultured keratinocytes have been used for resurfacing burn wounds and in the 
treatment of skin ulcers since the 1970s [95]. However, the clinical application of the cultured 
keratinocytes has been limited by the short-term and long-term results: variable graft take rate, 
limited mechanical resistance, hyperkeratosis, scar contracture, ulceration and blister 
formation due to reaction towards foreign fibroblasts in feeder media [96-98]. These results, 
accompanied by the long culture time (typically requiring three to four weeks), the fragility of 
the sheets, and the high cost, has limited the use of this technique to only specialised facilities 
[99].  
Newer methods developed to overcome these drawbacks, include pre-confluent keratinocytes 
combined with various delivery systems such as dermal substitute [99], polymer matrix [100, 
101], fibrin glue suspension [102], and aerosol spray [103] as well as co-culture with 
melanocytes [99] require advanced logistics and handling capacity which involves clean room 
facilities and the use of clinical-grade reagents that are compliant with the Advanced Therapy 
Medicinal Products (ATMPs) guideline [99]. Similar challenges are faced by tissue engineered 
skin grafts, which are often not easy to handle, lack durability, are expensive and not available 
off-the-shelf [104].  
EGs are advantageous as they do not require a carrier system, additional culture time, or a 
specialised facility. Several groups have previously reported good clinical results with the use 
of EGs for wound healing [91-93]. However, little is known about its mechanism of healing. 
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The goal of this review is to explore the mechanism of healing by EG. First, the evolution of 
the harvesting system over the last five decades and the structural advantages of EG will be 
highlighted before exploring the current hypothesis on its healing mechanism. This review 
ends with proposing the possible models to study the mechanism of healing by EG along with 
an overview on the ongoing clinical trials aimed at evaluating the efficacy of EG for wound 
healing.  
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Figure 4.6 3D images of weekly wound healing by EG and SSG. 
Wounds treated with EG forms a clear film over the wound a week after grafting. 
Subsequently, healthy granulation tissue are seen in the wound bed and the wound rapidly 
re-epithelialises from the edges. On the other hand, SSG integrates with the wound bed a 
week after grafting and the wound re-epithelialises from the integrated skin graft.  
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4.2.3 EG harvesting systems 
 
Various EG harvesting devices were used over the last fifty years with clear refinement in 
technology over the years [84, 105-108]. The three harvesting systems which were most 
commonly used to harvest EG were the Dermovac system (Oy Instrumentarium, Helsinki, 
Findland), the syringe system, and the CelluTome Epidermal Harvesting System (Acelity, San 
Antonio, Texas) (Figure 4.7). These devices rely on the same principle of applying continuous 
negative pressure onto healthy skin to promote blister formation, although they vary in the 
amount of the negative pressure generated and the size of graft harvested.  
 
Figure 4.7 Epidermal graft harvesting systems 
(A) The Dermovac system consists of a pair of transparent plexiglass suction cups and a 
handheld pump. (B) The syringe system consists of a small syringe with the piston removed 
and connected to a larger syringe via a three-way connector. The three-way connector is 
locked to maintain the negative pressure throughout the procedure. (C) The CelluTome 
Epidermal Harvesting System consists of a control unit connected to a vacuum head.  
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The earliest device used was Dermovac, first developed by Kiistala in 1968, which enabled 
separation of the epidermis from the dermis using purely mechanical forces without causing 
any chemical or thermal damage [108]. This device consisted of a transparent plexiglass 
suction cup and a hand pump that generated negative pressure of 250-300 mmHg with a 
blistering time of about 1 - 2 h (Figure 4.7a, above). The suction cup was equipped with an 
adapter plate, which allowed the user to determine the number and size of blisters to be 
harvested. The suction blisters were then excised separately by the surgeon and transferred 
to the site of interest. Smaller grafts were more convenient as larger grafts tended to curl at 
the edges, making the transfer challenging [90]. The long harvest time and the size of the 
equipment meant the techniques did not gain popularity [94]. 
The EG harvesting system more commonly associated with EG employs syringes [89, 94, 
109]. The syringe system was simple, comprising a syringe with the piston removed, placed 
onto the skin then suction applied through the nozzle. This could be simply achieved by a 
three-way connector linked to a larger syringe, which had two to three times the suction 
capacity of the smaller one (Figure 4.7b, above). The syringe system had a blistering time of 
one hour and raised a blister measuring 1.5 cm in diameter which required surgical excision 
for transfer [89, 94, 109]. Variations on the system include use of a smaller syringe or 
subepidermal local anaesthesia infiltration [89]. However, the reliability of the syringe system 
is dependent on numerous patient and environmental factors[91]. Furthermore, its clinical 
applicability has been limited by the long harvest time, the requirement for repeated grafting 
due to the small graft size as well as being tedious with inconsistent blister formation [91]. 
The most recent harvesting system, which has been commercially developed, is the 
CelluTome Epidermal Harvesting System [91-93]. This system consists of an automated 
harvester, a vacuum head and a control unit (Figure 4.7c, above). It combines negative 
pressure of 400-500 mmHg and temperature of 40PoPC, allowing 128 micro-blisters (each of 
2mm diameter, 2mm apart) to be raised within 30 min [84]. The harvester is equipped with an 
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in-built blade to excise the roof of the blister and the EG is then transferred by use of an non-
adherent dressing to the designated wound site. Being an automated device, it ensures 
consistency in the graft size and number. In contrast to the previous devices, the shorter 
harvest time of the CelluTome Epidermal Harvesting System comes from the high negative 
pressure, which is applied concurrently with mild thermal energy and its design which harvests 
an array of micro-blisters [91]. It also offers painless graft harvest without anaesthesia, which 
is easily performed in the outpatient and community setting due to the straightforward nature 
of the procedure [92, 93]. Serena et al highlighted several advantages of this technique in 
resource-poor setting, including simplicity, affordability, reproducibility, efficiency and the 
capacity of non-surgically trained clinician to perform the procedure [93].   
 
4.2.4 Histology of EG 
 
The epidermis is the upper most layer of the skin. The EG harvesting systems separate the 
epidermis from the dermis at the dermal-epidermal junction (DEJ) while preserving the 
histological architecture of the epidermis[108]. Ultrastructurally, the DEJ consists of four zones 
(Figure 4.8): first, the membrane of the basal keratinocytes which contains hemidesmosomes; 
second, the lamina lucida, an electron-lucent region as seen by electron microscopy, which 
anchoring filaments traverse; third, the lamina densa, an electron-dense area as seen by 
electron microscopy; and fourth, the sub-basal lamina which contains anchoring fibrils[110].  
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Figure 4.8 Ultrastructure of DEJ and blister cavity 
The DEJ consists of four zones: membrane of the basal keratinocytes, lamina lucida, lamina 
densa, and sub-basal lamina. Hemidesmosomes, present at the dermal pole of the basal 
keratinocytes, link to anchoring filaments that connect the basal keratinocytes to the lamina 
lucida. Anchoring fibrils link the lamina densa and the dermal matrix. Continuous negative 
pressure forms a blister at the level of sub-basal lamina. 
 
The anchoring filament links the basal keratinocytes to the lamina lucida while the anchoring 
fibrils link the lamina densa to the underlying dermal matrix [110, 111]. Histological study of 
the EG harvested from seven healthy volunteers showed that the separation is sub-epidermal, 
at the level of the sub-basal lamina, with a well-defined basement membrane lining the blister 
[112]. Immunohistochemical staining for collagen type IV, the primary component of lamina 
densa, further confirmed that the basement membrane components were contained within the 
micrografts [113, 114].  
Electron microscopic analysis of the EG harvested from healthy volunteers using Dermovac 
at -200 mmHg within 90 to 120 min revealed that the ultrastructure of the epidermis is 
preserved, although vacuoles were seen within the keratinocyte cytoplasm [115]. Similar 
finding of vacuoles within the cytoplasm was observed in another study analysing EGs 
harvested using the syringe system [116]. Despite the presence of vacuoles, the nuclear 
membrane remained intact [116]. Furthermore, the epidermal cells were found to be viable in 
a study that analysed EG harvested from healthy volunteers using the CelluTome Epidermal 
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Harvesting System, which demonstrated the presence of Ki67 stained proliferative cells at the 
basal layer of the grafts [113]. The presence of the nuclear protein Ki67, which is expressed 
in cycling cells (G1, S, G2, and M phases) and absent in resting G0 cells, indicates that the 
proliferative potential of the EG is preserved upon separation [117].  
The separation at the DEJ can be accelerated by heat, with the temperature ranging between 
40PoPC to 45PoPC being reported as the optimal temperature for rapid suction blister formation 
[118]. In a systematic review on the suction blistering time, skin temperature was identified as 
the strongest predictor for the blistering time, indicating that the DEJ loses its strength with the 
increasing temperature due to temperature related detachment of the hemi-desmosomes 
and/or the inflow of blister fluids [119]. The ability of the CelluTome Epidermal Harvesting 
System to raise blisters in a short period of time is due to negative pressure coupled with a 
temperature of about 40PoPC.  
 
4.2.5 Mechanism of wound healing by EG 
 
The separation at the DEJ maintains the entire ultrastructure of the epidermis, constituents of 
which contributes to its unique wound healing mechanism. The healing by EG is influenced 
by the interplay of three main mechanisms: keratinocyte activation, growth factor secretion 
and re-epithelialisation from the wound edge (Figure 4.9). Each of these mechanisms will be 
explored in detail in this section.  
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Figure 4.9 Mechanism of healing by EG 
(A, B, C) The aerial view of four EGs on a healthy wound bed. (D, E) The cross-sectional view 
of an EG on a wound bed. Upon grafting (B), the keratinocytes within the EGs are activated 
and migrate onto the wound bed (yellow arrows resemble keratinocyte migration). The 
activated keratinocytes concurrently secrete growth factors to the wound bed to stimulate 
endogenous process of wound healing (E) (green arrows resemble growth factor expression). 
The activated keratinocytes and the growth factors stimulate the wound edge keratinocytes to 
migrate into the wound, accelerating re-epithelialisation from the wound edge (C) (blue arrows 
resemble the migration of the wound edge keratinocyte into the wound). 
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4.2.5.1 Keratinocyte activation and migration onto the wound bed 
The first of these mechanisms is the activation of the basal keratinocytes within the EG. Whilst, 
keratinocyte activation in response to epidermal injury has been well reviewed (please see 
references [120, 121]) keratinocyte activation within EG, has not.  Keratinocyte activation 
within EG was proposed to occur in addition to the well understood phases of skin graft 
healing: plasmatic imbibition, inosculation, and revascularization [122]. The direct interaction 
between the basal keratinocytes within the EG and the wound bed contributes to this additional 
phase that is not seen in FTSG and SSG, which instead have a layer of dermis that interacts 
with the wound bed [122]. This phase was proposed based on the pronounced expression of 
Ki67 (marker of cell proliferation) and βR1R integrin subunit (a putative keratinocyte stem cell 
marker) in the basal keratinocyte layer and on the wound bed after epidermal grafting [122]. 
Both the Ki67 and βR1R integrin were seen in the first week post grafting and disappeared at the 
fourth week, suggesting that the keratinocyte activation phase begins as part of the 
inosculatory phase and persists into the early stages of the revascularisation phase. The 
activated phenotype is also marked by changes in the cytoskeleton and increased expression 
of the cytoskeletal keratins involved in re-epithelialisation, namely KRT6, KRT16 and KRT17 
[120, 121]. 
Arguably, keratinocyte activation could potentially be initiated upon separation of the EG from 
the DEJ during the graft harvest. As seen in epidermal injury, the exposure of the keratinocytes 
to their surrounding initiate the keratinocytes activation cycle[120]. This activation process is 
achieved by the expression of several cytokines, with interleukin-1 (IL-1) being the most 
common initiator [120, 121]. This cytokine, which is present in the cytoplasm of the 
keratinocytes in an unprocessed form, is converted by cellular injury to a processed form and 
released extracellularly, enabling the surrounding cells to perceive the injury [123]. The IL-1 
serves as an autocrine signal to activate the surrounding keratinocytes and as a paracrine 
signal to the dermal fibroblasts, enhancing their migration, proliferation, and production of 
dermal extracellular components [120, 124, 125]. The other common initiator of keratinocyte 
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activation is the pro-inflammatory cytokine, tumor necrosis factor-α (TNFα) [126]. Similar to 
IL-1, TNFα acts in an autocrine fashion to stimulate keratinocyte migration, and in a paracrine 
fashion activating fibroblast[126]. 
The activated keratinocytes are mitotically active and are capable of outgrowth from the 
multiple small epidermal islands onto the wound bed [113]. The proliferative capacity of these 
small islands is immense, as exemplified by the ability of Cultured Epidermal Autografts (CEA), 
harvested from a small area, to rescue patients with burn wounds over 30% of their total body 
surface area [127]. As the keratinocytes migrate away from the EG, these hyper-proliferative, 
migratory keratinocytes secrete components of basement membrane into the 
microenvironment of the wound bed [120]. EG from healthy donors cultured in vitro 
synthesized and secreted components of basement membrane, whereby fibronectin, laminin 
332 and type IV collagen were prominently stained at the expanding peripheries of the 
epidermal islands compared to the terminally differentiated upper layers of the epidermis [128, 
129]. This suggests that keratinocytes deposit basement membrane components on the 
wound which assist in the anchorage and migration of the keratinocytes [130]. This ability of 
keratinocytes to secrete products of basement membrane and extracellular matrix is being 
exploited in efforts at producing tissue engineered skin grafts[131]. These cell-derived 
matrices are advantageous for bioengineering as they are entirely cell-type specific and are 
processed and deposited onto the surface containing a full portfolio of ligands such as growth 
factors and proteoglycans[131]. The synergy between the extra-cellular matrix and cytokines 
plays a pivotal role in the regulation of keratinocyte proliferation during re-epithelialisation. 
  
4.2.5.2 Expression of cytokines to activate wound bed 
Activated keratinocytes are the principal source of cytokines in the epidermis [132]. The 
cytokines secreted can be broadly divided by their biological activities into three categories: 
growth factors, interleukins, and colony stimulating factors [132-134]. The production of these 
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cytokines are mediated by the change in cell cycle, cell-differentiation state, a wide range of 
biological and physiological agents, and even the cytokines themselves [132].  
A number of growth factors, including epidermal growth factor (EGF), transforming growth 
factor alpha (TGFα), heparin-binding EGF, and keratinocyte growth factor, are known to 
stimulate keratinocyte motility and proliferation in a wounded epidermis [120, 134]. EG 
harvested from three healthy donors and cultured in vitro for seven days have been shown to 
secrete vascular endothelial growth factor (VEGF), transforming growth factor-α (TGF-α), 
platelet-derived growth factors AA (PDGF AA), platelet-derived growth factors AB/BB  (PDGF 
AB/BB), hepatocyte growth factor (HGF), and granulocyte colony-stimulating factor (G-
CSF)[113]. These growth factors are known to modulate wound healing response and are 
able to stimulate endogenous process of wound healing [92]. Such benefit is seen even with 
allogenic cell therapy that has shown impressive therapeutic value in wound healing [135]. 
The allogenic cells, despite not attaching and covering the wound permanently, release growth 
factors, dermal extracellular matrix and basement membrane components to accelerate 
epithelialisation from the wound edge and promote granulation formation from the wound bed 
[135].  
It is known that growth factors in combination are more stimulatory for wound healing in vivo 
than topical application of isolated growth factor therapy [133]. However, the combination of 
growth factors has to be tailored to the needs of the wound at any given time. This points to 
the benefit of EGs, which have the potential to deliver a cocktail of growth factors continuously 
in keeping with the stage of healing.  
 
4.2.5.3 Stimulation of wound edge keratinocytes  
Given the potent mitogenic and motogenic effects of the many growth factors, it is likely that 
the EG enhances wound edge keratinocytes to proliferate and migrate into the wound, 
stimulating re-epithelialisation from the wound edge [134, 136]. Several authors have reported 
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that the EG do not exhibit graft take on the underlying wound bed, however observed re-
epithelialisation occurs from the wound edge, dubbed the ‘edge effect’ [88, 92]. Gabriel et al. 
and Serena et al., on the other hand, reported visible graft take and subsequent re-
epithelialisation from the wound edge as well as from within the wound bed when the EG 
exhibited graft take [91, 93]. Costanzo et al similarly reported graft take in 8 out of 29 cases 
but highlighted that the major effect appears to be the stimulation of re-epithelialisation from 
the wound edge [88].  
For re-epithelialisation to occur from the wound edge, keratinocytes must first disassemble 
their cell-cell and the cell-substratum adhesion. Numerous regulators modulate the 
proliferation and migration of keratinocytes during epithelialisation [121]. A key event in 
breaking the polarity between the tightly organised epithelial cells is the loss of epithelial 
junctions, mediated by the downregulation of the tight and adherens junction proteins, zonula 
occludens 1 (ZO-1) and E-cadherin, respectively. These molecules are the transmembrane 
proteins, which mediate cell-cell interaction and communication [44]. These transmembrane 
proteins are known to be co-localized and co-assembled in a multiprotein complex with the 
GJP, Connexins, especially Connexin 43, the most ubiquitous Connexin in the epidermis [44].  
Connexins play a vital role in the migratory property of keratinocytes in addition to other 
physiological processes, which includes cell differentiation, proliferation, electrical 
transmission and inflammation [40, 45]. Furthermore, Connexins form the centre of a protein 
complex or “nexus” acting as a master gene that can influence the expression of over 300 
other genes at the transcriptional level [137]. The cytoplasmic tail of Connexin 43 is associated 
with actin cytoskeletal proteins via E-cadherins, ZO-1, α- and β-catenin, either directly or via 
adaptors [44, 45]. These interactions affect both the cell adhesion and cytoskeletal dynamics 
and therefore the cell migration and wound healing. In acute wounding, Connexins are 
downregulated about 6 h after injury which correlates with the keratinocyte adopting a 
migratory phenotype as they start to crawl across the wound bed to re-epithelialise the wound 
[40]. The upregulation of Connexin 43, Connexin 30 and Connexin 26 at the wound edge, as 
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seen in chronic wounds, is known to reduce the migratory activity of keratinocytes and 
fibroblasts due to the substantially increased adhesion between cells [138, 139].  
The modulation of the GJPs by growth factors and cytokines has been reviewed extensively 
by Schalper et al [140]. The growth factors expressed by the EG are likely to downregulate 
Connexins at the wound edge, initiating keratinocyte migration. Although the exact type and 
concentration of growth factors expressed by the EG in vivo is yet to be outlined, the 
concentration of growth factors expressed by the grafts in vitro suggests that it is likely 
sufficient to modulate the GJPs at the wound edge [113, 140].  
 
4.2.6 Models to study wound healing mechanism of EG  
 
There is currently a paucity of data on the precise in vivo wound healing mechanism by the 
EGs.  As EG stimulates both the wound edge and wound bed to regenerate, analysis should 
involve tissues taken from these two locations. This could be performed by taking tissue 
biopsies prior to treatment and repeated again at week 1 post treatment or done repeatedly at 
several fixed intervals throughout the treatment. The skin biopsies taken at the wound edge 
can confirm the activation and proliferation of the keratinocytes upon grafting. This can be 
done by observing the morphologic changes of the keratinocytes by a simple haemotoxylin 
and eosin (H&E) staining as well as by immunostaining for proliferative markers and GJPs. 
The morphological changes and the downregulation of the GJPs can confirm the change of 
the keratinocytes into a migratory state [48, 138]. Tissue biopsy from the wound bed, on the 
other hand, will be able to confirm the activation of the wound bed and the presence of 
components of the basement membrane. Furthermore, staining for keratinocyte markers, such 
as KRT5, KRT6 and KRT14 can confirm the presence of the graft on the wound bed [141], as 
several studies have reported that graft take was not clinically visible in most cases [88, 91]. 
Besides tissue biopsy, non-invasive investigation such as the analysis of wound fluid collected 
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throughout the treatment will be able to provide invaluable information on the expression of 
cytokines and growth factors [142]. As well as confirming the type and concentration of growth 
factors expressed, this will provide insight into the changes in expression with treatment.  
Several clinical trials are currently underway to investigate the efficacy of EG in the clinical 
setting using the Cellutome Epidermal Harvesting System. There is currently a large 
randomised multicentre controlled trial comparing the safety and effectiveness of EG 
combined with multi-layered compression therapy for the healing of venous leg ulcers [143]. 
Similarly, the effectiveness of EG for chronic wounds in the outpatient setting is being 
investigated by a non-randomised study which compares EG against SSG from historical 
controls [144]. Besides chronic wounds, the efficacy of EG for wounds secondary to inherited 
connective tissue disease, epidermolysis bullosa, is also being evaluated [145]. The findings 
from these high-quality trials will define the efficacy of this technique and further improve our 
understanding of the mechanism of healing by EG.  
 
4.2.7 Conclusion 
 
The increased number of publications in the last couple of years testifies the growing clinical 
popularity of this technique as a form of autologous skin grafting in the outpatient setting. In 
this review, I have highlighted the possible mechanisms of wound healing by EG based on the 
current in vitro and in vivo evidence. However, more work needs to be done to better 
understand the mechanism of healing at the cellular level in order to propose an evidence 
based clinical pathway. The limitations identified here will be addressed in the subsequent 
chapters. 
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5.0 Pilot case series to evaluate epidermal grafting for wound healing in the 
outpatient setting 
 
5.1 Chapter summary 
 
Current wound management with the use of SSG often requires hospital admission, a period 
of immobility, attentive donor site wound care and pain management. This study evaluates the 
feasibility of using a novel epidermal graft harvesting device (CelluTome) which allows pain-
free EG in the outpatient clinic setting. A prospective series of 23 patients was performed, 
involving 10 acute and 13 chronic wounds. All patients were subjected to EG in the outpatient 
specialist clinic, without the use of anaesthesia, and allowed to return home after the 
procedure. Completely healed wounds were noted in 20 patients (86.7%). The overall mean 
time for 50% and 100% reduction in wound size was 2.55 ± 0.97 weeks and 5.10 ± 1.58 weeks 
respectively. There was no significant difference in healing times between the acute and 
chronic wounds (50% reduction in wound size; acute 2.22 ± 0.91 weeks versus chronic 2.9 ± 
0.94 weeks, p=0.152. Hundred percent reduction in wound size; acute 4.80 ± 1.53 weeks 
versus chronic 5.40 ± 1.56 weeks, p=0.422). The mean time for donor site healing was 5.57 ± 
0.97 days. The mean pain score during graft harvest was 1.78 ± 0.79 and the donor site 
Vancouver Scar Scale was 0 for all cases at 6 weeks. This automated device offers autologous 
skin harvesting in the outpatient setting with minimal or no pain and a scar free donor site, 
equally benefiting both the acute and chronic wounds. It has the potential to save NHS 
resources by eliminating the need for theatre space and a hospital bed, while at the same time 
benefiting patient care.  
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5.2 Introduction 
 
This study evaluates the feasibility of using a novel epidermal graft harvesting device, the 
CelluTome Epidermal Harvesting System[146], which allows EG to be performed in the 
outpatient clinic setting, with minimal or no pain, as an alternative to the current wound 
management methodology. 
 
5.3 Methods 
 
A prospective case series was conducted, from July 2014 to March 2015, at the Royal Free 
Hospital, London. EG was an established technique in the Trust so a Divisional protocol was 
developed with trust approval for a new device and all patients registered for a prospective 
audit. 
 
5.3.1 Patient Selection 
Adult patients who had been referred to the department of plastic surgery for consideration for 
SSG due to difficult or non-healing wounds were considered. The wounds were between 2cm 
x 2cm and 12cm x 12cm, and had clean and granulating wound beds. Prior to grafting, the 
wound bed was prepared as per standard clinical practice, either with negative pressure 
wound therapy or appropriate dressings, until healthy granulation tissue was present. Wound 
swabs were performed to exclude infection. Details on patient’s demographics, co-morbidities, 
wound aetiology, wound type, wound location, wound size, healing time, pain scores during 
graft harvest, wound measurements at each visit, and donor site scar quality were recorded. 
The wound type was classified into acute (<3 months in duration) and chronic (≥3 months in 
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duration). This study was conducted in the outpatient setting and patients were allowed to 
return home on the same day after the intervention.  
 
5.3.2 Epidermal graft harvest and post grafting wound care 
Epidermal grafts were harvested using an automated harvesting system, the CelluTome 
Epidermal Harvesting System (Acelity, San Antonio, TX, USA) (Figure 5.1). This device 
harvests epidermal micrografts, without the use of anaesthesia, via the formation of suction 
blisters, carried out in the outpatient setting. By combining negative pressure (400 – 500 
mmHg) and heat (40PoPC), this device produces an array of epidermal blisters within 30 to 50 
min, providing autologous keratinocytes for grafting. The microdomes were formed at the layer 
of the lamina lucida of the dermo-epidermal junction[146]. Following the harvest, the grafts 
were transferred onto a non-adherent silicone dressing (Adaptic Touch, Systagenix) and 
applied onto the wound. The graft was then secured with a secondary dressing, while the 
donor site was dressed with an occlusive dressing (Tegaderm Film, 3M). Patients were 
allowed to return home on the same day after the procedure and were reviewed on day 7±3 
post-grafting. The patients were reviewed weekly for a minimum of 6 weeks or until the wound 
had healed. 
During the post-operative review the donor site dressing was removed at week 1 and no 
further dressing was required.  The recipient wound was reviewed by the same clinician for 
every case to ensure continuity of care and practice as well as reliability in outcome measure 
assessment. Once the dressing was removed the bed was not tampered with, to allow for the 
fragile keratinocyte layers to set, and a new dressing was applied usually in the form of a non-
adherent silicone dressing, Adaptic Touch (Systagenix), followed by a secondary dressing 
which usually included iNadine (Systagenix) or Aquacel (Figure 5.2) to deal with the exudate 
levels.  In cases where the exudate level was moderate or high the secondary dressing was 
changed twice weekly.  
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Figure 5.1 Illustration of the epidermal graft harvesting device 
(A) The CelluTome epidermal graft harvesting system. (B) Illustration on the application of the 
harvester and vacuum head onto the patient’s thigh. (C) The system was turned on for about 
30-40 min to raise an array of blisters (shown in inset). The roof of the blisters was then excised 
by an in-built blade and the microdomes were transferred on to the wound using a non-
adhesive silicone dressing. 
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Figure 5.2 Secondary dressings 
The secondary dressing used were either (A) Aquacel, or (B) iNadine. (C) Further occlusive 
dressing was applied on top of either (A) or (B). 
 
5.3.3 Outcome measures 
The wounds were measured (length (cm) x width (cm)) and photographed before and after 
grafting, and at each wound review.  The primary outcomes measured were the time taken for 
50% and 100% reduction in wound size as well as the time taken for the donor site to heal. A 
completely healed wound (100% healed) is defined as a wound which does not require further 
dressing and can be left exposed. The secondary outcomes measured were pain score during 
graft harvest and donor site scar quality. The pain score was measured using a Numerical 
Rating Scale, with 0 being no pain and 10 being worst pain. The donor site scar quality was 
evaluated using the Vancouver Scar Scale (VSS) at 6 weeks post grafting[147]. The VSS 
assesses 4 variables: vascularity, height/thickness, pliability, and pigmentation. Each variable 
includes ranked subscales that were summed to obtain a total score ranging from 0 to 13, with 
0 representing normal skin and 13 representing maximum alterations of the skin.  
 
5.3.4 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics 21 software. The p values of 
<0.05 were considered statistically significant. Data was presented as the mean ± standard 
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deviation. The time for reduction in wound size between the acute and chronic wounds, and 
the size and type of wound were compared using the independent t-test. The Pearson 
correlation co-efficient was used to determine the association between age and the time for 
the donor site to heal. 
 
5.4 Results 
 
A total of 23 patients were treated with the EG with an average age of 61.1 years (range: 18-
93 years).  Of these patients, 10 were male (43.5%) and 13 were female (56.5%) (Table 5.1).  
The most common aetiology in this patient cohort were wound dehiscence and trauma (n=8). 
There were 10 acute wounds (mean duration: 1.45 ± 0.76 months) and 13 chronic wounds 
(mean duration: 12.8 ± 16.6 months) with the average wound duration of 7.87 months (range: 
0.5-60 months) (Table 5.2). The majority of the wounds treated were on the leg (39.1%), 
followed by foot (13.0%), ankle (13.0%) and thigh (13.0%). The average wound size was 17.1 
± 10.0 cmP2P. There was no difference between wound size and type of wound (acute: 19.6 ± 
9.8 cmP2P versus chronic: 15.3 ± 9.8 cmP2P, p=0.337, t-test). 
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 d
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VS
S 
of
 d
on
or
 s
ite
 
sc
ar
 
1 SB F 24 Nil Pyoge
nic 
granulo
ma 
Foot 4 6 Failed failed 5 1 0 
2 HB M 18 Nil Traum
a  
Knee 1 13.
5 
2 5 5 3 0 
3 RK F 85 IHD, CABG, 
HTN, asthma,  
Venou
s ulcer 
Leg 4 6 2 5 7 2 0 
4 BL F 93 Dementia, 
COPD, HTN, 
CCF 
Traum
a 
Leg 1 14 1 3 5 1 0 
5 JC M 54 Nil Amput
ation 
stump 
wound 
dehisc
ence 
Foot 2 28 2 4 5 2 0 
6 LH F 50 SLE (oral 
steroids) 
Venou
s ulcer 
Ankle 5 8 2 5 7 2 0 
7 JZ M 84 Right 
hemicolectomy
, postop fistula 
and hernia 
Abdom
inal 
wound 
dehisc
ence 
Abdo
men 
60 15.
8 
4 8 5 1 0 
8 GM F 62 Bowen’s 
disease, 
myasthenia 
gravis (on oral 
steroids), 
osteoporosis 
Traum
a 
Leg 1.5 12 2 6 5 2 0 
9 RF M 78 Prostate 
cancer, 
myelodysplasi
a, IHD, PVD, 
multiple 
BCC/SCC 
Wound 
dehisc
ence  
Leg 3 27 Failed failed 5 1 0 
10 NS F 91 Breast cancer, 
hypertension, 
smoker, CKD3,  
Traum
a 
Leg 3.5 3  2 3 5 3 0 
11 LR F 64 RA, COPD Traum
a 
Ankle 9 40 failed failed 5 0 0 
12 AL F 26 Anaemia 
smoker 
Burn Leg 0.5 19 1 3 7 1 0 
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13 DM F 50 Breast ca and 
chemo, 
previous DVT 
on warfarin 
Dehisc
ence of 
LD 
donor 
site 
Back 4 21 4 8 5 3 0 
14 JB F 52 Hypertension, 
gastric 
banding, 
abdominoplast
y, thigh lift 
Wound 
dehisc
ence 
Thigh 1 28 4 8 7 2 0 
15 JM F 76 Cerebral palsy, 
hypothyroid, 
osteoporosis 
SSG 
donor 
site 
Thigh 24 18 2 4 5 2 0 
16 OM M 32 Deaf Traum
a 
Foot 2 26 3 6 5 2 0 
17 KI M 82 IHD, CABG, 
HTN, T2DM, 
RA (on pred + 
methotrexate), 
Hypercholester
olaemia, CVA, 
AAA (4.5cm) 
Wound 
dehisc
ence 
Leg 2 16 3 6 5 1 0 
18 BR M 78 Prev sigmoid 
ca, colostomy, 
nec fas 
abdomen, CVA 
SSG 
donor 
site 
Thigh 36 39 2 5 7 2 0 
19 JS M 88 IHD, CABG, 
HTN 
Traum
a 
Forea
rm 
0.5 7 3 5 5 2 0 
20 SM M 93 IHD, CABG, 
HTN, AF 
SSG 
donor 
site 
Leg 3 9 2 3 5 2 0 
21 PS M 28 Nil Wound 
dehisc
ence 
Ankle 5 6 2 4 5 1 0 
22 LM F 39 GORD Wound 
dehisc
ence 
Arm 4 18 4 6 7 3 0 
23 JK F 58 PE/DVT, 
PCOS, asthma 
Traum
a 
Pretibi
al 
5 14 4 5 7 2 0 
Keys: M=male, F=female, IHD=Ischaemic heart disease, CABG=Coronary artery bypass graft, HTN=hypertension, COPD=Chronic 
obstructive pulmonary disease, CCF=congestive cardiac failure, SLE=systemic lupus erythematosus, PVD=peripheral vascular 
disease, BCC=basal cell carcinoma, SCC=squamous cell carcinoma, CKD=chronic kidney disease, RA=rheumatoid arteritis, 
DVT=deep vein thrombosis, T2DM=type 2 diabetes mellitus, AAA=abdominal artery aneurysm, CVA=cerebrovascular accident, 
AF=arterial fibrillation, GORD=gastro-oesophageal reflux disease, PE=pulmonary embolism, PCOS=polycystic ovary syndrome, 
LD=latissimus dorsi, SSG=split skin graft 
Table 5.1 Clinical data of patients treated with epidermal graft.  
Detailed breakdown of individual patient demographics along with the wound healing 
characteristics are presented.  
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Characteristics Number of patients (%) 
Mean age (years) 61.1 ± 24.0 
Gender 
  Male 
  Female 
 
10 (43.5%) 
13 (56.5%) 
Wound aetiology 
   Venous ulcer 
   Arterial ulcer 
   Burns 
   SSG donor site 
   Wound dehiscence 
   Trauma 
   Pyogenic Granuloma 
   Diabetic foot ulcer 
 
5 (14.3%) 
2 (5.7%) 
1 (2.9%) 
3 (8.6%) 
12 (34.3%) 
10 (28.6%) 
1 (2.9%) 
1 (2.9%) 
Type of wound 
  Acute 
  Chronic 
 
10 (43.48%) 
13 (56.52%) 
Mean wound duration (months) 7.87 ± 13.7 
Anatomical location 
  Foot 
  Ankle 
  Leg 
  Knee 
  Thigh 
  Abdomen 
  Back 
  Arm 
  Forearm 
 
3 (13.0%) 
3 (13.0%) 
9 (39.1%) 
1 (4.4%) 
3 (13.0%) 
1 (4.4%) 
1 (4.4%) 
1 (4.4%) 
1 (4.4%) 
Table 5.2 Summary of patient demography and wound characteristics.  
Summary of patient’s demography, overall wound aetiology, type of wound, mean wound 
duration and anatomical locations of the wounds.  
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Complete wound healing (100% reduction in wound size) was achieved in 20 patients (86.7%). 
Of these, 17 patients (85.0%) healed within 6 weeks and 3 patients (15.0%) within 8 weeks.  
The mean time for 50% and 100% reduction in wound size were 2.55 ± 0.97 weeks and 5.1 ± 
1.58 weeks, respectively. There was no significant difference in healing times between the 
acute wounds and the chronic wounds (50% reduction in wound size; acute 2.22 ± 0.91 weeks 
versus chronic 2.9 ± 0.94 weeks, p=0.152. Hundred percent reduction in wound size; acute 
4.80 ± 1.53 weeks versus chronic 5.40 ± 1.56 weeks, p=0.422). 
The mean time for the donor site to heal was 5.57 ± 0.97 days. There was no correlation 
between patient’s age and donor site healing time (Pearson correlation, p=0.915). The mean 
pain score during graft harvest was 1.78 ± 0.79 and the donor site Vancouver Scar Scale was 
0 for all cases at 6 weeks, whereby all donor sites looked and felt similar to the surrounding 
skin.  
There were three graft failures due to infection. No other complications were experienced by 
the patients. 
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5.4.1 Case examples 
 
Case 1: Patient 2/HB.  
A healthy young male sustained a traumatic wound over the left patellar region from a 
motorbike injury. The wound measured 4.5cm x 3.0cm with exposed infra-patellar tendon, 
requiring surgical debridement followed by four weeks of negative pressure wound therapy 
(NPWT). The wound granulated well with the NPWT and subsequently underwent EG (Figure 
5.3). Complete re-epithelialisation of the wound was noted at 5 weeks post-grafting while the 
donor site healed within the first week without any noticeable scar at week 6.  
 
Figure 5.3 The wound and donor site of Patient 2/HB 
(A) Healthy granulation tissue was seen on the wound bed after 4 weeks of NPWT. The wound 
measures 4.5cm x 3.0cm over the left patella region. (B) More than 50% of the wound was re-
epithelialised at week 3 post grafting. (C) Complete wound healing was seen at week 5. (D) 
Minimal scabs were seen at the donor site (black arrow) at week 3. (E) No visible scar was 
seen at the donor site (black arrow) at week 6. The donor site looks aesthetically similar to the 
surrounding skin.  
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Case 2: Patient 7/JZ.  
An 83-year-old fit and independent gentleman with history of appendicectomy and right 
hemicolectomy complicated by an incisional hernia in 2011, referred with chronic non-healing 
wound over the central abdomen. The wound measured 4.5cm x 3.5cm and was dressed with 
honey dressings, Inadine (Systagenix) and Silflex (Advancis Medical) prior to EG (Figure 5.4). 
50% reduction in wound size was achieved at week 4, and complete wound healing was 
achieved at week 8. 
 
 
Figure 5.4 The wound of Patient 7/JZ 
(A) 4.5cm x 3.5cm superficial, granulating wound over the central abdomen. (B) At week 4, 
50% of the wound was re-epithelialised. (C) The wound was completely healed at week 6. 
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Case 4: Patient 19/JS 
An 88-year-old male presented with a two-week history of a right forearm laceration following 
trauma. The wound measured 2 x 3.5cm, was granulating and had no growth on microbiology 
swabs. The patient had a past medical history of ischaemic heart disease only and was a non-
smoker. Epidermal grafts were taken from the right thigh and applied to the wound. Adaptic 
touch (Systagenix) dressings were applied. Within three weeks the wound had reduced in size 
by 50% and within five weeks the wound was 100% healed (Figure 5.5). The donor site healed 
within six days after harvest.  
 
 
Figure 5.5 The wound of Patient 19/JS 
(A) Right forearm 2x3.5cm laceration wound. (B) At 3 weeks post EG the wound was 50% 
healed; (C) at 5 weeks the wound was 100% healed. 
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5.5 Discussion 
The use of epidermal grafts or blister grafts for the treatment of vitiligo and chronic wounds 
has already been widely reported but it’s use has been limited due to the lack of reproducible 
and efficient harvesting techniques for the outpatient setting [148, 149]. This study 
demonstrates the feasibility of using a novel epidermal harvesting device to achieve definitive 
wound coverage in the outpatient setting.  
The CelluTome device produces an array of epidermal microdomes, comprising of epidermis 
down to the basal layer, immediately available for transfer to the recipient site. Epidermal 
grafts are made of multi-layered keratinocytes, in which a variety of other cell types with 
specialised functions are embedded, such as the melanin pigment-producing melanocytes, 
the immune-competent Langerhans cells, and the neuroendocrine Merkel cell; while its basal 
layer contains epidermal stem cells [150]. During the early stages of wound healing, 
keratinocytes begin to migrate from wound edges within 24 h to the wound bed where they 
proliferate and form new epithelium [151]. Migrating keratinocytes synthesise and deposit a 
variety of extracellular matrix components, such as laminin, fibronectin, and type IV collagen 
[152]. In addition, numerous growth factors are also produced, namely, epidermal growth 
factor (EGF), transforming growth factor alpha (TGF-a), and heparin-binding growth factor 
(HB-EGF), which acts on the epidermis to drive wound closure [153]. The epidermal grafts, 
hence act more like a bioengineered skin, stimulating the endogenous process of wound 
healing.  
Another key factor to the success of EG is the ability for basal cell outgrowth from the graft 
edge and this occurs for up to a 2mm distance [113].  This is intrinsic to the design of the 
harvester, which consists of 128 micrograft pores set at a 2mm distance apart to allow for the 
grafts to be raised in this manner (Figure 5.1, above).  
Wound healing was a key outcome measured and the results demonstrated that 86.7% of the 
wounds fully healed with the use of Cellutome.  50% wound healing was achieved within 2.55 
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± 0.97 weeks and complete wound closure was achieved within 5.1 ± 1.58 weeks.  Of the 
wounds that healed, 56.52% were chronic wounds that were not responding to dressings and 
conservative management, which potentially implies that the EGs stimulate the healing 
process in quiescent wounds. The donor site wound healed within 5.57 ± 0.97 days with 
excellent aesthetic outcome, requiring neither frequent nursing care nor scar management. 
This result is encouraging as a donor site from a SSG can take up to 21 days to re-epithelialise 
with current donor site dressing methods[154]. Furthermore, donor site complications such as 
infection, pain, and hypertrophic scarring can be avoided.  Interestingly there was no 
significant difference in wound healing time between the acute and chronic wounds making 
the CelluTome equally useful in both types of wounds.  The aetiology of the wound and 
anatomical site also had no significant impact on the wound healing times. This is likely due 
to the wound bed preparation as all wounds were prepared to have healthy granulating wound 
bed prior to grafting using standard wound bed preparative methods. Donor site healing was 
excellent in all patients with all cases scoring 0 on the Vancouver Scar Scale at 6 weeks, 
implying that the skin looked and felt similar to the surrounding normal skin. As for the pain 
scores, these were reported to be very low for all patients with a mean pain score during graft 
harvest was 1.78 ± 0.79 making this a very tolerable technique.  
As with all new technologies the costs of intervention need to be assessed. We did not formally 
undertake a cost analysis. However, the series included 10 acute wounds (mean duration: 
1.45 ± 0.76 months) and 13 chronic wounds (mean duration: 12.8 ± 16.6 months) a total of 
181 months of dressing care was performed before the intervention of CelluTome. If these 
wounds had been dressed 2-3 time per week, a total of 1448-5792 dressing changes would 
have been performed. In total 23 interventions were performed with 200-300 dressing changes 
in the 8 weeks of care with over two thirds of patients achieving a dressing free (healed) 
outcome. The intervention and subsequent treatment therefore costing less than 10% of the 
previous management costs.  
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Our experience shows that this harvesting device can be introduced routinely in the outpatient 
setting for both acute and chronic wounds.  Once a patient has been assessed they can be 
invited back to a routine ‘cellutome’ clinic and undergo the epidermal harvest followed by 
routine dressing changes by the delivering clinical team.  Chronic wounds pose a significant 
burden on the NHS, representing at least 5.5% of NHS budget expenditure, therefore such 
technologies that can introduce lasting improvements to wound management should be 
welcomed[155].   
 
5.6 Study limitation 
This is an observational study and therefore prone to selection bias. The data reported 
includes all cases performed in a sequential manner and patients were identified from routine 
referrals. Learning curve was experienced in the first few cases and this was attributed to three 
main points; 1) the quality of the wound bed preparation, 2) ensuring absence of wound bed 
infection (responsible for three graft failures), and 3) the harvest and post-operative wound 
care.   Following some graft failures due to infection, assessing wounds with a pre-operative 
swab has become the standard approach. The fragility of the epidermal grafts and keratinocyte 
sheets that develop in the weeks post-operatively was acknowledged and as such our practice 
has changed whereby the wound bed is not touched during the first 3-4 weeks of dressing 
changes.  Furthermore, better management of exudate levels with various secondary 
dressings was achieved which also improved results.  
The feasibility of treating acute wounds in the outpatient setting reduces the need for patients 
to be admitted for autologous skin grafting. In addition, the prospect of using this device in the 
emergency department for the management of acute wounds could potentially reduce the 
number of hospital visits. The CelluTome is easy to use and well tolerated by patients. Elderly 
patients with multiple co-morbidities would benefit from this technique as it does not require 
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anaesthesia and avoids the complications of bed rest, maintaining patient’s independence and 
quality of life.  
 
5.7 Conclusion 
This automated device offers a novel method in autologous skin harvesting resulting in 
minimal or no pain and a scar free donor site in the outpatient setting. Complete wound 
coverage is achieved, while maintaining patient independence. It has the potential to save 
healthcare resources by eliminating the need for theatre space and a hospital bed, while at 
the same time benefiting patient care.  
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6.0 Patient reported outcome measure (PROM) and cost evaluation study 
 
6.1 Chapter summary 
 
This chapter is aimed to compare EG with SSG by evaluating patient reported outcome 
measures (PROMs) and cost implications of both. Twenty patients answered a graft 
satisfaction questionnaire which evaluated: donor and graft site noticeability, aesthetic 
concerns, adverse problems and patient satisfaction. Cost per patient was calculated based 
on total operative expenses and five clinic follow-ups. In 100% of EG cases there were no 
donor site noticeability or adverse problems compared to 25% in the SSG group. Complete 
satisfaction with donor site appearance was observed in 100% of EG cases (50% in the SSG 
group). Noticeability, adverse problems and overall satisfaction were significantly better in the 
EG group (p<0.05). Graft site parameters were comparable with similar healing outcomes. 
The estimated cost per patient for EG was £776 and £1487 for SSG with an annual profit to 
the trust of £41400 based on ten grafts per month. For the right patient, EG with CelluTome 
provides comparable wound healing with reduced donor site morbidity and higher patient 
satisfaction. 
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6.2 Introduction 
 
This chapter aims to evaluate the patient reported outcome and cost efficiency of using 
CelluTome to provide EG in an outpatient setting against SSG. The systematic use of 
information from PROMs is known to lead to overall better decision making between doctors 
and patients and results in patients being more satisfied with their treatment [156]. By 
comparing PROMs and the cost of EG versus SSG in an analogous cohort of patients, we aim 
to determine if EG with CelluTome is a viable alternative to current wound management 
technique besides being cost effective for the NHS and patients.  
 
6.3 Methods 
 
6.3.1 Patient Reported Outcome Measures (PROMs) 
Twenty demographically matched patients (ten who had undergone SSG and ten who had 
undergone EG with CelluTome) were retrospectively selected for inclusion in the study. All 
patients received grafting once wounds showed healthy granulation tissue with good 
vascularity. PROMs were assessed using a validated patient skin graft satisfaction 
questionnaire (Appendix B2).  All patients received the questionnaire at least six weeks after 
their procedure. The questionnaire assessed patient views on donor and graft site, 
noticeability; problems; concerns about cosmetic appearance; and, overall outcome. The 
results were found to be non-normally distributed using Shapiro-Wilk normality test and were 
analysed using the Mann-Whitney U test. 
Patients also underwent weekly wound assessment in the dressings clinic to monitor progress 
of healing.  
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6.3.2 Cost Analysis 
A calculation was made for cost and income for inpatient SSG, an EG with CelluTome and 
conservative dressing management. The cost of each patient event was calculated using the 
corresponding Office of Population Censuses and Surveys Classification of Surgical 
Operations and Procedures (OPCS) codes and overall cost of each treatment event was 
calculated as an average of the patients included in this study taking into account co-
morbidities. The cost and income per patient based on the OPSC code is shown in Table 6.1. 
For both the SSG and CelluTome procedures, costing included one initial and four follow-up 
dressing clinic appointments, which is the average standard practice in our department. For 
conservative dressing management, costing included one initial and fourteen follow-up 
dressing clinic appointments, based on the average number of dressing changes for a patient 
with chronic wound. 
An annual cost was also calculated based on an estimate of ten patients per month, which is 
the expected case volume once the EG service is fully operational. 
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Patient Event 
OPSC 
Code 
Average cost per 
event (£) 
Average income 
per event (£) 
Loss/profit 
per event 
Inpatient SSG S35.2 1060 1032 -28 
EG with Cellutome S36.8 349 668 319 
Initial dressing clinic 
appointment 
S57.4 91 137 46 
Follow-up dressing clinic 
appointment 
S57.5 84 79 -5 
 
Table 6.1 Summary of average cost and income per patient event 
Average cost per event takes into account the cost of manpower and materials involved per 
hospital or clinic visit. Average income per event represents the payment received by the trust 
per hospital or clinic visit. Loss or profit per event represents the difference in the average cost 
and income per event. 
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6.4 Results 
 
6.4.1 Patient demography 
The demography of patients included in this study is presented in Table 6.2. 
 
 EG patients (n=10) SSG patients (n=10) 
Age: Average (range) 74 (50-93) 54.6 (19-94) 
Male: Female 3:7 4:6 
Aetiology of wound   
Chronic traumatic wound 5 7 
Acute wound 3 3 
Venous ulcer 2 0 
Location of wound   
Leg 9 10 
Abdomen 1 0 
Average wound size (mean 
cmP2P) 
16.5 21 
 
Table 6.2 Demographics of patients included in the study 
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6.4.2 Patient Recorded Outcome Measures 
 
6.4.2.1 Donor site: 
There was no donor site noticeability, adverse problems or concerns in 100% of patients 
undergoing EG. All patients were either very (80%) or somewhat (20%) satisfied with their 
donor site outcome. All donor sites healed fully with an average healing time of 5 days. 
In comparison, only two patients in the SSG group stated that they did not find their donor site 
noticeable, with six patients finding it either somewhat or very noticeable. Six of the SSG 
patients found their donor site to be problematic to some degree. Four patients were 
unsatisfied to some degree with the overall outcome. However, only two patients were 
concerned about their donor site appearance. All donor sites healed fully. 
Donor site noticeability, adverse problems and overall satisfaction were statistically 
significantly better in EG (p<0.05). Figure 6.1 shows the results of the PROMs for donor sites.  
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Figure 6.1 PROM for Donor Sites  
Data were compared using Mann-Whitney U test. Statistically significant results (p<0.05) 
were highlighted by *. 
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6.4.2.2 Graft recipient site:  
 
Overall, 80% of the EG patients were completely satisfied with the appearance of their graft 
site.  Only 30% of patients found their graft site very noticeable, whilst 10% found it not 
noticeable at all.  40% of patients had no concerns or adverse problems with their graft site.  
Those that complained of it being problematic were referring to the length of time it took for 
the graft to heal, but none complained about pain or infection.  
Eight EG patients had evidence of healing at the graft site, with two having a 50% reduction 
in wound size and six having a 100% reduction. Average healing time for 100% reduction was 
six weeks. Two patients had failed grafts, one who had a chronic venous ulcer and one who 
had a chronic surgical wound following skin lesion excision; both patients were 
immunocompromised. 
The graft site in SSG was noticeable to some degree in all patients, with 70% of patients 
finding it very or somewhat noticeable.  Despite this, the majority of patients (70%) were not 
concerned at all about their graft site appearance, with only two patients suffering adverse 
problems. Overall satisfaction rates showed 100% of people were satisfied to some degree.  
Figure 6.2 shows the results on the PROMs regarding the graft site in the EG and SSG groups.  
There was no statistically significant difference in the outcomes of the two groups.  
Four SSG patients had 100% reduction in wound size, with the other six having at least 50% 
reduction. Average healing time for 100% reduction was 7 weeks. There were no graft failures. 
One patient suffered a graft site infection requiring a course of antibiotics. Two patients 
expressed dissatisfaction about long healing times. A comparison of EG and SSG graft site 
healing is shown in Table 6.3. 
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Noticeability Concerns Adverse
problems
Overall
satisfactions
0
1
2
3
4
5
6
PROM graft site  EG  SSG
 
Figure 6.2 PROM for Graft Sites 
Data were compared using Mann-Whitney U test. No statistically significant difference was 
seen between groups.  
 
 
 
100% reduction 50% reduction Failed grafts 
Average time to 100% 
reduction (weeks) 
EG 6 2 2 6 
SSG 4 6 0 7 
 
Table 6.3 Comparison of EG and SSG graft site healing outcomes 
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6.4.3 Cost Analysis 
Figure 6.3 shows the overall treatment cost (including dressing clinic follow-up) for an 
individual patient. 
The overall loss or profit per treatment option (including dressing clinic follow-up) for 120 
patients annually is summarized in Table 6.4.  
 
 
Figure 6.3 Overall treatment cost per individual patient.  
The costing for SSG and EG included one initial and four follow-up dressing clinic 
appointments. For conservative dressing management, costing included one initial and 
fourteen follow-up dressing clinic appointments. 
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Treatment Option Cost per 
patient (£) 
Income 
per patient 
(£) 
Annual cost 
for 120 
patients (£) 
Annual 
income for 
120 patients 
(£) 
Annual loss or 
profit for 120 
patients (£) 
SSG + dressing 
clinic follow-up 
1487 1489 178440 178680 -240 
EG + dressing 
clinic follow-up 
776 1121 93120 134520 41400 
Dressing 
management only 
1267 1243 152040 149160 -2880 
 
Table 6.4 Summary of annual loss/profit per treatment option 
Cost per patient takes into account the treatment itself, dressing cost for the treatment 
and subsequent clinic follow-ups. Income per patient represents the payment received 
by the trust for the treatment and subsequent clinic follow-ups. Annual cost and income 
represent the cost and income for a total of 120 patients (10 patients per month). 
Annual loss or profit is the difference in the annual cost and income for a total of 120 
patients. 
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6.5 Discussion 
Management of acute and chronic wounds cost the NHS billions of pounds per annum, and 
had been identified by the WHO as a significant health problem. Current management options 
include SSG or conservative management. However, SSG often requires anaesthesia in a 
setting with access to the correct equipment, and can cause significant donor site morbidity 
and discomfort for the patient. Conservative dressing management is often an extremely long 
process requiring many attendances by nurses (either in the community or in a hospital 
dressing clinic) with varying outcomes and occasional progression to theatre for a SSG or 
commencement of negative pressure wound therapy. 
Our pilot case series (Chapter 5) shown that the CelluTome epidermal graft harvesting device 
is effective in managing a variety of acute and chronic wounds in a wide range of patients, 
offering a viable alternative to SSG. 
This study is the first to evaluate PROM in patients treated with the CelluTome epidermal 
harvesting device. Currently there is a growing need for transparency in results and procedural 
outcomes from both operator and patient’s perspective.  Chronic non-healing wounds often 
cause stress and morbidity to patients.  Treatment options that do not involve anaesthesia, 
donor site morbidity and an admission to hospital (whether as a day case or longer stay) 
should be widely available. PROMs have been used to monitor outcomes for certain 
procedures in the surgical community for several years now.  They have been widely shown 
to improve public transparency, aid surgeons to improve their practice, to offer patients 
informed choices about their care, whilst aiding health service commissioners to make 
sensible funding decisions[157]. Subjective rating scale questionnaires such as the one used 
in this study are validated tools for assessment of psychological impact of skin grafting and 
provide a review of a patient’s opinion on a specific treatment[158]. 
We found that 100% of patients who had EG had no concerns, adverse outcomes or issues 
with noticeability of their donor site, with all patients being either somewhat or very satisfied 
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with the final outcome and all donor sites showing complete healing. This is in comparison 
with SSG patients, of which three-quarters found their donor site to be significantly more 
noticeable, half of whom experienced problems such as on-going pain, requiring analgesia 
and the donor taking longer than expected to heal, and only half being satisfied with the final 
outcome. EG patients have reduced discomfort, with previous studies also illustrating rapid 
healing of the donor site within a few days[92, 93]. 
There was no statistically significant difference between the EG and SSG group when patients 
were asked about their opinion of their graft site. 80% of EG patients were completely satisfied 
with the graft site outcome and the majority of patients showed good evidence of healing at 
the graft site. These findings illustrate that patient perception of wound site healing with EG is 
satisfactory and similar to current standard therapy. However, larger studies are required to 
evaluate the effectiveness of CelluTome derived EG in wound healing compared to SSG and 
a RCT comparing the two options is essential. 
Our study also found that the average cost of using the CelluTome device was considerably 
less than both SSG and conservative dressing management per individual patient. An annual 
estimate based on twenty EG patients per month shows a significant saving compared to 
traditional treatment options. The calculations were estimates and do not represent actual 
spending; however, they provide an excellent overview of the potential financial benefits of 
this procedure. A particular benefit of EG is its ease of use in an outpatient setting which is 
cost effective and more importantly convenient for patients. Serena et al (2015) have also 
highlighted that the cost and simplicity of the device make it an excellent option for resource-
poor nations, as well as developed regions under contemporary austerity pressures[93]. 
A limitation of the cost analysis is that the ultimate cost of each treatment event was based on 
an average of the patients in this study according to the OPSC code. Therefore, ultimate 
revenue of each procedure will be variable as a Health Resource Group code (HRG code) will 
be calculated for each patient based on the treatments given and co-morbidities. It must also 
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be highlighted that the costing in this study is based on UK coding procedures and therefore 
costing will vary in other healthcare systems based on different coding practices per 
geographical variation. 
The small sample size and heterogeneity in patient population are the main limitations of this 
study, limiting the evidence. Furthermore, as this is a retrospective study with convenient 
sampling, it raises the question of selection bias. However, given this is a new procedure, 
there is not yet a large patient population from which to draw data and further studies are 
required to provide more evidence. 
 
6.6 Conclusion 
EG using a CelluTome epidermal graft-harvesting device is associated with a significant 
improved patient perceived donor site outcome when compared to SSG. This combined with 
the possible financial benefits and comparable graft site outcomes means EG could be 
considered as a first line treatment option for both small chronic and acute wounds requiring 
skin coverage in the right patient.  
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7.0 EPIGRAAFT: Epidermal grafting versus split-thickness skin grafting for 
wound healing: a randomised controlled trial 
 
7.1 Clinical Protocol 
7.1.1 Chapter summary 
EPIGRAAFT is a randomised controlled trial that compares the clinical efficacy and wound 
healing mechanism of EG against SSG for wound healing. The co-primary outcome measures 
are the proportion of wounds healed in 6 weeks and the donor site healing time. The secondary 
outcome measures include the cellular mechanism of healing, mean time for complete wound 
healing, patient satisfaction, health care utilisation, cost analysis, and incidence of adverse 
events.  A total of 44 patients were included, 22 in each arm. The healing outcome (proportion 
of wound healing and healing time) of EG and SSG were similar at week 6. EG had faster 
donor site healing (p<0.001) and lesser donor site morbidity (p<0.001). Greater 
downregulation of GJPs was seen in the EG group, especially in the chronic wounds, 
suggesting different healing mechanism between these two treatment groups. The massive 
downregulation in the EG group suggests that it initiates keratinocyte migration from wound 
edge and activates wound edge keratinocytes into a remodelling state of wound healing. The 
wound bed biopsies revealed increased inflammatory cells after EG in both acute and chronic 
wounds, with increased expression of proliferative markers, suggesting the activation of the 
wound bed. Keratinocyte markers revealed that the EG does not integrate to the wound bed, 
suggesting that it behaves more like a bioactive dressing instead of a skin substitute as 
previously believed. The EPIGRAAFT trial outlined that both techniques have comparable 
clinical efficacy, however EG has superior donor site outcomes and further highlighted that 
the two autologous skin grafts have unique healing mechanism. 
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7.1.2 Introduction 
 
SSG is the current standard of care for wound closure for non-healing wounds. Despite SSG 
being an important modality for wound closure, the donor site becomes a second, often painful 
wound, which may take more time to heal than the graft site itself and holds the risk of infection 
and scarring. 
This study evaluates the efficacy of EG, using the CelluTome Epidermal Harvesting System, 
as an alternative to the more invasive SSG (Figure 7.1). In our pilot study carried out using 
this system (reported in Chapter 5), EG was noted to be an effective method of autologous 
skin grafting with complete wound healing achieved in two thirds of selected patients with 
minimal or no pain and a scar free donor site. The ability to perform EG in outpatient setting 
eliminates the need for a theatre space and a hospital bed, contributing to better patient 
satisfaction and lower cost (reported in Chapter 6). However, it is not known if EG is an 
effective clinical alternative to SSG. 
The mechanism of wound healing by EG may be different compared to SSG. EG is postulated 
to promote wound healing by expressing growth factors that accelerate wound healing and 
encourage keratinocytes to migrate from the wound edge (reviewed in Chapter 4B). We 
hypothesise that EG has similar wound healing rates to SSG at 6 weeks but with less donor 
site morbidity. We wish to evaluate the efficacy of EG as an alternative to SSG and to further 
investigate the mechanism by which each technique achieves wound healing.  
 
  
144 
 
Figure 7.1 Comparison between the two surgical procedures (EG and SSG)  
(A) Epidermal grafting. (i, ii, iii) The harvester and vacuum head are strapped to patient’s 
thigh and the device is turned on for 30min, which raises an array of blisters. (iv) The roof of 
the blister is then excised by an in-built blade and transferred to the wound using a non-
adhesive dressing (v, vi). (B) Split-thickness skin grafting. (i) Skin is often harvested from 
patient’s thigh using an air dermatome which excises the epidermis and dermis of the skin, 
resulting in a donor site wound (ii). (iii) The excised skin is then transferred to the wound and 
secured with sutures (iv). 
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7.1.3 Trial design 
This study was single-centre, prospective, randomised, open-label, non-inferiority, controlled 
trial with 2 parallel groups. Eligible patients were randomised to EG or SSG using a computer 
randomisation method. This protocol is reported in accordance to the Standard Protocol Items: 
Recommendations for Interventional Trials (SPIRIT) 2013 guideline [159]. Clinicaltrials.gov 
identifier: NCT02535481 (Date of registration: 11 August 2015) 
 
7.1.4 Research ethics approval 
This trial was approved by the National Research Ethics Service Committee London-Fulham 
(project ID: 15/LO/0556) and from the National Health Service Research & Development 
Department, Royal Free Hospital (project ID:9417) (see Appendix B3). This trial was 
conducted in accordance to the Declaration of Helsinki and the recommendations of Good 
Clinical Practice.  
 
7.1.5 Study setting 
Participants were recruited at the Royal Free Hospital (RFH), London which is an academic 
teaching hospital and is associated with UCL.  
 
7.1.6 Eligibility criteria 
Patients referred by consultant plastic surgeons for skin grafting were eligible for this study. 
Before enrolment, patients were screened for inclusion into the trial and a patient information 
sheet was given (see Appendix B4). This process involved an explanation of the aims, 
methods of skin grafting and subsequent wound management, anticipated benefits, and 
potential hazards of the study. Patients were given sufficient time (offered a period of 24 h or 
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more if needed) to consider whether they wish to participate (see Appendix B5). Patients were 
then offered participation in the study and informed consent was obtained. Treatment was 
given within seven days of patient enrolment. 
Inclusion criteria are as follow: 
1. Age ≥18 years 
2. Wound measuring more than 1cm x 1cm and less than 6cm x 6cm (1 percent total 
body surface area) 
3. Clean, healthy granulating bed 
4. Patient understand and willing to participate in the trial and can comply with the weekly 
visits and follow-up regime 
Exclusion criteria are as follow: 
1. Infected wound 
2. Wound at the plantar of the foot 
3. Unsuitable for SSG 
4. Previous history of excessive bleeding associated with surgical biopsies or trauma 
5. Uncontrolled diabetes mellitus, as measured by HbA1c ≥10 percent 
6. Presence of one or more medical conditions including renal, hepatic, hematologic, 
active auto-immune or immune diseases 
7. Use of systemic steroid or immunosuppressant  
8. Not fit for surgery (ASA classification ≥4) 
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7.1.7 Interventions 
 
UWound bed preparation 
All wounds were prepared as per normal clinical practise which was either using the negative 
pressure wound therapy (NPWT) or appropriate wound dressings to achieve a healthy 
granulating bed. Wound swabs were performed to ensure no bacterial growth. During the time 
of wound bed preparation, the patients were referred to the research team. When the wound 
bed was deemed ready for grafting, as agreed between two treating clinicians, patients were 
screened and offered a patient information sheet for inclusion into the trial.  Once the patients 
were ready for intervention, following review by the study team, patients underwent informed 
consent and randomisation. 
 
UEpidermal grafting 
Prior to grafting, the wounds were cleaned using wound irrigation solution by the surgeon and 
debrided if necessary. The suction head of the CelluTome Epidermal Harvesting System was 
applied to the donor site (thigh) for 30-40 min to harvest epidermal graft as per protocol [84, 
160]. The harvested epidermal grafts were then transferred onto the wound using a non-
adhesive silicone dressing (Adaptic Touch, Systagenix). The wound was then dressed with a 
secondary dressing based on the wound type and exudate amount as deemed appropriate by 
the treating clinician. The dressings were secured with a crepe bandage or a Mefix dressing 
(Mölnlycke Health). The donor site was dressed with Tegaderm (3M). The wound and donor 
site were reviewed on day 7 ± 2 post-grafting, and then on a weekly interval. 
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USplit thickness skin grafting  
Patients underwent this procedure in the operating theatre under general or local anaesthesia. 
The wound was initially debrided by the treating surgeon in a similar manner to the EG group. 
Skin was harvested from the thigh using an electric air dermatome, set to cut at the thickness 
of 8-10/1000 inch, which was then meshed by 1:1.5. The wound was grafted and dressed with 
Adaptic Touch (Systagenix), gauze and a Mefix or wool and crepe bandage depending on the 
site of the graft. The donor site was dressed with Kaltostat (Alginate dressing) with a 2.5cm 
overlay beyond the wound margins and secured with Mefix. As per standard clinical practise, 
the graft was checked at day 7 ± 2, and then on a weekly interval. 
 
UPunch biopsy  
Skin punch biopsies (4mm) were taken from two locations, at the centre of the wound and at 
the wound edge, after administering adequate local anaesthesia (1% lidocaine). This 
procedure was done prior to grafting and repeated at day seven post-grafting. The specimens 
were placed in a sterile vial containing four percent paraformaldehyde and transferred to the 
laboratory.   
 
7.1.8 Study Outcome 
The co-primary endpoints were the proportion of wounds with complete healing at six weeks 
post grafting and the time for donor site healing. Complete wound healing was defined as 100 
percent re-epithelialisation and not requiring dressings. The assessment of wound healing 
was done via wound measurement at each review using a three-dimensional (3D) camera 
(LifeViz 3D camera (from Quantificare)) to obtain high quality, accurate and standardised 
images for digital measurement of the wound surface area [161]. The 3D photographs of the 
wounds and the donor sites were taken at each weekly visit and stored in the patients’ digital 
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photo diary. An independent blinded analysis of the photo diary was carried out by 2 plastic 
surgeons. 
The secondary endpoints include the mean time for complete wound healing, donor site 
healing quality (measured using Vancouver Scar Scale), PROM (assessed using the validated 
patient skin graft satisfaction questionnaire as used in Chapter 6) [158], healthcare utilisation 
and cost analysis (measured by the consumables used and the frequency of visits), and the 
incidence of adverse events. The incidence of serious adverse events (SAEs) include mortality 
of any cause within the three-months duration from the time of initial therapy, the incidence of 
device-related adverse events (DAEs) and the incidence of wound-related adverse events 
(WAEs) occurring within the study duration. The patient skin graft satisfaction questionnaire 
was completed by the participants at the sixth-week and third-month visit. 
Further, we determined the wound healing mechanism of EG compared to SSG by analysing 
the expression of Connexin proteins (GJP), proliferative marker and keratinocyte markers at 
the wound edge and the centre of the wound before and after grafting (elaborated in Chapter 
7.2).  
 
7.1.9 Participant timeline 
The study was opened to recruitment in October 2015 and closed in February 2017. Each 
patient was followed up weekly for six weeks or until the wound heals. The final review was at 
the third month from the initiation of treatment. Figure 7.2 summarises the patient’s journey 
throughout the trial. 
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Figure 7.2 Flow chart illustrating patient’s journey throughout the study 
 
Wound bed preparation  
Patient screened & a patient information leaflet given 
Patient consented & enrolled 
Biopsy 
samples 
sent to 
the 
laboratory 
Patient followed up weekly for 6 weeks in the clinic or until the wound heals 
Patient reviewed on day 7 ± 2 and undergoes 4-mm 
punch biopsies 
 
Patient underwent 4-mm punch biopsies followed by 
treatment 
SSG (n=22) EG (n=22) 
Randomisation 
(n=44) 
Final review at 3 months from the initiation of treatment 
Patient referred by a consultant plastic surgeon for skin grafting 
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7.1.10 Sample size 
Our pilot study and historical control revealed that both techniques offer the same healing rate 
at 6 weeks’ post grafting, however the donor site morbidity was present in 40% of patients 
with SSG while only 5% was seen in patients with EG. Donor site morbidity includes 
discolouration, scarring, pain, and risk of infection. 
Given a significance level of 0.05 for 80 percent power, this yields a sample size of 19 patients 
per group. Taking into consideration the potential dropout rate of 15 percent, the sample size 
has been adjusted to 22 patients per treatment arm. A total of 44 patients were recruited into 
the study. The timeline for recruitment was 24 months, although enrolment was completed 
ahead of schedule. 
 
7.1.11 Randomisation, allocation concealment and blinding 
Once consented, patients were randomly assigned to one of the treatment groups. A random 
allocation sequence was computer generated using SPSS version 24 (IBM, Armonk, NY, 
USA). The allocation sequence was sealed in opaque, identical envelopes and given to the 
enrolling researcher upon consenting patients.  The surgical team, clinical staffs, and patients 
were not blinded to the intervention status.  
 
7.1.12 Data collection and management 
All data collected was recorded on paper forms and digital clinical research folder (CRF). Any 
adverse events were recorded and reported to the primary investigators and the institutional 
ethics committee.  
Wounds were assessed and recorded in a wound assessment form at each visit (see 
Appendix B6). Details on patient’s co-morbidities, wound duration and type, and previous 
wound bed preparation methods were recorded. 3D photographs were used to digitally 
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measure the wound surface area. The number and cost of outpatient visits were recorded and 
the type and cost of the dressings used were documented. 
 
7.1.13 Statistical analysis 
All analysis was conducted according to the intention-to-treat principle with the use of SPSS 
version 24 (IBM, Armonk, NY, USA). Patients are evaluated for analysis if they received a 
study treatment. If the clinical course cannot be fully evaluated, the last point of visit was 
considered as the last data analysed. Baseline demographics of the two groups were 
recorded. The continuous variables were compared using independent t-test. The categorical 
variables were compared using Pearson’s chi-square or Fisher’s exact test depending on the 
number of events.   
The proportion of wounds healed with each treatment was compared using Fisher’s exact 
tests (expected count was less than 5 in 2 cells). Mean time to wound and donor site healing 
were determined on the basis of the number of days until complete re-epithelialisation, using 
Kaplan-Meier analysis of cumulative wound healing, followed by a log rank test. 
Donor site healing quality as assessed using Vancouver Scar Scale (VSS) was compared 
using independent t-test. PROM for wounds and donor site was found to be not normally 
distributed using Shapiro-Wilk test and the continuous variables were compared using Mann-
Whitney U test.  
A p value of less than 0.05 was considered significant and all tests were two-sided.  
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7.2 Laboratory Protocol 
 
7.2.1 Introduction 
The laboratory protocol used for tissue biopsy analysis was similar to the protocol used in 
Chapter 2. Additional protocol specific for this study will be elaborated here. 
The punch biopsies were taken at the wound edge and wound bed, prior to treatment and at 
week 1 post treatment (Figure 7.3). Patients were then followed up for 3 months as per trial 
protocol. 
 
Figure 7.3 Brief illustrative outline of the study protocol 
The punch biopsies were taken at the wound edge and wound bed. Following that, patients 
were randomised to either of the treatment arms. Biopsies were repeated at week 1 post 
treatment at the two similar locations.  
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7.2.2 Biopsy preservation and cryosectioning 
Samples from a total of 24 patients were analysed. These included 12 patients from EG group 
and 12 patients from SSG group. 
Sample preservation and cryosectioning were similar as performed in Chapter 2.4.1.  
 
7.2.3 H&E staining 
H&E staining was performed using the similar protocol as in Chapter 2.4.2 and imaged using 
Zeiss AxioScan Z1 slide scanner at 40x magnification at the Division of Biosciences, UCL with 
the assistance of Mr Christopher Thrasivoulou. 
 
7.2.4 Immunohistochemical staining for wound edge biopsies 
Tissue sections were thawed, immersed in PBS to dissolve excess OCT, permeabilized for 
15 min in 0.2% Triton X-100 and blocked using 0.1M lysine-PBS for 30 min to block non-
specific binding. Primary antibodies were prepared in PBS: anti-Cx43 (1:4000; C6219, Sigma 
- Poole, UK), anti-Cx26 (1:200; 10202093, Fisher Scientific, UK), and anti-Cx30 (1:200; 
10795723, Fisher Scientific, UK). The tissues stained for Cx43 were incubated with the 
primary antibody for 1 at RT, while tissues stained for Cx30 and Cx26 were incubated with the 
primary antibody overnight at 4PoPC. For negative controls, the primary antibody was omitted 
from the preparation. The tissue was washed with PBS for 3 x 5 min and stained with 
secondary antibody (Alexa Fluor 488 goat anti-rabbit, 10729174, 1:400; Fisher Scientific, UK) 
at RT for 1h. Nuclei were stained using Hoechst (1:10000; 10150888, Fisher Scientific, UK) 
for 5 min followed by 3 x 5 min PBS washes. Coverslips were mounted using Citifluor 
(Glycerol/PBS solution, Citifluor Ltd, London, UK) and sealed with nail varnish.  
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7.2.5 Immunohistochemical staining for wound bed biopsies 
Staining was performed using protocol obtained from our collaborator Dr John Connelly from 
Blizard Institute, Barts and The London, Queen Mary University of London. Tissue sections 
were thawed and placed in a staining dish containing Citrate Buffer solution (10mM Sodium 
Citrate, 0.05% Tween 20, pH 6.0) and placed in a water bath at 90PoPC for 15 min to break 
protein cross-linking for enhanced staining intensity of antibiotics. Slides were then allowed to 
cool down at RT for 20 min. Tissues were then rinsed twice with 0.1% PBS Tween 20 and 
permeabilized for 5 min in 0.2% Triton X-100. Sections were then blocked with 0.25% Gelatin 
from cold water fish and 10% fetal bovine serum for 60 min. Primary antibodies were prepared 
in PBS: anti-Ki67 (1:400; rabbit polyclonal, ab15580, abcam, UK), anti-cytokeratin 6 (1:100; 
mouse monoclonal, ab18586, abcam, UK), and anti-cytokeratin 14 (1:100; mouse monoclonal, 
ab7800, abcam, UK). Tissue sections were incubated with the primary antibody overnight at 
4PoPC. For negative controls, the primary antibody was omitted from the preparation. The tissue 
sections were washed with PBS for 2 x 5 min and stained with secondary antibody and 
incubated at RT for 1h. Alexa Fluor 488 goat anti-rabbit (1:400; 10729174, Fisher Scientific, 
UK) was used for anti-Ki67, while DyLight 488 goat anti-mouse IgG (1:400; ab96879, abcam, 
UK) was used for anti-cytokeratin 6, and anti-cytokeratin 14. Nuclei were stained using 
Hoechst (1:10000; 10150888, Fisher Scientific, UK) for 5 min followed by 2 x 5 min PBS 
washes. Coverslips were mounted using Citifluor (Glycerol/PBS solution, Citifluor Ltd, London, 
UK) and sealed with nail varnish.  
 
7.2.6 Confocal microscopy 
Leica TCS SP8 confocal microscope (Leica, Mannheim, Germany) was used to obtain 40x 
images: Hoescht was excited by a 405nm laser and Alexa Fluor 488 by a 488nm laser.  
Images for Connexin proteins at the wound edge biopsies were taken at six locations per 
biopsy (as per chapter 2.4.5) to ensure that the staining pattern observed truly represented 
the distribution of the protein of interest.  
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Images for collagen and Ki67 at the wound bed were taken at 3 locations: 500µm from each 
edge and one at the center of the biopsy, taken with a zoom factor of 2.0 to magnify the nuclei 
(Figure 7.4). Cytokeratin 6 and cytokeratin 14 were imaged at 3 random locations at the top 
part of the sections taken from the wound bed (Figure 7.4).  
All parameters were kept constant between the week 0 and week 1 skin sections to allow 
direct comparison.  
 
Figure 7.4 Areas images within the skin section 
Rectangular areas within the skin section represents the areas imaged for (a) Ki67, and (b) 
for cytokeratin 6 and cytokeratin 14.  
 
 
7.2.7 Connexin quantification 
ImageJ was used for Cx quantification using similar protocol as described in chapter 2.4.6. 
The Cx levels of the six confocal images from each tissue section were used to quantify the 
mean Cx expression. This data was presented as the ‘absolute connexin expression’. 
Subgroup analysis was performed based on wound type; acute (<3 months in duration) and 
chronic (≥3 month in duration). Statistical analysis was performed for both the absolute 
connexin expression and subgroup analysis and results presented in graphs. 
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7.2.8 Assessment for Ki67 
The number of nucleus expression Ki67 was manually calculated for each image and 
presented as ‘absolute Ki67 expression’. Subgroup analysis was performed based on wound 
type: acute and chronic wounds. Statistical analysis was performed for both absolute Ki67 
count and subgroup analysis and results presented in graphs. 
Due to damaged sample during processing, only total of 5 patients from the EG group and 4 
in the SSG group were included in the final analysis of Ki67. 
 
7.2.9 Assessment for cytokeratin 6 and cytokeratin 14  
Qualitative assessment was performed. The captured confocal images were used to 
evaluate for the presence or absence of the protein of interest.  
 
7.2.10 Statistical analysis 
All data were presented as the mean ± standard deviation. Statistical differences were 
determined using paired t-test for paired group (week 0 Vs week 1). Normality testing was 
performed using Shapiro-Wilk test; the Cx and Ki67 expressions were normally distributed in 
each group. All statistical analyses were performed using IBM SPSS Statistics 24 software.  
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7.3 Clinical results 
 
7.3.1 Patient demography 
Forty-four patients were enrolled between October 2015 and February 2017 and randomised, 
with twenty-two patients in each group. The monthly enrolment progress is summarised in 
Figure 7.5. The clinical results were reported here as per Consolidated Standards of Reporting 
Trials (CONSORT) guideline. All randomised patients received the intended treatment (Figure 
7.6: CONSORT diagram for the trial). There was no protocol deviation and analysis was 
performed as per intention-to-treat. 
The two groups did not differ in age, sex, or wound size (Table 7.1). The duration of wound in 
the EG group was significantly longer, with more chronic wounds compared to the SSG group.  
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Figure 7.5 Monthly enrolment progress 
Summary of the monthly enrolment progress for the 44 patients.  
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Figure 7.6 CONSORT flow diagram for the trial   
Assessed for eligibility (n=61) 
Excluded due to not meeting inclusion 
criteria (n=17) 
• Wound not ready for skin graft (n=12) 
• Wound size too small/large (n=4) 
• Wound at plantar surface of foot (n=1) 
Analysed (n=22) 
Lost to follow-up (n=0) 
Allocated to EG (n=22) 
 Received allocated intervention (n=22) 
 Did not receive allocated intervention (n=0) 
Lost to follow-up (n=0) 
Allocated to SSG (n=22) 
 Received allocated intervention (n=22) 
 Did not receive allocated intervention (n=0) 
Analysed (n=22) 
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EG SSG p (t-test) 
Mean age 58 ± 20 59 ± 18 0.86 
Sex ratio (Male: Female) 13:9 17:5 0.20 
Wound size (cmP2P) 12.7 ± 9.9 16.5 ± 11.0 0.24 
Duration of wound (week) 48.9 ± 75.4 7.86 ± 16.1 0.02 
Type of wound 
   
Acute 11 18 
 
Chronic 11 4 
 
Cause of wound 
   
Dehiscence 7 2 
 
Amputation 0 1 
 
Trauma 11 8 
 
Debridement 1 3 
 
Excision 1 7 
 
DFU 0 1 
 
Arterial ulcer 1 0 
 
Radiotherapy 1 0 
 
Location of wound 
   
Hand 1 1 
 
Forearm 0 1 
 
Foot 3 2 
 
Ankle 2 0 
 
Leg 7 9 
 
Knee 3 3 
 
Thigh 0 2 
 
Groin 0 1 
 
Abdomen 2 1 
 
Chest 1 0 
 
Back 1 1 
 
Breast 1 0 
 
Scalp 1 1 
 
Values are mean ± s.d 
Table 7.1 Demographics   
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7.3.2 Wound healing  
No statistically significant difference was noted in the proportion of complete wound healing 
between both groups at 6 weeks (EG: 40.9% vs SSG:59.1%; p=0.366, Fisher’s exact test) 
and 3 months’ time point (EG:72.7% versus SSG:90.9%; p=0.24, Fisher’s exact test). The 
Kaplan-Meier mean estimate for complete wound closure was 7.81(95 percent CI 6.44-9.19) 
weeks for EG versus 6.59 (95% CI 5.29-7.89) weeks in patients who had SSG, with no 
statistical significance between groups (p=0.12, log rank test) (Figure 7.7). 
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Figure 7.7 Kaplan Meier plot of time for complete wound healing with EG and SSG 
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7.3.3 Donor site healing 
Time for donor site healing was significantly shorter in patients with EG: the Kaplan–Meier 
mean estimate of time for complete donor site healing was 4.86 (95 percent c.i. 4.41 to 5.32) 
days versus 21.32 (95 percent c.i. 15.65 to 26.99) days for SSG (p<0.0001) (Figure 7.8). All 
donor sites achieved complete healing for both treatment groups.  
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Figure 7.8 Kaplan Meier plot of time for complete donor site healing 
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7.3.4 Donor site morbidity 
Vancouver Scar Scale scores were lower in the EG group than in the SSG group both at 6 
weeks (0.14±0.45 vs 3.73±0.69; p=0.001, independent t-test) and at 12 weeks (0.09±0.29 vs 
2.91±0.67; p=0.001, independent t-test) (Figure 7.9). Figure 7.10 illustrates the clinical 
outcome of the donor sites for both treatment groups. 
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Figure 7.933T Vancouver Scar Scale for donor site morbidity 
 
 
Figure 7.1033T Clinical outcome of donor sites for EG and SSG 
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7.3.5 Patient reported outcome measure (PROM) 
PROM of the donor site at week 6 and month 3 reveals that patients in the EG group reported 
significantly lower noticeability (week 6: p=0.001; month 3: p=0.001, Mann-Whitney U test), 
concerns (week 6: p=0.001; month 3: p=0.001, Mann-Whitney U test) and adverse problems 
(week 6: p=0.001; month 3: p=0.001, Mann-Whitney U test), and higher overall satisfaction 
(week 6: p=0.001; month 3: p=0.001, Mann-Whitney U test) (Figure 7.11).  
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Figure 7.11 PROM of the donor site at week 6 and month 3 
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PROM of the wound site at week 6 and month 3 reported no significant difference in the wound 
noticeability(week 6: p=0.266; month 3: p=0.072, Mann-Whitney U test), concerns(week 6: 
p=0.462; month 3: p=0.056, Mann-Whitney U test), adverse problems(week 6: p=0.470; month 
3: p=0.272, Mann-Whitney U test) and overall satisfaction(week 6: p=0.252; month 3: p=0.106, 
Mann-Whitney U test) (Figure 7.12).  
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Figure 7.12 PROM of the wound site at week 6 and month 3 
 
 
  
167 
7.3.6 Incidence of adverse event 
No incidence of adverse events experienced by any patients. 
There was no post-operative complication in both groups. All patients were followed up for 12 
weeks. During follow-up visits, both groups demonstrated good wound strength, as measured 
by the assessing clinicians. No recurrent wound was recorded in the EG group, whereas one 
patient with arterial ulcer in the SSG group developed wound breakdown at the graft site. This 
patient underwent wound dressings until complete healing. 
 
7.3.7 Health economics 
Health economics were not included in this thesis although data was collected. The data is 
still being analysed and will be included into future publication.  
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7.4 Laboratory results 
 
7.4.1 Analysis of wound edge biopsy 
7.4.1.1 Histological feature of wound edge 
The histological observation of the wound edge biopsies did not reveal any obvious change in 
the wound edge epidermis and dermis after treatment in both groups (Figure 7.13). There was 
no obvious difference in the thickness of the epidermis or the distribution and depth of rete 
ridges. No prominent change in the distribution of inflammatory cells or density of collagen 
fibres in the dermis was observed. 
 
 
Figure 7.13 Histology of the epidermis and dermis at the wound edge 
H&E stained section of the skin biopsies of both treatment groups. No obvious difference was 
observed in the epidermis and dermis between both treatment groups with treatment. 
EPI=epidermis, DER=dermis. Scale bar = 100µm. Magnification 20x.   
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7.4.1.2 Connexin expression at the wound edge 
 
A general downregulation of the Cx proteins were seen at the wound edge after treatment, 
which was more prominent in the EG group. The pattern of downregulation differed between 
acute and chronic wounds for all three Cx proteins.  
A significant downregulation of Cx43 was seen after EG (p=0.021, paired t-test) (Figure 7.14). 
Subgroup analysis based on wound type revealed significant downregulation of Cx43 in the 
chronic wounds after EG (p=0.023, paired t-test). Downwards trend of Cx43 expression was 
observed in the acute wounds after EG, however this was not statistically significant (p=0.246, 
paired t-test). 
The absolute Cx30 expression demonstrated similar pattern of downregulation as Cx43, with 
significant overall downregulation in the EG group (p=0.046, paired t-test) (Figure 7.15). 
Similarly, subgroup analysis revealed significant downregulation in chronic wounds after EG 
(p=0.027, paired t-test). 
Despite Cx26 demonstrated reduction in the mean Cx expression after treatment in both 
treatment arms, the downregulation was not statistically significant in either groups (EG: 
p=0.162; SSG: p=0.299, paired t-test), and in either wound types (Figure 7.16).  
A change in the distribution pattern of the three Cx proteins were observed after treatment in 
both groups. Reduced expression of the Cx proteins in the basal layer of the epidermis was 
observed, which was most prominently observed in Cx43.  
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Figure 7.14 Connexin 43 expression at the wound edge 
(A) Confocal images of Cx43 expression in each group at week 0 and 1. Scale bar = 50µm. 
Magnification 40x. (B) Mean absolute Cx43 expression. (C, D) Subgroup analysis of mean Cx 
expression in acute wounds and chronic wounds. Values expressed as mean ± standard 
deviation. *P<0.05 (paired t-test)  
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Figure 7.15 Connexin 30 expression at the wound edge 
(A) Confocal images of Cx30 expression in each group at week 0 and 1. Scale bar = 50µm. 
Magnification 40x. (B) Mean absolute Cx30 expression. (C, D) Subgroup analysis of mean Cx 
expression in acute wounds and chronic wounds. Values expressed as mean ± standard 
deviation. *P<0.05 (paired t-test)  
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Figure 7.16 Connexin 26 expression at the wound edge 
(A) Confocal images of Cx26 expression in each group at week 0 and 1. Scale bar = 50µm. 
Magnification 40x. (B) Mean absolute Cx26 expression. (C, D) Subgroup analysis of mean Cx 
expression in acute wounds and chronic wounds. Values expressed as mean ± standard 
deviation. *P<0.05 (paired t-test)  
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7.4.2 Analysis of wound bed biopsy 
 
7.4.2.1 Histological feature of wound bed 
The histological observation of the wound bed biopsies revealed distinct feature between 
groups. At week 1, increased inflammatory cells were seen after EG, both in acute and chronic 
wounds (Figure 7.17 A, B). Multinucleated cells, which are neutrophils, were observed to be 
increased after EG. In addition, chronic wound treated with EG demonstrated a change in the 
density of extracellular matrix, whereby it was noted to be more compact and dense.  
In the wounds treated with SSG, the newly integrated skin graft was visible as a clear layer of 
epidermis (Figure 7.17 C). A reduction in expression of inflammatory cells was observed.  
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Figure 7.17  Histology of the wound bed of wounds treated with EG and SSG.  
(A) H&E stained section of the acute wound treated with EG and the corresponding clinical 
photograph of the wound at week 0 and week 1 at 5x and 63x magnification. Increased 
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expression of inflammatory cells was observed after treatment. (B) H&E stained section of the 
chronic wound bed treated with EG and the corresponding clinical photograph of the wound 
at week 0 and week 1 at 5x and 63x magnification. Increased expression of inflammatory cells 
was observed after treatment. The ECM of the wound bed after treatment appears more 
compact and dense compared to before treatment. (C) H&E stained section of the wound bed 
treated with SSG and the corresponding clinical photograph of the wound at week 0 and week 
1 at 5x and 63x magnification. A clear layer of epidermis is seen at week 1 along with 
decreased expression of inflammatory cells.  
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7.4.2.2 Ki67 expression in wound bed biopsy 
A general increase in the nuclear expression of Ki67 antigen was observed, which was 
significant in the EG group (p=0.002, paired t-test) (Figure 7.18). Subgroup analysis revealed 
significantly increased expression of Ki67 in both the acute (p=0.017, paired t-test) and chronic 
(p=0.048, paired t-test) wounds after EG. Despite an increased expression of Ki67 after 
treatment in the SSG group, statistical significance was not achieved (absolute Ki67 
expression: p=0.124, paired t-test; acute wound: p=0.124, paired t-test; chronic wound: no 
statistical test performed due to single sample in this group) 
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Figure 7.18 Ki67 expression at the wound bed 
(a) Confocal images of Ki67 expression in each group at week 0 and 1. Ki67 is stained green 
(excited with 488nm laser). Scale bar = 50µm. Magnification 40x. (b) Mean absolute Ki67 
expression. (c, d) Subgroup analysis of mean Cx expression in acute wounds and chronic 
wounds. Values expressed as mean ± standard deviation. *P<0.05 (paired t-test)   
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7.4.2.3 Cytokeratin 14 expression in wound bed biopsy 
Cytokeratin 14 expression in the wound bed biopsies was observed in all wounds treated with 
SSG (Figure 7.19). No positive staining was observed in any of the wounds treated with EG 
at week 1 post grafting.  
 
Figure 7.19 Cytokeratin 14 expression on the wound bed 
Confocal images of cytokeratin 14 expression in each group at week 0 and 1. Cytokeratin 14 
staining was seen at week 1 in the SSG group. Epi = epidermis, WB = wound bed. Dotted line 
represents the surface of the wound bed. Cytokeratin 14 is stained green (excited with 488nm 
laser). Scale bar = 50µm. Magnification 40x.  
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7.4.2.4 Cytokeratin 6 expression in wound bed biopsy 
Cytokeratin 6 expression in the wound bed biopsies was observed in all wounds treated with 
SSG (Figure 7.20). No positive staining was observed in any of the wounds treated with EG 
at week 1 post grafting.  
 
Figure 7.20 Cytokeratin 6 expression on the wound bed 
Confocal images of cytokeratin 6 expression in each group at week 0 and 1. Cytokeratin 6 
staining was seen at week 1 in the SSG group. Epi = epidermis, WB = wound bed, Film = 
clear layer of film/wound fluid overlying wound. Dotted line represents the surface of the wound 
bed. Cytokeratin 6 is stained green (excited with 488nm laser) while the nuclei is stained blue 
(excited with 405nm laser). Scale bar = 50µm. Magnification 40x.  
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7.5 Discussion 
This study examined the clinical efficacy of EG and SSG and the mechanism of healing 
between these two autologous skin grafts. This is the first RCT to compare EG against SSG 
and is the first time that the in vivo mechanism of healing of EG is being outlined and compared 
against SSG.  
The clinical results proved the non-inferiority of EG against SSG for wound healing. EG, 
however, demonstrated superior outcome in the donor site with shorted healing time, lower 
morbidity, and higher patient satisfaction. The donor site of EG displayed similar pigmentation, 
pliability and vascularity to the surrounding skin, with consistently short healing time in all 
patients. Hence, the key advantage of EG is the faster donor site healing and lower donor site 
morbidity which is associated with better patient satisfaction. This likely has a major positive 
implication to clinical practise as SSG, the current primary choice of autologous skin graft, 
often results in donor site which is painful, prone to infection and requires meticulous donor 
site management [162]. Furthermore, the optimal donor site dressing for SSG is yet to be 
determined and a systematic review of donor site dressings found no clear evidence to support 
the choice of a particular dressing [163]. Hence, the rapid donor site healing of EG does not 
only improve patient satisfaction, but likely reduces cost and healthcare resources as it only 
requires a single application of a simple film dressing.  
Although the proportion of wound healing at 6 weeks and 12 weeks was slightly higher in the 
SSG group, this difference was not statistically significant. This study was not powered to 
detect the difference in wound healing outcome, instead it was powered to detect the 
difference in the donor site morbidity, as the wound healing outcome was assumed to be 
comparable between both treatment groups based on pilot data and historical control. 
However, despite the difference in the mean time for complete wound healing of about 1 week, 
there was no reported difference in patient satisfaction for the wound site between both 
treatment groups. Although the cost was not calculated for the purpose of this thesis, the lower 
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cost of EG with CelluTome (as reported in Chapter 6) and faster donor site healing reduces 
the number of dressing changes and clinic visits, hence is expected to have a lower overall 
cost.  
The mechanistic study revealed that both the autologous skin grafts have different mechanism 
of healing. Significant downregulation of Cx43 and Cx30 was seen at the wound edge after 
EG, especially in chronic wounds. In this study, the Cx proteins were used as a marker of 
keratinocyte migration from the wound edge. The downregulation of Cx proteins by antisense 
have previously been shown to accelerate keratinocyte and fibroblast migration from the 
wound edge (reviewed in Chapter 1). The downregulation of Cx proteins in this study suggests 
the increased migration of keratinocytes from the wound edge into the wound bed in chronic 
wounds after EG. Despite demonstrating a reduced expression of Cx43 and Cx30 in acute 
wounds, it was not statistical significant as these proteins were known to be only minimally 
overexpressed in acute wounds as compared to chronic wounds. Hence, the low Cx levels 
still suggests that keratinocytes were actively migrating into the wound. This correlates with 
our previous clinical observation whereby an acute wound treated with EG demonstrated 
accelerated healing compared to another untreated acute wound in the same patient[164]. 
A change in the distribution of Cxs at the wound edge was also observed, whereby the Cxs 
were observed to be confined to the superior part of the epidermis and less expressed in the 
basal layer after treatment, emulating the expression pattern of an acute wound. As Cxs were 
known to act as a nexus interacting with other adhesion molecules and cytoskeletal 
components, the decreased expression in the basal layer suggests reduced adhesion and 
increased cytoskeletal dynamics, hence increased migration of the actively proliferating basal 
cells into the wound bed after treatment. 
The wound bed, on the other hand, demonstrated increased inflammatory cells and 
proliferative marker (Ki67) expression after EG, suggesting the activation of the wound bed 
after grafting. Similar activation was not seen after SSG as the grafted skin forms an epithelial 
coverage for the wound, hence progressing towards the phenotype of a healed wound[165]. 
182 
In chronic wounds, the wound bed activation after EG was accompanied by re-organisation of 
ECM, more compact and dense after treatment. In normal wound healing, the first step of the 
healing cascade is inflammation which involves recruitment of neutrophils and macrophages 
that secretes cytokines, chemokines and growth factors, which then initiates the production of 
collagen, seen clinically as granulation tissue[35, 121]. This process of increased inflammatory 
cells and collagen deposition were observed in the histology of chronic wounds after EG, 
confirming the activation of wound bed after EG. The increased collagen content in the ECM 
is a change which is normally observed in the proliferative phase of wound healing, whereby 
the growth and deposition of granulation tissue is critical for an inductive and supportive role 
for re-epithelialisation from the wound edge [166]. Therefore, the transplanted keratinocytes 
in the form of EG stimulates cell proliferation and creates a conducive micro-environment for 
healing.  
Wound bed activation was seen despite the absence of keratinocytes on the wound bed from 
the transplanted graft at week 1 after EG, as demonstrated by the absence of cytokeratin 6 
and 14. This suggests that EG does not integrate to the wound bed as seen with SSG. A SSG 
becomes incorporated to the host bed through the process of graft “take”. The success of a 
graft take depends on the extent and speed at which vascular perfusion is restored. The skin 
graft take occurs in three phases[165, 167]. The first phase is known as “plasmatic imbibition”, 
lasting about 24-48 h, which involves movement of fluid, carrying nutrients and dissolved 
oxygen, from wound bed to the graft. This is followed by “inosculation”, a process of fine 
network of capillary and fibrin layer ingrowth into the transplanted graft, which is then followed 
by active invasion by host vessels to produce definitive vasculature for the graft within the fifth 
or sixth day post-graft day.  
The difference in the graft take phenomenon between EG and SSG is likely due to the 
structural difference between them. A SSG consists of epidermis and a thin layer of dermis, 
while an EG comprises of the epidermis only. The failure of skin graft take of EG is likely due 
to the lack of dermis in the EG, which prevents capillary ingrowth into the graft as the epidermis 
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is an avascular layer. The absence of dermis, however, enables direct interaction between the 
actively proliferating basal keratinocytes and the wound bed. This interaction enables wound 
bed activation as the basal keratinocytes carry keratinocyte stem cells and at the same time 
expresses a cocktail of cytokines and growth factors onto the wound bed (reviewed 
extensively in Chapter 4.2). Hence, the EG behaves like a bioactive dressing instead of 
providing an instant wound coverage as a SSG does. Figure 7.21 below summarises the 
proposed mechanism of healing by EG based on previous reports and our current finding. 
 
Figure 7.21 Proposed mechanism of wound healing by EG 
 
Tranfer of EG to the wound
Secretion of growth factors, cytokines, and basal stem cells to 
the wound bed
Stimulation of wound edge and wound bed
Wound bed activation:
increases granulation tissue, remodels ECM
Wound healing
Wound edge stimulation:  
accelerates keratinocyte migration 
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This novel finding on the mechanism of healing of EG changes our perception towards EG as 
well as the clinical protocol of wound management after EG. Prior to this, EG was treated as 
a very fragile skin graft and the wound was usually left untouched for three to four weeks after 
grafting. Furthermore, there have been mixed reporting on the visibility of the grafts on the 
wound bed after grafting in several observational clinical study [92, 93]. Our finding provides 
a robust evidence that EG does not integrate to the wound bed. The increased keratinocyte 
migration from the wound edge and wound bed activation suggests that patients may benefit 
from multiple EG, repeating the procedure every 2 or 3 weekly. The repeated stimulation of 
the wound bed could provide autologous growth factors and cytokines to continuously 
encourage and promote healing of chronic, hard to heal wounds. Similarly, this may also 
benefit acute wounds - accelerate healing and reduce the number of dressing changes, hence 
improving patient’s quality of life. However, despite the potential advantage of recurrent 
stimulation to the wound bed, the repeated grafting would likely reduce the cost effectiveness 
of this technique. Hence further evaluation is required to assess the advantage of repeated 
grafting and its cost implication compared to the single application of EG. 
There were several limitations to this study. Despite no significant difference in the proportion 
of wound healing and the wound healing time between both groups, a difference in mean was 
observed. To determine the accuracy of the difference, a larger sample size that is powered 
to detect this difference is required. Besides that, despite the dressings used in the first week 
were standardised for both groups, the dressings used in the subsequent weeks were not kept 
constant as they had to be tailored to the wound exudate level at that time. However, the 
variation between dressings were limited. On the other hand, the wound biopsies taken from 
the patients could be subjected to interpatient variability and some histological features could 
have undergone minor alteration during the vigorous laboratory process. To limit tissue 
damage or histological alteration, all laboratory work was only performed after obtaining 
sufficient training with other samples that were not related to this trial.  
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7.6 Conclusion 
This study suggests that treating wounds with EG has similar efficacy in terms of wound 
healing as SSG, but hold several advantages including quicker donor site healing, lower donor 
site morbidity, and superior long-term aesthetic appearance. The two autologous skin grafts 
have unique healing mechanism due to their structural construct. This study proved the 
feasibility of setting-up a translation RCT in wound healing and its benefit to patient care. 
Larger study is necessary to further define the treatment algorithm of EG and to compare the 
healing outcome on different types of wound.  
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8.0 Overall Conclusion 
The main aim of this thesis was to explore the role of GJP in wound healing in two clinical 
settings: venous disease and epidermal grafting. Various study designs were involved in an 
attempt to achieve this. The work done in the initial few chapters (Chapter 1-6) generated pilot 
data in order to design a translational RCT with sound clinical and laboratory methodology 
(Chapter 7). All the initial studies were invaluable learning steps for me to methodologically 
progress into designing and executing a clinical trial. Surgical RCTs are often difficult to 
undertake successfully, and pose practical and methodological challenges. However, RCTs 
are essential in the assessment of a surgical innovation to inform best practise. Translational 
trials, such as this, are required to not only evaluate a new surgical technology, but to 
understand the underlying mechanism, which is an absolute necessity to further advancing 
surgical practise and improving patient’s care.  
The initial work in this thesis involves a review on the role of GJP in venous disease followed 
by an observational study on GJP expression in the early stages of venous disease. The 
review outlined the current understanding on the pathophysiology underlying skin changes 
that takes place in venous disease and the role of Cx proteins in poor healing of VLU. Cx 
proteins were previously known to play an important role in chronic, non-healing wounds, 
whereby they are overexpressed in these wounds and perturbs re-epithelialisation. Here, the 
upregulation of Cx in the early stages of venous disease (prior to wound formation) was 
proposed as both venous disease and upregulation of Cx proteins in chronic wounds are 
linked to ischaemia-reperfusion cycle and chronic inflammation. Following that, we carried out 
an observational study involving patients across different stages of venous disease to test our 
hypothesis that the epidermal Cx proteins were upregulated in the early stages of the disease. 
In this study, for the first time, we showed that Cx proteins were upregulated prior to wound 
formation, as early as in patients with varicose veins. This finding demonstrated that varicose 
veins are associated with Cx upregulation, likely suggesting that the skin in patient with venous 
disease is preconditioned for poor wound healing even prior to ulceration.  This finding raises 
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a very important and interesting question on whether early treatment of varicose veins could 
prevent upregulation of Cx proteins and hence reduce the risk of disease progression and 
ulcer formation. Following that, the next question that needs to be address will the underlying 
mechanism behind the upregulation of the epidermal Cx proteins in patient with venous 
disease as it remains unclear if the ischaemia-reperfusion cycle secondary to venous 
hypertension is the causative factor of Cx upregulation. These questions will be addressed in 
the future work outlined in Chapter 9. 
The next phase of the thesis involves a series of clinical studies to evaluate a novel surgical 
technology in harvesting EG in the outpatient setting. These studies were designed to 
generate pilot data for a RCT which was aimed at evaluating the efficacy and mechanism of 
wound healing of EG. The expression pattern of GJP was used here to evaluate the healing 
mechanism of EG. This section started with a systematic review to synthesis current evidence 
on EG for wound healing. I found that current studies lacked level 1 evidence, suggesting a 
need for a robust RCT to evaluate the efficacy of this technique in clinical practise. I then 
performed a review on the current understanding of the mechanism of wound healing by EG 
and outlined the possible mechanism based on the various in-vitro and in-vivo studies. This 
was then followed by a prospective study to evaluate the feasibility of EG in the outpatient 
setting as well as a cost analysis and patient reported outcome measure studies. These 
studies demonstrated that the use of EG in the outpatient setting likely results in improved 
wound healing and potentially saves healthcare resources and have desirable patient 
satisfaction. This then raised the question if the outcome of this technique is comparable with 
the current standard of care which is the SSG. This was addressed by performing the 
EPIGRAAFT trial to evaluate the efficacy of EG against SSG. Based on our pilot data and 
historical control, the outcome of both treatments at week 6 were noted to be comparable, 
hence the wound healing and donor site outcome were evaluated at this time point within the 
trial. The trial interestingly demonstrated that EG is not inferior to SSG in term of wound healing 
and is superior compared to SSG in terms of donor site outcomes. EG was noted to have 
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faster donor site healing with lower donor site morbidity due to the superficial nature of the 
harvest. This desirable outcome was further coupled with higher patient satisfaction. However, 
despite no significant difference in the proportion of wound healing and the wound healing 
time between both groups, a difference in mean healing time was observed. As this study was 
powered to detect the difference in the donor site morbidity instead of the proportion of wound 
healing between the two treatments, a larger sample size that is powered to detect this 
difference is required. This is the basis of the future work outlined in Chapter 10, which aims 
to determine the difference in healing outcome based on wound aetiology. 
This trial also outlined the mechanism of wound healing by EG which was previously not well 
understood. Prior to this, the mechanism of healing by EG was just studies in several in-vitro 
and animal studies which involves well controlled environment. In this study, the histological 
findings were directly correlated with patient information and clinical outcome to further 
substantiate the clinical and laboratory findings. The finding of this study changed our 
understanding on the mechanism of healing of EG as we now know that it does not integrate 
to the wound bed as previously expected, hence behaves like a bioactive dressing instead of 
a skin substitute. This changes the way these wounds are managed post treatment and 
suggests the possibility of performing multiple EG or repeated EG. This study was designed 
to outline the general principles of wound healing by EG with the intention of improving current 
understanding on wound management involving EG for a more evidence based practise. The 
precise mechanism of EG, however, remains to be explored. In this study, the histological 
changes were observed and several protein markers were used to provide a broad 
understanding on the effect of the EG to the wound. However, the changes in the 
microenvironment of the wounds such as the changes in expression of growth factor, 
cytokines, MMPs and molecular regulators needs to be explored. It is important to further 
understand this mechanism in order to guide improvement of clinical practise. The future work 
described in Chapter 10 will explore the molecular mechanism of wound healing by EG. 
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9.0 Future work for Part 1 
The effect of varicose vein treatment on the connexin-43 protein expression in patients 
with venous disease. 
 
9.1 Chapter summary 
 
The aim of this study is to determine whether treatment of superficial varicose veins reduces 
Cx43 expression, hence preventing disease progression. In Chapter 3, we identified a step-
wise increase of Cx43 with venous disease progression, suggesting that skin is predisposed 
to poor wound healing and venous ulceration from early stages of the disease. We 
hypothesise that early treatment of varicose vein could downregulate Cx43, hence prevents 
disease progression. If the downregulation of Cx43 with the treatment of varicose vein is 
observed, this would suggest that early treatment prevents future ulceration and further 
confirms that Cx43 is a biomarker of venous ulceration. 
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9.2 Aim 
We aim to determine whether patients, at CEAP C2 onwards, will demonstrate a reduction of 
Cx43 expression following treatment of superficial varicose veins. If Cx43 expression 
responds to treatment, this could firmly suggest that early treatment of varicose veins could 
prevent future ulceration and re-affirm our finding that Cx is a biomarker of venous ulceration, 
which could help guide treatment in the future. 
 
9.3 Study Objectives 
9.3.1 Primary Objective 
To determine the changes in the expression pattern of Cx43 GJP levels in the skin of patients 
with venous disease with treatment of varicose vein. 
9.3.2 Secondary Objective 
To determine the role of Cx43 as a biomarker to identify patients who need treatment of 
superficial veins to prevent leg ulceration. 
 
9.4 Study design 
This study is an observational study that involves taking skin biopsies from patients 
undergoing routine elective surgical care for varicose veins.  
A minimum of 8 and maximum 20 patients in the C2 and C4 group of the CEAP classification 
will be enrolled in this study. The maximum sample size will be 40 patients. The biopsy will be 
part of a normal surgical incision within the clinical care pathway.  A follow up biopsy will be 
taken at 3 months following treatment. Table 9.1 summarises the inclusion and exclusion 
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criteria while Figure 9.1 illustrates the patient’s journey throughout the study. There are no 
further therapeutic interventions, changes to patient care, or patient treatment options. 
 
UFollow-up protocol 
Following the varicose vein surgery, patients will be followed up as per routine clinical care. 
At 3 months following the initial treatment, patients will be reviewed in the outpatient clinic to 
assess the clinical outcome. During this follow-up, venous duplex ultrasound will be performed 
to confirm the absence of venous reflux. Patients will then undergo 4mm punch biopsies at 
two locations: one above the knee and one between the knee and ankle. 
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Inclusion Criteria Exclusion Criteria 
1. Male or female 
2. Age >18 at time of consent 
3. Patients with a venous 
disease, either C2 or C4 
4. Patients undergoing planned 
surgery 
5. Patients with venous reflux 
as documented by venous 
duplex ultrasound 
6. Patient understands and is 
willing to participate and can 
comply with follow-up regime 
1. Previous history of excessive bleeding 
associated with surgical biopsies or 
trauma 
2. Allergies to local anaesthesia 
3. Known uncontrolled Diabetes Mellitus, as 
measured by HbA1c > 10%. 
4. Presence of one or more medical 
conditions, including renal, hepatic, 
hematologic, active auto-immune or 
immune diseases that, would make the 
subject an inappropriate candidate 
5. Any relevant medical problems causing 
concern 
 
Table 9.1 Inclusion and Exclusion Criteria for Study Participants   
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Figure 9.1 Flow chart illustrating patient journey throughout the study 
 
9.5 Biopsy acquisition 
Punch wound biopsies (4mm) will be taken from the surgical incision sites during surgery for 
varicose vein. Biopsies will be taken at the venous catheter insertion site at 2 locations: 5-
10cm above the knee and 5-10cm above the ankle. 
Routine venous duplex ultrasound suggests varicose veins 
 
Patient screened & patient information leaflet given 
Patient consents & enrolled 
Biopsy 
sample 
sent for 
laboratory 
analysis  
Routine follow up as part of normal clinical care and discharged 
Patient reviewed at 3 months with venous duplex 
ultrasound and undergoes 4-mm punch biopsies 
 
Patient undergoes varicose vein surgery and 4-mm 
punch biopsies 
Patient identified from vascular outpatients or varicose vein waiting list 
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All biopsies will be taken after written informed consent is obtained from the patients. This 
study will be executed in accordance with the principles of the Declaration of Helsinki and the 
recommendations of Good Clinical Practice.  
 
9.6 Laboratory studies methodology summary 
Biopsy samples will be sectioned and stained for Cx43 as per previous protocol in Chapter 3.  
The confocal images of the tissue sections will be used for quantitative analysis of Cx43 levels 
in the epidermis as per previous protocol to determine the changes in expression with 
treatment. Supportive tests and analysis will also be performed using RT-PCT and gene 
expression assay. 
 
9.7 Study setting 
Participants will be recruited at two centres: University College London Hospital, London and 
the Royal Free Hospital, London.  
 
9.8 Statistical Considerations 
Sample size 
We plan to investigate a minimum of eight and maximum of twenty patients from CEAP C2 
and C4. A maximum of 40 patients will be included. 
The sample size was determined through discussion with academic clinical and laboratory 
supervisors. Formal sample calculation is not possible at this time point as the proportion of 
difference in the Cx43 expression between groups with treatment is not known.  We anticipate 
it would take 12 months to 24 months to recruit patients. 
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Baseline demographics of the groups will be recorded. The changes in the Cx43 expression 
with treatment will be recorded using paired t-test (normally distributed data) or Wilcoxon 
signed-ranked test (non-normally distributed data). Normality test will be performed using 
Shapiro-Wilk test.  Significance will be taken at value p<0.05. All statistical analyses will be 
performed using IBM SPSS Statistics 24 software. 
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10.0 Future work for Part 2 
 
A platform adaptive randomised controlled trial on the role of UepiUdermal UgraftUing for 
wound healing (EPIGRAFT) 
 
 
10.1 Chapter summary 
EPIGRAFT aims to define the treatment algorithm for EG. We will use a novel Multi-Arm Multi-
Stage (MAMS) platform protocol that incorporates different types of wounds, both acute 
wounds and chronic wounds. Further by undertaking early interim analysis we can assess 
those treatments that are most likely to work. This means as the trial progresses, patients are 
most likely to receive the best treatment for them (the trial adapts and learns).  
In patients with acute wounds we will assess whether EG compared to dressings result in 
improved wound healing by 8 weeks. 
In patients with chronic wounds (more than 3 months duration) we will compare EG, SSG and 
dressings. The study will look at how well wounds are healing over 8 weeks. If EG works well 
in chronic wounds at this point, we will offer multiple EG (MEG) where the procedure is 
performed many times to try and encourage the wound to heal.  
We will also undertake a detailed laboratory study to look at how and why EG works by looking 
at healing wound at the molecular level. Because EG is still a new procedure, the study will 
need to train nurses and doctors on how to perform the procedure and look after the wound 
afterwards. We will use new ways of training by using virtual reality technology to watch and 
advice from afar.  
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10.2 Study Aim  
In Chapter 8 we identified that EG has several advantageous in the donor site outcome, and 
not inferior to SSG in terms of wound healing. However, a difference in the mean healing time 
and proportion of wound healing was observed despite not statistically significant. This study 
aims to define treatment algorithm for EG by outlining the healing outcome based on wound 
type and correlating this to the molecular mechanism of healing. 
 
10.3 Study design 
EPIGRAFT is a novel Multi-Arm Multi-Stage (MAMS) platform protocol, which uses an efficient 
design to answer multiple questions in a single protocol. 
The multi-arm part enables two trials to run concurrently: acute wounds (EPIGRAFT ACUTE) 
and chronic wounds (EPIGRAFT CHRONIC). They will start as simple randomisations. 
Following interim analysis, the EPIGRAFT CHRONIC trial will adapt to include new 
comparisons. 
 
The multi-stage part enables the possibility to discontinue randomisation to arms not showing 
sufficient activity, based on pre-planned, interim, lack of-benefit analyses (at week 8); further 
to adapt and add new arms as new questions arise. This Platform protocol reduces the total 
number of patients needed to answer each question and time needed for trial completion. 
 
10.3.1 EPIGRAFT pathway 
Patients will be identified from the standard wound care clinical pathways. The trial protocol 
will be based in the outpatient dressing clinic. All patients will undergo routine clinical care 
using a standardised dressing protocol. Following screening, patients will be randomised. All 
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treatment arms will be based in the dressing clinic. Follow up in the study will be undertaken 
weekly till wound healing or 8 weeks and assessments made as part of these clinic visits. 
 
 
EPIGRAFT ACUTE: 
Patients will be randomised to either dressings (control arm) or EG group and followed up for 
8 weeks. Figure 10.1 illustrates the study design for EPIGRAFT ACUTE. 
 
Dressing
8wk wound healing rate=40%
Epidermal Grafting (EG)
8wk wound healing rate=70%
Randomisation
Analysis
Dressing
Epidermal 
Grafting (EG)
Run-in 
phase 
(~2 weeks)
un-in 
phase 
( 2 eeks)
EPIGRAFT 
Acute Wounds
I  
t  
 
Figure 10.1 Study design for EPIGRAFT ACUTE 
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EPIGRAFT CHRONIC: 
Patients will be randomised to either dressings, EG or SSG. MEG arm will be introduced after 
Stage 1 analysis. Following interim analysis, treatments that deemed beneficial will proceed 
to Stage 2(final analysis stage). Treatments that are deemed lack-of-benefit will be excluded 
from Stage 2. Figure 10.2 illustrates the study design for EPIGRAAFT CHRONIC. 
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Figure 10.2 Study design for EPIGRAAFT CHRONIC 
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10.3.2 Mechanistic components of the study 
Epidermal grafts are expected to behave like biologically active dressings, modulating wound 
healing response and are able to stimulate endogenous process of wound healing. Therefore, 
we further propose that the overarching mechanism of action of EG will be more as a bioactive 
wound dressing than traditional skin coverage (as seen in SSG) (hence the MEG arm of the 
trial). 
All patients within the trial will undergo 4mm punch biopsy at week 0 and week 1 after 
treatment, as per previous protocol (described in Chapter 7.1.7). The tissue will be stored in 
RNAlater (Sigma-Aldrich) and immediately stored at -80oC to preserve the RNA. Molecular 
analysis will be performed in collaboration with Blizard Institute, Queens Mary University 
London. Molecular analysis will be performing using RNA sequencing and ATAC sequencing. 
These techniques will allow the quantification of growth factors, cytokines, inflammatory 
markers, MMPs as well as other regulators of wound healing. The expression pattern of these 
factors before and after treatment will be determined.  
Wound exudate sampling will be performed by applying a filter paper onto the wound for 2 
minutes until it is moist. The filter paper will then be stored in a sterile vial and transferred to 
the laboratory. We will perform ELISA to determine the type and concentration of growth 
factors expressed by the EG and its response to the wound, both pre- and post-grafting, 
comparing it with SSG, MEG and control (dressings only). 
 
10.3.3 Training and education 
The technique of EG, protocol of wound care, dressing changes and wound appearances 
requires a 'learning curve'. Consequently, to ensure consistency of training, the EPIGRAFT 
lead center will provide centralised training masterclasses with advanced practice guidelines. 
This will be supported by augmented reality technology to enable onsite supervision and 
training at all centers. Fidelity of implementation will be formally assessed in Stage 2 of 
EPIGRAFT CHRONIC by the nested educational sub-study. 
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10.3.4 Trial team and collaboration 
EPIGRAFT will be led by a multidisciplinary team of clinical trialists & academics (MRC & 
UCL), clinicians (consultants, trainees and nurses) who developed the technique in the NHS. 
This study will be carried out with industry partnership (Acelity). 
 
10.4 Study Setting 
Royal Free Hospital London will be the leading centre. The trial will be extended to 6 other 
plastic surgery units within London before expending to other centres within UK via trial 
networks. 
 
10.5 Study population 
Two populations of patients with significant wounds will be enrolled concurrently: 
EPIGRAFT Acute wound trial: wounds less than 3 months in duration 
EPIGRAFT Chronic wound trial: wounds greater than 3 months in duration 
 
A wound is defined as, an epidermal deficit of greater than the size of a 50pence coin and less 
than the size of a palm. All patients will be those referred, following assessment and review, 
by a Consultant Plastic Surgeon, where SSG would be a reasonable option. There is no clear 
cut scientific definition of the ideal wound for this study but this clinical definition has been 
validated in our observational study (Chapter 5) and pilot RCT (Chapter 7 and 8). 
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10.6 Eligibility criteria 
 
Inclusion criteria are as follows: 
1. Age ≥ 18 years 
2. Wound measuring more than 1 cm x 1 cm and less than 6 cm x 6 cm (1 % total body surface 
area) 
3. Clean, healthy granulating bed 
4. Patients will be required to understand and be willing to participate in the trial and be able 
to comply with the weekly visits and follow-up regime 
 
Exclusion criteria are as follows: 
1. Infected wound 
2. Wound at the plantar of the foot 
3. Unsuitable for SSG 
4. Previous history of excessive bleeding associated with surgical biopsies or trauma 
5. Uncontrolled diabetes mellitus, as measured by HbA1c ≥ 10 percent 
6. Presence of one or more medical conditions including renal, hepatic, hematologic, active 
auto-immune or immune diseases  
7. Use of systemic steroid or immunosuppressant 
8. Not fit for surgery (ASA classification ≥ 4) 
 
10.7 Interventions  
10.7.1 Run-in-phase 
All patients will undergo a 'run in phase' that will follow the routine dressing clinic protocol, to 
ensure appropriate debridement for wound bed preparation, that is free from infection 
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(clinically clean and two clear wound swabs). Following trial enrolment & informed consent, 
baseline 3D wound photographs will be taken for audit control and validation. 
 
10.7.2 Split skin grafting 
Patients will undergo this procedure in the operating theatre or in minor operations designated 
clinic room under general or local anaesthetic. SSG will be harvested from the thigh using an 
air dermatome, set to cut at the thickness of 5-10/1000 inch and meshed by 1:1.5. The wound 
will be dressed with Adaptic Touch (Systagenix), gauze and a Mefix or wool and crepe 
bandage depending on the site of the graft. The donor site will be dressed with Kaltostat 
(Alginate dressing) with a 2.5cm overlay beyond the wound margins and secured with Mefix. 
As per standard clinical practise, the graft will be checked at day 7 ± 2, and then on a weekly 
interval. 
 
10.7.3 Epidermal grafting 
Prior to grafting, the wound and donor sites are cleaned by the operating surgeon. The 
harvesting device will be applied to the donor site (thigh) for 3-40 min to harvest the EG as 
per existing clinical practice. The harvested epidermal grafts will then be transferred onto the 
wound using a non-adhesive silicone dressing (Adaptic Touch, Systagenix). The wound will 
then be dressed with a secondary dressing based on the wound type and exudate amount as 
deemed appropriate by the treating clinician. The dressings will be secured with a crepe 
bandage or a Mefix dressing (Mölnlycke Health). The donor site will be dressed with Tegaderm 
(3M). The wound and donor site will be reviewed on day 7 ± 2 post-grafting, and then on a 
weekly interval. 
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10.7.4 Multiple epidermal grafting (MEG) 
The procedure will be identical to a single epidermal grafting. However, in line with mechanistic 
hypothesis that EG acts as a 'biological dressing' the procedure will be repeated at each 
fortnightly follow-up and dressing change. EG will be repeated with sequential application of 
fresh grafts to the wound, for 6 weeks or until the wound has achieved > 75% wound healing 
whichever is sooner. 
 
10.7.5 Standard of care by dressings (Control) 
Patients will receive standard of care by dressing management in a specialist dressing clinic. 
For the purpose of EPIGRAFT the dressing used will be standardised and mirror those 
dressings use in the intervention arms, namely Adaptic touch, Aquacel and then an outer 
dressing as described. 
 
10.8 Outcomes 
All patients will be followed at 7 days (+/-2days) following randomisation then weekly for 8 
weeks or trial termination. On every follow-up visit, 3D photographs and measurements of the 
wound and donor site will be taken. The dressings will be changed and the wound gently 
cleaned. Fresh dressings will be reapplied. 
 
10.8.1 Primary endpoint 
Wound healing, defined as complete epithelialisation of the wound with no need for further 
dressings, as deemed clinically appropriate by two trial clinicians. 3D wound photographs will 
be taken for audit control and validation. 
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10.8.2 Secondary endpoints 
• Rate of wound healing, as assessed by weekly 3D photography. 
• Time for donor site healing 
• Pain scores during dressing changes, reported by patients using Numerical Rating 
Scale, for donor site and wound dressing. 
• Patient satisfaction, by PROMS from randomisation and at 8 weeks. 
• Cost analysis of the interventions. 
• Mechanistic and Education sub-studies. 
 
  
210 
10.9 Randomisation and power calculation 
Power calculation and randomisation technique was discussed and designed along with MRC 
UCL Clinical Trials Unit, led by Professor Max Palmer. Sample size calculation was performed 
by Dr Gordana Jovic (statistician at MRC UCL Clinical Trials Unit). 
 
EPIGRAFT Acute: 
Patients with acute wounds, following the 'run in phase', will undergo informed consent then 
randomised on a 1:1 basis to either standard of care by dressings (control) or intervention by 
EG. Primary outcome measure is the proportion of patients whose wounds have healed at 8 
week after randomisation, predicted to be 40% in control and 70% in EG arm. The comparison 
between EG and control arms will be done by testing the difference (EG vs. control) in 
proportion of patients whose wounds have healed at 8 weeks after randomisation. Using 
targeted power 90% and one-sided significance level 0.05, 90 patients are needed for the 
comparison of EG vs control (45 control, 45 EG). Table 10.1 outlines the sample size for 
EPIGRAFT ACUTE. 
 
 
Arm Allocation ratio, 
Research arm vs 
Dressing 
Total number of 
patients 
Nominal one-sided 
significance level [power] 
Dressing  n/a,  
comparator arm 
45 n/a,  
comparator arm 
Epidermal 
Grafting 
1:1 45 0.05 [90%] 
Total n/a 90 n/a 
 
Table 10.1 EPIGRAFT Acute Wound randomisation, sample size 
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EPIGRAFT CHRONIC: 
Following the 'run in phase', patients with chronic wounds will undergo informed consent and 
randomised to either standard of care by dressings(control), EG, SSG or MEG. It was 
predicted that the 8 weeks wound healing rates are: control 20%, EG 50%, SSG 60%, MEG 
60% (lower than acute as 'hard to heal wounds'). EPIGRAFT CHRONIC is a two-stage trial; 
an early interim analysis will exclude 'lack of effect' intervention and trial feasibility followed by 
adaption in stage 2 to include a MEG arm. Table 10.2 outlines the sample size for EPIGRAFT 
CHRONIC. 
 
Stage 1: 
Initial randomisation will start between; control, EG, SSG on a 1:2:1 basis. Interim analysis will 
be performed; EG arm will be compared to control and SSG arm compared to control. The 
comparison will be done by testing the difference in proportion of patients whose wounds have 
healed at 8 weeks after randomisation (EG-control and SSG-control) using z-core; EG arm 
will be tested at 0.28 significance level and SSG at 0.27 with targeted power at 90%. A 
minimum of 71 patients in total are needed for Stage 1 interim analysis (18 control, 36 EG, 17 
SSG).  
 
Stage 2: 
Assuming both EG and SSG will continue randomisation to Stage 2 and that MEG arm will be 
added, the overall allocation ratios would be; control 1, EG 2, SSG 1, MEG 2. To preserve 
overall type I error at 0.05 and due to the three comparisons being made, significance level of 
0.05/3=0.016 and targeted power of 90% was used for the trial design. Sample size was 
calculated using Multi -Arm Multi-Stage methodology, as described by Bratton et al and 
implemented in Stata 14.1, -nstagebin- and - nstagebinopt- commands. 
An additional 132 patients are required in stage 2. 
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The total maximum sample size for EPIGRAFT CHRONIC is 203 patients. Final comparison 
will include a maximum of: 45 control arm patients, 82 EG, 32 SSG, and 44 MEG arm patients. 
All calculations include 5% of patients expected to be lost to follow-up. 
 
 
Arm Allocation 
ratio, 
Research 
arm vs 
Dressing 
STAGE 1 
Number of 
patients to 
recruit for 
analysis 
STAGE 1 
Nominal one-
sided 
significance 
level [power] 
STAGE 2 
Total 
number of 
patients to 
recruit¥ 
Pairwiseπ 
significance 
level 
[power] 
Dressing  n/a, 
comparator 
arm 
18 n/a,  
comparator arm 
45 n/a,  
comparator 
arm 
Epidermal 
Grafting 
2:1 36 0.28 [96%] 82 0.0164 
[90%] 
Split Skin 
Grafting 
1:1 17 0.27 [97%] 32 0.0162 
[90%] 
Multiple 
Epidermal 
Grafting 
2:1* n/a n/a  
one stage only 
44 0.016 [90%] 
Total n/a 71 n/a 203 n/a 
*from Stage 2 
¥assuming that EG and SSG will continue recruitment to Stage 2 and that MEG arm will be added. It also accounts 
for the rate of lost to follow-up  
πone-sided significance level and power for each comparison, EG vs Dressing, SSG vs Dressing, MEG vs Dressing 
 
Table 10.2 EPIGRAFT Chronic Wound randomisation, sample size 
 
10.10 Impact 
If EG does not prove to be beneficial over standard of care by dressings in either acute or 
chronic wounds, we anticipate this technique will cease practice. 
If EG does prove beneficial in patients with acute wounds, it is anticipated that that this 
technique will be proposed for wound management in A&E department or dressing clinics. 
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If EG is proven beneficial for patients with chronic wounds, it is anticipated that the platform of 
the EPIGRAFT could be expanded to include other comparators, perhaps as part of a HTA 
application of industry funded research program. 
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NRES Committee London - South East 
Bristol Research Ethics Committee Centre 
Level 3, Block B Whitefriars, Lewins Mead, 
Bristol BS1 2NT 
Tel: (0117) 3421382 
05 June 
2014  
Mr Toby Richard 
Senior Lecturer in Surgery, Honorary Consultant in Vascular & Endovascular Surgery 
University College Hospital 
UCL Division Surgery and 
Interventional Science Fourth floor, 
74 Huntley Street 
London WC1E 6AU 
Dear Mr Richard 
 
 
 
 
 
 
 
 
 
 
The above amendment was reviewed by the Sub-Committee in correspondence. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable 
ethical opinion of the amendment on the basis described in the notice of 
amendment form and supporting documentation. 
 
Approved documents 
 
The documents reviewed and approved at the meeting were: 
 
Document Version Date 
Covering letter on headed paper [Summary of changes]   
Study title: An observational study determining and comparing 
connexin 43 protein-expression in adult chronic foot 
wounds, with further laboratory study of isolated fibroblast 
migration rates and gap junctional communication 
REC reference: 11/LO/1483 
Amendment number: 1 
Amendment date: 14 May 2014 
IRAS project ID: 79542 
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GP/consultant information sheets or letters 1.3 01 April 2014 
Notice of Substantial Amendment (non-CTIMP) [First amendment]  14 May 2014 
Other [Email with submission attached]  15 May 2014 
Other [Muholan(CV) February 2014]  01 February 2014 
Participant consent form 1.3 01 April 2014 
Participant information sheet (PIS) 1.3 01 April 2014 
Research protocol or project proposal [amended protocol 
01042014N] 
1.3 01 April 2014 
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the attached 
sheet. 
 
R&D approval 
 
All investigators and research collaborators in the NHS should notify the R&D office 
for the relevant NHS care organisation of this amendment and check whether it 
affects R&D approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
 
Yours sincerely 
 
Mr Wai Yeung 
Research Ethics Committee (REC) Assistant 
 
pp Professor David 
Caplin Chair 
 
E-mail: nrescommittee.london-southeast@nhs.net 
 
 
 
Copy to: Ms Shahina Begum-Meah , University College London 
Ms Anna Jones, 
 
11/LO/1483: Please quote this number on all correspondence 
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NANYANG 
TECHNOIOGICAL 
UNIVERSITY 
 
Research Support Office 
Reg. NO. 200604393R 
IRB-2015-05-003 
25 May 2015 
Professor David Laurence Becker 
Lee Kong Chian School of Medicine 
NTU INSTITUTIONAL REVIEW BOARD APPROVAL 
Project Title: Investigations into wound/disease tissues 
(Amount Approved: SGD$132,651.4; to be funded by University College London and Lee 
Kong Chian School of Medicine. NTU) 
I refer to your application for ethics approval with respect to the above project. 
The Board has deliberated on your application and noted from your application that your 
research involves collecting biological data from participants through punch biopsies 
You have also confirmed that informed consent will be obtained from the participants and you 
have guaranteed the confidentiality of your participants' biodata obtained from them, 
The documents reviewed are: 
a) NTIJ IRB application form dated 04 May 2015 
b) Participant information sheet and consent form: version 1 dated 04 May 2015 
c) Data collection form: version 1 dated 04 May 2015 
The Board is therefore satisfied with the bioethical consideration for the project and 
approves the ethics application under Expedited review. The approval period is from 25 
May 2015 to 05 January 2018. The NTU IRB reference number for this study is IRB-2015-
05-003. Please use this reference number for all future correspondence. 
The following protocol and compliances are to be observed upon NTU IRB approval 
1. All research involving procedures greater than minimal risk on minors (individuals 
who are less than the legal age of 21 years old) requires IRB approved written 
Parental Consent and assent from the participant to be obtained before any research 
protocols can be administered. Minimal risk refers to an anticipated level of harm and 
discomfort that is no greater than that ordinarily encountered in daily life, or during 
the performance of routine educational, physical, or psychological examination. 
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NANYANG 
TECHNOIOGICAL 
UNIVERSITY 
 
Research Support Office 
2. Only the approved Participants Information Sheet and Consent Form should be used, 
it must be signed by each subject prior to initiation of any protocol procedures. In 
addition, each subject should be given a copy of the signed consent form. 
3. Consent forms are important documents therefore they should be stored in the strictest 
arrangement. Loss of consent form would result in disciplinary action. 
4. No deviation from, or changes of, the protocol should be initiated without prior written 
NTU IRB approval of an appropriate amendment. 
5. The Principal Investigator should report promptly to NTU IRB regarding: 
a. Deviation from, or changes to the protocol, 
b. Changes increasing the risk to the subjects and/or affecting significantly the 
conduct of the trial 
c. All serious adverse events (SAEs) which are both serious and unexpected. 
d. New information that may affect adversely the safety of the subjects of the 
conduct of the trial. 
e. Completion of the study. 
6. Continuing Review Request/ Notice of Study completion form should be submitted to 
NTU IRB for the following: 
a. Annual review: Status of the study should be reported to the NTU IRB at least 
annually using the Continuing Review Request/ Notice of Study completion 
form  
b. Study completion or termination: Continuing Review Request/ Notice of Study 
completion form is to be submitted within 4 to 6 weeks of study completion or 
termination. 
7. All Principal Investigators should comply with existing legislation that would have an  
impact on the domain of their research. 
 
 
 
Professor Lee Sing Kong, 
Chair, NTU Institutional Review 
Board encl. 
cc Dean, Lee Kong Chian School of Medicine 
        Members, NTU Institutional Review Board 
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Mr Daryll Baker BSc, PhD, FRCS 
 
15/08/2014 
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Department of Vascular Services 
University College Hospital 
250 Euston Road 
London 
NW1 2PG 
 
Administrative Enquiries 
PA: Tomisin Olarewaju 
Tel: 020 3447 5173 
Fax: 020 3447 9217 
oluwatomisin.olarewaju@uclh.nhs.uk 
 
Surgical Admission Enquiries: 
Carina Nobrega 
Tel: 0203 447 9112 
Fax: 0203 447 9217 
carina.nogrega@uclh.nhs.uk 
 
Switchboard: 0845 155 5000 
Outpatient Clinic Appointments: 0203 447 9393 
 
 
 
UCLH Project ID number:                                 Form version:  April 1 PstP 2014 Version 1.3  
 
PATIENT INFORMATION LEAFLET 
 
Study Title: Connexin-43 protein expression in venous disease 
 
Principal Researcher:  Dr Muholan Kanapathy  
42Tmuholan.kanapathy.13@ucl.ac.uk42T  
07459029770  
 
As a patient of UCLH or RFH NHS Trust you are being invited to take part in a research study. Before 
you decide whether you would like to take part, it is important for you to understand why the 
research is being done and what it will involve. Please take time to read the following information 
carefully and discuss it with friends, relatives and your GP if you wish. Ask us if there is anything 
that is not clear or if you would like more information. Take time to decide whether or not you wish 
to take part. 
 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and You’. This 
leaflet gives more information about medical research and looks at some questions you may want 
to ask. A copy or it may be obtained from CERES, PO Box 1365, London N16 0BW. 
 
The purpose of the study People with venous disease are prone to poor wound healing and may 
develop leg ulceration. Leg Ulceration is a serious problem and causes patients to suffer considerable 
pain and discomfort.  Poor wound healing is usually caused by a particular medical condition.  These 
medical conditions include diabetes, infection, varicose veins, or chronic ischaemia (reduced blood 
supply).  The purpose of this study is to understand the reasons why patients may develop poor 
wound healing.  We would like to determine the levels of a particular protein called Connexin-43. It 
is known that high levels of Connexin-43 protein can interfere with the movement of certain cells 
necessary for skin to close over and heal the wound.  This research will further our knowledge about 
the human wound healing process and it may help development of beneficial treatments in the 
future. 
 
Why have I been chosen? We have chosen you because you have venous disease and undergoing 
routine clinical care and treatment. We plan to study up to 84 patients in total. 
 
Do I have to take part?  It is up to you to decide whether or not to take part. If you decide to take 
part, you will be given a copy of this information sheet and a signed copy of the consent form to 
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keep and be asked to sign a consent form. If you wish to withdraw from the study you may do so at 
any time and without giving a reason. If you decide not to take part in the study, this will not affect 
the standard of care you receive. 
 
What will happen to me if I take part?  
You will undergo three small 4-mm biopsies, during routine care at your operation.  The biopsies 
will be taken from two locations on the leg undergoing treatment. The first will be at the level of 
the knee where the normal catheter to treat your varicose vein is placed and the second will be 
between the knee and ankle where you have varicose veins (or ulcer). A third biopsy will be taken 
from the other (normal) leg. This will be done by an experienced surgeon and a doctor will be 
present throughout.  The sample will be carefully transferred and stored in the laboratory for 
further analysis.  The sample will be ‘gifted’ by you for purposes of this research study.  Following 
the laboratory studies required for this research study, the sample will be stored by the research 
team at UCL, in accordance to the Human Tissue Authority Code of Practice. The samples will then 
be transferred to our laboratory in Lee Kong Chian School of Medicine, Singapore. Ethical approval 
will be sought for additional projects in the future, should other researchers wish to use your 
sample.   
 
Will taking part change my treatment? Here at UCLH, we would be undertaking a surgical 
incision as part of your operation. The small biopsy will be from the edge of this incision and not 
affect your care plan discussed between you and your consultant.   
 
What data will be collected?   
As mentioned above, a small 4-mm biopsy will be taken from you.  Laboratory studies will be 
undertaken to determine the levels of Connexin-43 protein and further analyse cell movement. 
You may also have a clinical photograph taken of your leg before your biopsies are taken, for 
purposes of the study.  Should there be wider publication of the photograph in clinical journals or 
publications, you will be contacted and informed and further consent and permission to do this will 
be sought.  All clinical photographs will remain anonymous and it will not be possible to identify you 
from the photograph. 
The research team will also collect the data in the ‘Varicose Veins Questionnaire’ which you will be 
completing as part of your normal clinical pathway.  
 
What are the benefits of taking part? You will not benefit directly from the study however it may 
help patients in the future. 
 
What are the disadvantages or risks of taking part? The disadvantages or risks of taking part 
are minor.  The biopsy should not affect the healing of your wound, and should you become 
concerned about your wound at any time, a further outpatient follow-up appointment can be 
arranged.  
 
It is unlikely that the addition of a small biopsy to the surgical wound would result in any additional 
discomfort or pain at the time of biopsy.  Local anaesthesia may be used to minimize this risk; this 
involves using a fine needle to deliver the anaesthetic just below the skin surface to numb the skin.  
Patients may experience some minor bleeding (a few drops of blood, similar to when a patient has 
a needle finger-prick blood glucose ‘BM’ test).  If this happened it would be necessary to apply a 
small gauze dressing temporarily until the bleeding stops. Finally, there is small risk that the biopsy 
taken from you will not be suitable for use or in other words ‘insufficient’.  This means that the 
biopsy procedure has been unsuccessful due to technical problems at the time of taking biopsy, and 
it is inappropriate for the sample to be sent to the laboratory.  If this occurs, you will be informed.  
It would be up to you to decide whether you wish to undergo further biopsy or withdraw from the 
research study. 
 
What if new information becomes available? Sometimes during the course of a research 
project, new information becomes available about the subject being studied. If this happens your 
research doctor will tell you about it and discuss with you whether you want to continue in the study. 
If you decide to withdraw your research doctor will make arrangements for your care to continue. If 
you decide to continue in the study you will be asked to sign an updated consent form. It is possible 
that on receiving new information your research doctor might consider it to be in your best interests 
to withdraw from the study. He/she will explain the reasons and arrange for care to continue. 
 
What happens if something goes wrong? All biopsies will be taken by an experienced surgeon 
and a qualified doctor will be present throughout the test with immediate access to emergency 
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equipment should it be required.  We will take every care in the course of this study. If through our 
negligence any harm results you will be compensated. However, a claim may need to be pursued 
through legal action. The NHS Trusts are not permitted to carry indemnity for non-negligent (no-
fault) harm. 
 
Will my taking part in this study be kept confidential? All information which is collected about 
you during the course of the research will be kept strictly confidential. Any information about you 
which leaves the hospital will have your name and address removed so that you cannot be recognised 
from it. We are required to keep the data for a minimum of 5 years after the study has been 
completed. The biopsy samples will be stored in such a way that your details will linked to the stored 
tissue but not identifiable to researchers.  The biopsy sample will be stored in the tissue bank for 5 
years. 
 
What will happen to the results of the research study? We plan to run the study for 2 years, 
after which the research team will analyse the results. The results will be published as soon as 
possible after study completion. You will not be identified in any report or publication. 
 
Who is organising and funding the research? The Research fellow is organizing the research as 
part of an PhD thesis, supervised by Mr Toby Richards, Senior Lecturer and Consultant Vascular & 
Endovascular Surgeon.  The laboratory studies will be undertaken in collaboration with Professor 
David Becker.  The research is sponsored by the NHS.   
Ethics Committee review All research using human subjects are reviewed before an ethics 
committee before they can proceed. This proposal was reviewed by UCLH Joint Research Ethics 
Committee. 
 
Contact details for further information 
Mr Toby Richards, Senior Lecturer & Consultant Vascular and Endovascular Surgeon  
UCL Division of Surgery and Interventional Science, Fourth Floor 
74, Huntley Street, 
London, 
WC1E 6AU 
Email: 42T oby.Richards@ucl.ac.uk42T 
Tel: 0207 6796454 
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A3: Patient Consent Form 
Consultant Vascular Surgeons 
Mr O Agu MS FRCS FRCS (Gen) 
Mr Toby Richards BSc MBBS FRCS MD 
Mr Daryll Baker BSc, PhD, FRCS 
 
15/08/2014 
TR1/PRN/OOO 
 
 
Department of Vascular Services 
University College Hospital 
250 Euston Road 
London 
NW1 2PG 
 
Administrative Enquiries 
PA: Tomisin Olarewaju 
Tel: 020 3447 5173 
Fax: 020 3447 9217 
oluwatomisin.olarewaju@uclh.nhs.uk 
 
Surgical Admission Enquiries: 
Carina Nobrega 
Tel: 0203 447 9112 
Fax: 0203 447 9217 
carina.nogrega@uclh.nhs.uk 
 
Switchboard: 0845 155 5000 
Outpatient Clinic Appointments: 0203 447 9393 
 
 
CONSENT FORM 
Study Title:  Connexin 43 protein expression in venous disease 
 
Principal Researcher:  Dr Muholan Kanapathy    Form version: April 1PstP 2014 Version 1.3  
Centre Number:        UCLH Project ID number: 
 
Patient identification number for this study: ____________ 
 
To be completed by the volunteer        
                              
 Please initial each box                              
1) I confirm that I have read and understood the information sheet dated April 1PstP 2014 
version 1.3 for the above study, and have had the opportunity to ask questions. 
 
2) I confirm that I have had sufficient time to consider whether or not I want to be included 
in the study. 
 
3) I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected. 
 
4) I understand that sections of my medical notes may be looked at by responsible 
individuals from list below or from regulatory authorities where it is relevant to my taking 
part in research. I give permission for these individuals to have access to my records. 
 
5) I agree to take part in the above study. 
 
6) I agree to biopsies to be taken at: 
    a) The level of the knee on the leg undergoing venous treatment 
       Yes 
 
        Yes 
         
       Yes 
 
        Yes 
 
        Yes 
 
         Yes 
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    b) Between the ankle and knee on the leg undergoing venous treatment 
 
    c) Between the ankle and knee on the leg which is not undergoing venous treatment 
 
7) I agree that my GP can be informed of my involvement in this study. 
 
 
8) I agree that an anonymous clinical photograph may be taken of my wound 
    during this study. 
        Yes 
        
        Yes 
        
        Yes 
        
        Yes 
 
 
 
 
________________________      _________________________       _______________ 
Name of Patient    Signature    Date 
 
 
 
________________________   _________________________               _______________ 
Name of Person taking   Signature     Date 
consent (if different from researcher) 
 
 
 
________________________   _________________________               _______________ 
Researcher     Signature            Date 
 
Comments or concerns during the study 
If you have any comments or concerns you may discuss these with the investigator. If you wish to go further 
and complain about any aspect of the way you have been approached or treated during the course of the 
study, you should write or get in touch with the Complaints Manager, UCL hospitals. Please quote the UCLH 
project number at the top this consent form. 
 
 
Principal Researcher:  Dr Muholan Kanapathy    April 1PstP 2014: version 1.3 
 
final page/ 
1 form for Patient, 
1 to be kept as part of the study documentation, 
1 to be kept with hospital notes. 
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A4: GP Letter 
Consultant Vascular Surgeons 
Mr O Agu MS FRCS FRCS (Gen) 
Mr Toby Richards BSc MBBS FRCS MD 
Mr Daryll Baker BSc, PhD, FRCS 
 
15/08/2014 
TR1/PRN/OOO 
 
 
Department of Vascular Services 
University College Hospital 
250 Euston Road 
London 
NW1 2PG 
 
Administrative Enquiries 
PA: Tomisin Olarewaju 
Tel: 020 3447 5173 
Fax: 020 3447 9217 
oluwatomisin.olarewaju@uclh.nhs.uk 
 
Surgical Admission Enquiries: 
Carina Nobrega 
Tel: 0203 447 9112 
Fax: 0203 447 9217 
carina.nogrega@uclh.nhs.uk 
 
Switchboard: 0845 155 5000 
Outpatient Clinic Appointments: 0203 447 9393 
 
 
UCLH Project ID number:          Form version:  April 1 PstP 2014 Version 1.3 
Dear Dr. 
 
Title of project:  Connexin 43 protein expression in venous disease 
 
Patient Name:        Patient d.o.b: 
Patient NHS Number: 
 
Your patient is taking part in a study by the Vascular Surgical Research Unit at University College 
London. 
The study aims at investigating the levels of a protein called Connexin-43 in patients with venous 
disease.   
Your patient will undergo small 4-mm wound edge biopsies, during routine care at their planned 
operation.   
The biospies should not have an adverse effect on your patients’ wound healing and your patient 
will continue their routine podiatry and dressing care.  Please do not hesitate to contact the 
Vascular Research Team should you have any concerns or require any further information.  I can 
be contacted either by email (muholan.kanapathy.13@ucl.ac.uk)or telephone (UCL  0207 6796454 
or 07459029770). 
Yours sincerely, 
 
 
Dr Muholan Kanapathy 
Research Fellow to Mr Toby Richards 
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A5: Clinical Wound Assessment Form 
Wound assessment & biopsy form       Version: April 1PstP 2014 Version 1.3 
 
WOUND ASSESSMENT & WOUND EDGE BIOPSY FORM 
 
Study Title:  Connexin 43 protein expression in venous disease 
Centre Number:     UCLH Project ID number: 
Date  Patient identification 
number 
 
Location of Ulcer (please circle 
and tick as appropriate for all 
ulcers apart from abdominal) 
Left     /      Right 
 
 Forefoot  
 Heel  
 Planter aspect 
 Lateral aspect 
 1PstP MTP 
 Toes (indicate which number)  
___________ 
Length (in cm) 
 
Width (in cm) Depth (in cm) 
Appearance (please tick as 
appropriate) 
 
Wound Base 
 Pink (epithelializing) 
 Red (granulating) 
 Yellow (sloughy)  
 Black (necrotic) 
Surrounding 
Skin 
 
Healthy/intact  
 Erythema 
 Dry/Scaly 
 
 Oedematous 
 Fragile 
 Macerated  
Other features (please tick as 
appropriate)  
Pain 
 Continuous 
 On touch or movement 
 None 
 
Light touch sensation 
 Present  Absent 
Infection   Yes  No  
 
Exudate    Yes  No  
(if yes please tick boxes below)   
Quantity      high  medium  low 
Type      blood   serous  pus 
Odour      offensive  none 
Limb pulses present 
 DP                    popliteal 
 PT                     femoral 
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Wound illustration (please indicate location of wound edge biopsies) 
 
 
 
 
 
 
 
 
 
Clinical photograph taken?    Yes  No   
Complications of wound edge biopsies?      Yes  No  (please state free text below) 
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B1: PROSPERO registration 
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B2: Patient Satisfaction Questionnaire  
Study Title:  A Multicentre Randomised Controlled Trial to Evaluate the Efficacy of Epidermal Grafting in 
Wound Healing (EPIGRAAFT) 
Subject ID: ___________     Follow-up week:         Week 6   3 months 
 
1. How noticeable do you find your donor site? 
Very noticeable (5) Somewhat noticeable (4) Slightly noticeable (3) Not noticeable at all (2) No particular feeling (1) 
     
2. Do you worry about your donor site appearance? 
I worry very much (5) I worry somewhat (4) I worry a little (3) I do not worry (2) No particular feeling (1) 
     
3. Did you suffer any problems with your donor site? 
Very problematic (5) Somewhat problematic (4) Slightly problematic(3) Not problematic at all(2) No particular feeling (1) 
     
4. Overall how would you rate the outcome of your donor site? 
Very satisfied 
(7) 
Somewhat 
satisfied (6) 
Slightly satisfied 
(5) 
No particular 
feeling (4) 
Slightly 
unsatisfied (3) 
Somewhat 
unsatisfied (2) 
Very unsatisfied 
(1) 
       
5. How noticeable do you find your graft site? 
Very noticeable (5) Somewhat noticeable (4) Slightly noticeable (3) Not noticeable at all (2) No particular feeling (1) 
     
6. Do you worry about your graft site appearance? 
I worry very much (5) I worry somewhat (4) I worry a little (3) I do not worry (2) No particular feeling (1) 
     
7. Did you suffer any problems with your graft site? 
Very problematic (5) Somewhat problematic (4) Slightly problematic(3) Not problematic at all(2) No particular feeling (1) 
     
8. Overall how would you rate the outcome of your graft site? 
Very satisfied 
(7) 
Somewhat 
satisfied (6) 
Slightly satisfied 
(5) 
No particular 
feeling (4) 
Slightly 
unsatisfied (3) 
Somewhat 
unsatisfied (2) 
Very unsatisfied 
(1) 
       
 
Patient skin graft satisfaction questionnaire 
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B3: Ethical Board Approvals 
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B4: Patient Information Sheet 
     
Project ID number:                                      Form version:  April 26PthP 2016, Version 1.2  
 
PATIENT INFORMATION LEAFLET 
Study Title: A Multicentre Randomised Controlled Trial to Evaluate the Efficacy of Epidermal 
Grafting in Wound Healing (EPIGRAAFT) 
Chief Investigator:  Mr Afshin Mosahebi / Professor Toby Richards  
 
As a patient of RFH NHS Trust you are being invited to take part in a research study. Before you decide 
whether you would like to take part, it is important for you to understand why the research is being 
done and what it will involve. Please take time to read the following information carefully and discuss 
it with friends, relatives and your GP if you wish. Ask us if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not you wish to take part. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Medical Research and You’. This 
leaflet gives more information about medical research and looks at some questions you may want to 
ask. A copy or it may be obtained from CERES, PO Box 1365, London N16 0BW. 
 
The purpose of the study: Split thickness skin grafting is the normal standard of care for wound 
closure. However, this is an invasive procedure and associated with pain also there can be additional 
donor site morbidity. Epidermal grafting is an emerging clinical alternative that is gaining clinical 
practise. Epidermal grafting (EG) is an alternative method of autologous skin grafting that ‘harvests’ a 
finer layer of skin than traditional Split Skin grafting (SSG). This potentially results in less pain and 
reduced donor site morbidity but only delivers several cell layers to the wound so may be less effective 
at healing a wound. It is not known if EG is an effective alternative to SSG. 
We wish to compare these two clinical practises; epidermal grafting and split thickness skin grafting 
in wound healing. Further to undertake a translational study to investigate the mechanism by which 
each technique achieves wound healing. 
Further the mechanism to achieve wound healing may be different. EG promotes wound healing by 
expressing growth factors that accelerates wound healing and encourages cell migration. Whereas 
SSG is a transplant of several skin layers that integrated to the existing wound bed as a formal skin 
covering. Specifically, EG is expected to accelerate wound healing by expressing favourable growth 
factors and regulating a particular protein called Connexin-43. It is known that high levels of Connexin-
43 protein can interfere with the movement of certain cells necessary for wound closure.  This 
research will further our knowledge about the human wound healing process and it may help 
development of beneficial treatments in the future 
 
Why have I been chosen? We have chosen you because you have wound that your consultant plastic 
surgeon considers would benefit from skin grafting. You have been selected as appropriate criteria 
and undergoing routine clinical care and treatment. We plan to study up to 40 patients in total. 
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Do I have to take part?  It is up to you to decide whether or not to take part. If you decide to take part 
you will be given a copy of this information sheet and a signed copy of the consent form to keep and 
be asked to sign a consent form. If you wish to withdraw from the study you may do so at any time 
and without giving a reason. If you decide not to take part in the study, this will not affect the standard 
of care you receive. 
 
What will happen to me if I take part?  
You will be provided with this Patient Information Sheet and given appropriate time to consider the 
trail and ask any questions. Following Informed Consent, you will undergo a wound fluid sampling and 
two small 4-mm biopsies. The wound fluid sampling will be performed by simply applying a filter paper 
onto your wound for about 2 minutes until it is moist. The biopsies will be taken from two locations 
on the wound undergoing treatment. The first will be at the center of the wound and the second will 
be at the wound edge. This will be done by an experienced surgeon and a nurse will be present 
throughout.  The sample will be carefully transferred and stored in the laboratory for further analysis.  
The sample will be ‘gifted’ by you for purposes of this research study.  Following the laboratory studies 
required for this research study, the sample will be stored by the research team at UCL, in accordance 
to the Human Tissue Authority Code of Practice. Ethical approval will be sought for additional projects 
in the future, should other researchers wish to use your sample.   
Upon completing the biopsies, you will be randomised into either the epidermal graft group or the 
split thickness skin graft group. You will then receive the designated treatment. You will be reviewed 
in outpatient specialist clinic weekly for up to 6 weeks or until your wound heals. If your wound fails 
to heal at week 6 ± 2, the treating clinician will discuss with you regarding the need for re-grafting 
along with repeat biopsies as per protocol. 
 
What data will be collected?   
Some parts of your medical record will be included into this study. As mentioned above, two 4-mm 
biopsies will be taken from you. Laboratory studies will be undertaken to determine the levels of 
growth factors, cytokeratin and Connexin-43 protein. 
Clinical photographs of your wound will be taken before and after the biopsies, for purposes of the 
study.  These photographs will be stored in our photo diary and used to analyse the size and the wound 
healing rate. These photographs might be used in clinical journals or publications.  All clinical 
photographs will remain anonymous and it will not be possible to identify you from the photograph. 
You will be asked about the pain at the wound and the donor site at day 1, 2, 3, 4, 5, 6, 7, 14, 21, 
28, 35, and 42. You will also be required to complete a Patient skin graft satisfaction questionnaire 
as part of your normal clinical pathway.  
 
What are the benefits of taking part? It is possible that there may be no direct benefits from taking 
part in this study, however the treatment may improve your wound healing. The information obtained 
from this study may likely benefit the future patients.  
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What are the disadvantages or risks of taking part? The disadvantages or risks of taking part are 
minor. There is possibility that the epidermal graft will not benefit your wound healing. There are 
several reasons this could take place; namely, infection and your general medical condition. 
The biopsy should not affect the healing of your wound, and should you become concerned about 
your wound at any time, a further outpatient follow-up appointment can be arranged.  
It is unlikely that the addition of a small biopsy to the surgical wound would result in any additional 
discomfort or pain at the time of biopsy.  Local anaesthesia may be used to minimize this risk; this 
involves using a fine needle to deliver the anaesthetic just below the skin surface to numb the skin.  
Patients may experience some minor bleeding (a few drops of blood, similar to when a patient has a 
needle finger-prick blood glucose ‘BM’ test).  If this happened it would be necessary to apply a small 
gauze dressing temporarily until the bleeding stops. Finally, there is small risk that the biopsy taken 
from you will not be suitable for use or in other words ‘insufficient’.  This means that the biopsy 
procedure has been unsuccessful due to technical problems at the time of taking biopsy, and it is 
inappropriate for the sample to be sent to the laboratory.  If this occurs, you will be informed.  It would 
be up to you to decide whether you wish to undergo further biopsy or withdraw from the research 
study. 
 
What if new information becomes available? Sometimes during the course of a research project, new 
information becomes available about the subject being studied. If this happens your research doctor 
will tell you about it and discuss with you whether you want to continue in the study. If you decide to 
withdraw your research doctor will make arrangements for your care to continue. If you decide to 
continue in the study you will be asked to sign an updated consent form. It is possible that on receiving 
new information your research doctor might consider it to be in your best interests to withdraw from 
the study. He/she will explain the reasons and arrange for care to continue. 
 
What happens if something goes wrong? If you experience any problem from the treatment, you 
should contact us straight away. All biopsies will be taken by an experienced surgeon and a nurse will 
be present throughout the test with immediate access to emergency equipment should it be required.  
We will take every care in the course of this study. If through our negligence any harm results, you will 
be compensated. However, a claim may need to be pursued through legal action. The NHS Trusts are 
not permitted to carry indemnity for non-negligent (no-fault) harm. 
 
Will my taking part in this study be kept confidential? All information which is collected about you 
during the course of the research will be kept strictly confidential. Any information about you which 
leaves the hospital will have your name and address removed so that you cannot be recognised from 
it. We are required to keep the data for a minimum of 5 years after the study has been completed. 
The biopsy samples will be stored in such a way that your details will linked to the stored tissue but 
not identifiable to researchers.  The biopsy sample will be stored in the tissue bank for 5 years. 
 
What will happen to the results of the research study? We plan to run the study for 2 years, after 
which the research team will analyse the results. The results will be published as soon as possible 
after study completion. You will not be identified in any report or publication. 
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Who is organising and funding the research? The Research fellow is organizing the research as part 
of a PhD thesis, supervised by Mr Toby Richards, Senior Lecturer and Consultant Vascular & 
Endovascular Surgeon and Mr Afshin Mosahebi, Consultant Plastic Surgeon. The research is sponsored 
by the NHS.   
 
Ethics Committee review All research using human subjects are reviewed before an ethics committee 
before they can proceed. This proposal was reviewed by Research Ethics Committee. 
 
Contact details for further information 
Professor Toby Richards, Professor of Surgery & Consultant Vascular and Endovascular Surgeon,                                               
UCL Division of Surgery and Interventional Science, Fourth Floor 74, Huntley Street, London, WC1E 
6AU Email: toby.richards@ucl.ac.uk Tel: 0207 6796454 
Mr Afshin Mosahebi, Consultant Plastic Surgeon and Honorary Senior Lecturer,                                                  
Department of Plastic and Reconstructive Surgery, Royal Free Hampstead NHS Trust Hospital, Pond 
Street, London, NW3 2QG Email: a.mosahebi@ucl.ac.uk Tel: 020 77940500 ext 35556 
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B5: Patient Consent Form 
 
CONSENT FORM 
Study Title:  A Multicentre Randomised Controlled Trial to Evaluate the Efficacy of Epidermal 
Grafting in Wound Healing (EPIGRAAFT) 
                         Form version: May 11PthP 2015, Version 1.1 
Project ID number: 
Chief Investigator : Mr Afshin Mosahebi / Professor Toby Richards 
 
To be completed by the volunteer       Please initial each box                              
1) I confirm that I have read and understood the information sheet dated May 11PthP 2015, 
version 1.1 for the above study, and have had the opportunity to ask questions. 
 
 
2) I confirm that I have had sufficient time to consider whether or not I want to be included in 
the study. 
 
 
3) I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
 
4) I understand that relevant sections of my medical notes and data collected during the study 
may be looked at by investigators of the trial, from regulatory authorities or from the NHS 
Trust, where it is relevant to my taking part in this research. I give permission for these 
individuals to have access to my records (which may include them being sent a copy of this 
consent form). 
 
 
5) I agree to biopsies to be taken at the wound bed and the wound edge at the start of the 
treatment and at day 7. 
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6) I understand that I am gifting my tissue to the investigators and in doing so I give up all 
future claims to its use that may include further research. 
 
 
        
7) I agree that my GP can be informed of my involvement in this study. 
 
 
        
8) I agree that anonymous clinical photographs may be taken of my wound during this study   
follow-up. 
 
 
       
9) I agree to take part in the above study.         
 
 
_______________________      _________________________      _______________ 
Name of patient    Signature    Date 
________________________  _________________________           _______________ 
Name of person taking   Signature    Date 
consent (if different from researcher) 
________________________  _________________________           _______________ 
Researcher     Signature           Date 
When completed: 1 form for patient, 1 to be kept as part of the researcher site file, 1 to be kept with 
hospital notes. 
Contact details for further information 
Professor Toby Richards, Professor of Surgery & Consultant Vascular and Endovascular Surgeon,                               
Email: toby.richards@ucl.ac.uk Tel: 0207 6796454  
Mr Afshin Mosahebi, Consultant Plastic Surgeon and Honorary Senior Lecturer,                                      
Email: 42Ta.mosahebi@ucl.ac.uk 42T Tel: 020 77940500 ext 35556 
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B5: GP Letter 
         
Project ID number:      Form version:  January 1PstP 2015 Version 1.0 
Dear Dr. 
 
Title of project: A Multicentre Randomised Controlled Trial to Evaluate the Efficacy of Epidermal 
Grafting in Wound Healing 
 
Patient Name:        Patient d.o.b: 
Patient NHS Number: 
 
Your patient is taking part in above research study, by the Department of Plastic Surgery at the Royal 
Free Hospital. We are performing a clinical trial to determine the efficacy of epidermal graft in wound 
healing against split thickness skin graft. 
In this clinical trail, we wish to determine the wound healing at 6 weeks as well as the donor site 
healing rate. Patients will be randomise to receive the epidermal graft or split thickness skin graft. 
Your patient will undergo two small 4-mm biopsies, one at the centre of the wound and one at the 
wound edge, followed by skin grafting (either epidermal graft or split thickness skin graft) over the 
wound. We will review your patient weekly for the duration of 6 weeks or until wound heals.    
The biospies should not have an adverse effect on your patients’ wound healing and your patient will 
continue their dressing care.  Please do not hesitate to contact the Department of Plastic Surgery at 
the Royal Free Hospital should you have any concerns or require any further information.  I can be 
contacted either by email (toby.richards@ucl.ac.uk) or telephone (UCL 0207 6796454). 
 
Yours sincerely, 
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B6: Clinical Wound Assessment Form 
   Form version: July 27PthP 2015 Version 1.1 
 
 
 
Research ID Number :     Date of Birth  :   
Patient Name  :    Hospital Number/MRN : 
Phone number  : 
 
Age : _________     Sex  Male    Female   
Weight : _________ kg   
Height : _________ cm 
 
 
Diabetes       Yes  No  If yes, specify type:  Type 1 
            Type 2 
Hypertension      Yes  No 
Peripheral Arterial Disease    Yes  No 
Chronic Venous Disease (Varicose veins/DVT)  Yes  No 
Lymphoedema      Yes  No 
Cancer       Yes  No If yes, specify type:   Skin 
            Others 
Renal insufficiency (exclusion criteria)    Yes  No 
Liver Disease (exclusion criteria)    Yes  No 
Haematological condition (exclusion criteria)  Yes  No 
Active auto-immune disease (exclusion criteria)  Yes  No 
 
Oral/topical steroid    Yes  No. If yes, specify treatment: ___________________________ 
Anticoagulant/Antiplatelet  Yes  No. If yes, specify treatment: ___________________________ 
 
Smoker     Current smoker   Never smoked    Previous smoker 
 
 
Has the patient meet the inclusion and exclusion criteria?    Yes  No 
 
 
PATIEN T INFORM ATIO N 
MEDICAL HISTORY 
WOUND ASSESSMENT FORM 
Study Title:  A Multicentre Randomised Controlled Trial to Evaluate the Efficacy of Epidermal Grafting 
in Wound Healing (EPIGRAAFT) 
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Type of wound    Acute wound (<3 months)   Chronic wound (>3months) 
Duration of wound : ________ weeks 
 
Wound aetiology   Venous ulcer   Arterial Ulcer   Diabetic ulcer   
 Pressure ulcer    Trauma   Wound dehiscence   
 Burns    Pyogenic Granuloma   Split skin graft donor site 
 Others, specify: _________________________  
 
Location of wound:         Foot   Ankle   Leg   Knee   Thigh 
    Hand   Arm   Forearm 
    Abdomen  Chest   Back 
 
   For limbs, specify site:   Left   Right 
 
Size of wound:  Length : ______________ cm Total wound area : __________ cmP2 
  Width : ______________ cm 
  Depth : ______________ cm 
 
Wound base appearance:    Pink (epithelializing)   Red (granulating)  
 Yellow (sloughy)   Black (necrotic) 
 
Surrounding skin appearance:  Healthy/intact   Erythema    Dry/Scaly 
 Oedematous    Fragile   Macerated 
 
Exudate:  Yes  No  
If yes, specify: Quantity        high    medium   low 
Type             blood    serous   pus 
Odour           offensive  none 
 
Pain:   Continuous  On touch or movement   None 
  Pain score (0 to 10): _____________ 
 
Wound bed preparation:  NPWT  Dressing, specify: ____________ _______________ 
Microbiological investigation: Date of test: __________   Result:  No bacterial growth 
         Positive bacterial growth  
            If positive, specify: ________________ 
WOUND INFORM ATION  
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Clinical photograph taken?     Yes  No   
Biopsy taken?       Yes   No   
Wound fluid taken?   Yes   No   
 
PUSH Tool Score of wound:   
 
Length 
x Width 
 
 
 
 
(in cmP2P) 
0 
 
 
0 
1 
 
 
< 0.3 
2 
 
 
0.3-0.6 
3 
 
 
0.7-1.0 
4 
 
 
1.1-2.0 
5 
 
 
2.1-3.0 
Sub-score 
 6 
 
 
3.1-4.0 
7 
 
 
4.1-8.0 
8 
 
 
8.1-12.0 
9 
 
 
12.1-24.0 
10 
 
 
>24.0 
Exudate 
Amount 
0 
 
 
None 
1 
 
 
Light 
2 
 
 
Moderate 
3 
 
 
Heavy 
  Sub-score 
Tissue 
Type 
0 
 
Closed 
1 
 
Epithelial 
Tissue 
2 
 
Granulation 
Tissue 
3 
 
Slough 
4 
 
Necrotic 
Tissue 
 Sub-score 
       Total Score 
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Date of treatment:  _____________________ 
 
Type of treatment:  Epidermal graft (CelluTome)   Split thickness skin graft (SSG) 
 
Site of graft harvest:  Left thigh  Right thigh  others, specify: ____________________ 
Pain score (0 to 10): _____________ 
 
Dressing  Wound:  _________________________ Donor site: __________________________ 
 
Procedure setting:  Inpatient   Outpatient 
If inpatient,  Duration of immobilisation: ___________ days  
Length of hospitalisation: _____________ days  
 
Complication:    Hematoma    Graft infection   Others: ________________ 
    None 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Completed by: 
Name: _____________________________________  Signature: _________________ 
TREATM ENT/PROCEDU RE 
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Date of review  : 
Research ID Number :     Date of Birth  :   
Patient Name  :    Hospital Number/MRN : 
 
Follow-up week  :   Week 1   Week 2   Week 3   Week 4 
 Week 5   Week 6   3 months  Others: _________ 
Pain score (0 to 10) : __________ 
 
Size of wound:  Length : ______________ cm Total wound area : __________ cm P2 
  Width : ______________ cm 
  Depth : ______________ cm 
 
Wound base appearance:    Pink (epithelializing)   Red (granulating)  
 Yellow (sloughy)   Black (necrotic) 
 
Surrounding skin appearance:  Healthy/intact   Erythema    Dry/Scaly 
 Oedematous    Fragile   Macerated 
 
Exudate:  Yes  No  
If yes, specify: Quantity        high    medium   low 
Type             blood    serous   pus 
Odour           offensive  none 
PUSH Tool Score for wound: 
Length 
x Width 
 
 
 
 
(in cm P2P) 
0 
 
 
0 
1 
 
 
< 0.3 
2 
 
 
0.3-0.6 
3 
 
 
0.7-1.0 
4 
 
 
1.1-2.0 
5 
 
 
2.1-3.0 
Sub-score 
 6 
 
 
3.1-4.0 
7 
 
 
4.1-8.0 
8 
 
 
8.1-12.0 
9 
 
 
12.1-24.0 
10 
 
 
>24.0 
Exudate 
Amount 
0 
 
 
None 
1 
 
 
Light 
2 
 
 
Moderate 
3 
 
 
Heavy 
  Sub-score 
Tissue Type 0 
 
Closed 
1 
 
Epithelial 
Tissue 
2 
 
Granulation 
Tissue 
3 
 
Slough 
4 
 
Necrotic 
Tissue 
 Sub-score 
       Total Score 
 
WEEKLY REVIEW FORM 
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Donor site healed?   Yes  No         If no, specify percentage of healed area:  ____% 
Donor site appearance   Scab  Hypopigmentation  Hyperpigmentation   Unnoticeable 
   
 
PUSH Tool Score for donor site:  
Length 
x Width 
 
 
 
 
(in cm P2P) 
0 
 
 
0 
1 
 
 
< 0.3 
2 
 
 
0.3-0.6 
3 
 
 
0.7-1.0 
4 
 
 
1.1-2.0 
5 
 
 
2.1-3.0 
Sub-score 
 6 
 
 
3.1-4.0 
7 
 
 
4.1-8.0 
8 
 
 
8.1-12.0 
9 
 
 
12.1-24.0 
10 
 
 
>24.0 
Exudate 
Amount 
0 
 
 
None 
1 
 
 
Light 
2 
 
 
Moderate 
3 
 
 
Heavy 
  Sub-score 
Tissue Type 0 
 
Closed 
1 
 
Epithelial 
Tissue 
2 
 
Granulation 
Tissue 
3 
 
Slough 
4 
 
Necrotic 
Tissue 
 Sub-score 
       Total Score 
 
Biopsy taken (only for week 1 post grafting)?     Yes   No   
Wound fluid taken?     Yes   No   
Clinical photograph taken?       Yes   No   
 
Dressing  Wound:  _________________________ Donor site: __________________________ 
 
Comment:  
 
 
 
 
 
 
Completed by: 
Name: _____________________________________  Signature: _________________ 
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 Study completed 
Date of completion: __________________ 
 
 Subject withdrew consent prior to completing all required visits 
If checked, please describe: _______________________________________ 
 
Investigator withdrew the subjects 
If checked, please describe: _______________________________________ 
 
 Subject lost to follow-up 
Date of last contact: __________________ 
 
 Death 
 
 
 
 
 
 
 
 
 
 
 
 
 
Completed by: 
Name: _____________________________________  Signature: _________________ 
 
STUDY EXIT 
 
